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Cysteine cathepsins are a family of lysosomal proteases that include the most potent 
mammalian collagen and elastase, meaning they degrade collagen and elastin better than 
any other mammalian enzyme.  Normally, these proteases are involved in protein turnover 
and degrade proteins to maintain cellular homeostasis. In addition to their lysosomal 
proteolytic activity, cathepsins can be secreted from cells and degrade extracellular matrix 
(ECM) with differing affinities in a variety of tissue destructive diseases such as cancer 
metastasis, atherosclerosis, and osteoporosis.  
Previous work showed cathepsin S could preferentially degrade cathepsin K in the 
presence of traditional substrate, a phenomenon termed cathepsin cannibalism, reducing 
expected substrate degradation. Moreover, once cells secret these proteins, they are subject 
to reaction diffusion kinetics, cell surface kinetics, and some other unidentified interactions 
that all must be considered beyond traditional ECM degradation kinetics. These potent 
enzymes are known to be upregulated in tissue destructive diseases, but researchers have 
been limited in their ability to successfully target cathepsin dysfunction. It is important not 
only to understand how these enzymes remodel the ECM, but also how they interact with 
each other, to effectively dose inhibitors to regulate cathepsin dysfunction.  
This research develops a mechanistic model of how cathepsins interact with ECM 
and each other for tissue remodeling as produced and regulated by living cells, to target 
these cathepsin mechanisms in the treatment of tissue destructive diseases and remodeling 
of synthetic environments. The central hypothesis of this dissertation is that when cells 
secrete multiple species of cathepsins, these cathepsins exhibit complex cathepsin 
 xvi 
cannibalism interactions, which reduces expected ECM degradation and thus 
concentrations of cathepsins. This dissertation is innovative because it analyzes cathepsin 
activity through molecular biology and computational simulation approaches to develop 
mechanistic models to drive targeting strategies for cathepsin-mediated diseases and 
sustainable fabrication of biological machines. 
In summary, using experimental and computational techniques, we confirmed that 
these cathepsin cannibalism interactions are occurring between pairs of cathepsins, 
ultimately reducing cathepsin concentrations catalytically active toward substrate 
degradation. Furthermore, this research introduces bioinformatics tools to design mutations 
to interrupt these cannibalism interactions to increase substrate degradation.  This brings 
researchers closer to reliably predicting responses to perturbations of the cathepsin 
proteolytic network, which is a key requirement for targeting cathepsin proteolysis in 
treatments for tissue destructive disease. 
Understanding the cathepsin proteolytic network is also necessary for design and 
control of engineered living systems, such as locomoting biological machines. By 
characterizing the cathepsin and MMP proteolysis in the muscle strips of these engineered 
livings systems found that they are making increasing amounts of protease over time, 
which is degrading the fibrin matrix and destabilizing the biological machines. 
Specifically, inhibiting the cathepsin activity can reduce this cathepsin-mediated 
destabilization and prolong biological machine survival time. The engineered living 
system’s functional time can be controlled by modifying the machine’s proteolytic 




CHAPTER 1. INTRODUCTION 
When proteins are aged, defective, or taken up by the cell, they are often degraded 
by enzymes in the lysosomes, such as cysteine cathepsins [1, 2]. These proteases play a 
major role in cellular homeostasis. In addition to their proteolytic activity inside lysosomes, 
cathepsins can be secreted from cells and degrade extracellular matrix (ECM). Over 
secretion of cathepsins plays a role in a variety of tissue destructive diseases such as cancer, 
atherosclerosis, and osteoporosis. Cathepsins are a family of understudied proteases that 
include the most potent human collagenase and elastase [3-6]. Previous work shows 
cathepsin S preferentially degrades cathepsin K, reducing the degradation of collagen, in a  
process termed cathepsin cannibalism [7]. Moreover, once cells secret these proteins, they 
are subject to reaction diffusion kinetics, cell surface kinetics, and some other unidentified 
interactions, that all must be considered beyond traditional extracellular matrix degradation 
kinetics. Cathepsins are also secreted with a propeptide covering the enzyme’s active site, 
which is cleaved to activate the enzyme [8-11]. Cells produce cystatins, endogenous 
cathepsin inhibitors, to control proteolytic activity by these enzymes [3, 12]. 
These potent enzymes are known to be upregulated in tissue destructive diseases, 
but researchers have been limited in their ability to successfully target cathepsin 
dysfunction in these diseases. It is important that we not only understand how these 
enzymes remodel the extracellular matrix, but also how these proteases interact with each 





1.1 Research Objectives and Specific Aims 
The main objective of this research was to develop a mechanistic model describing 
of how cathepsins interact with ECM and each other for tissue remodeling as produced and 
regulated by living cells, to target these cathepsin mechanisms in the treatment of tissue 
destructive diseases and remodeling of synthetic environments. Therefore, the central 
hypothesis of this dissertation was that when cells secrete multiple species of cathepsins, 
these cathepsins exhibit complex interactions between cathepsins K, L, S, and V, which 
reduce expected concentrations of cathepsins and thus the overall ECM protein 
degradation. The central hypothesis was tested through the following specific aims:   
 
Aim 1: Distinguish proteolytic interactions between cathepsins K, L, S, and V among 
key natural substrates to develop a proteolytic network computational model. The 
hypothesis of this aim was that cathepsin cannibalism occurs between cathepsins K, L, S, 
and V, reducing target substrate degradation. To expand this idea, cannibalistic 
relationships between cathepsins K, L, S, and V on collagen and elastin, two major 
components of ECM, were explored. Time course kinetic assays of individual, pairs, 
triplets, and quadruplet were used to determine ECM substrate degradation over time and 
modeled using mass-action kinetics.  This work was highlighted in Chapter 7. Furthermore, 
mutant cathepsins were designed and tested to verify the cathepsin cannibalism 
directionality as determined in silico in the cathepsin proteolytic network model, which 




due to multiple cathepsins being active extracellularly in the presence of one or more 
substrates. 
 
Aim 2: Determine the role of proteolytic activity in destabilizing locomoting biological 
machines. The hypothesis of this aim was that proteases, specifically cysteine cathepsins, 
secreted by C2C12 myoblast cells in biological machines degrade collagen and other 
matrix proteins used in machine assembly/construction, thereby reducing stability of the 
machine, and ultimately shortening its lifespan. Using a locomoting biological machine 
constructed from a stereolithography device seeded with C2C12 myoblast cells, the 
machine’s proteolytic network was quantified by Western blots and zymography both 
before and after the biological machine was electrically stimulated to trigger contractile 
motion. The protease activity of these biological machines and capacity to degrade the 
fibrin(ogen) substrates of these machines was explored in Chapters 4-6.  Using 
computational analysis and proteolytic profiling of the biological machine, strategies using 
cathepsin protease inhibitors or mutant cathepsins were developed to prolong the 
machine’s functional lifespan, which was discussed in Chapter 6. 
1.2 Significance of Results 
This dissertation is innovative because it analyzes cathepsin activity through 
molecular and computational approaches to develop mechanistic models to drive effective 
targeting strategies for cathepsin-mediated diseases and sustainable fabrication of 




non-intuitive way, which provides proof-of-concept that proteases bind and degrade other 
proteases in addition to substrate proteins, which is important for both treating tissue 
destructive diseases as well as developing the next generation of biological machines. The 
long-term goal of this project is to reliably predict perturbations to the proteolytic network 
and use this information to exploit protease-on-protease interactions in therapies for tissue 
destructive diseases and synthetic environments. 
 
Figure 1-1. Overview of Dissertation. 
  
































































































CHAPTER 2. BACKGROUND 
Proteases are enzymes that degrade proteins and play a major role in cellular 
homeostasis through control of physiological processes including immune response, cell 
cycle and death, wound healing, food digestion, and protein and organelle recycling [3, 
13]. Proteases composed about 2% of the human genome, accounting for almost 600 
proteins, which are divided into five major classes of mammalian proteases distinguished 
by their catalytic mechanism: serine, cysteine, metallo, aspartic, and threonine [13, 14]. 
These proteases’ specificities can range from highly selective, such as thrombin cleavage 
of fibrinogen in blood clotting, to highly non-specific, such as those involved in protein 
turnover [13].  Proteases “signal” through these proteolytic cleavage events which 
ultimately change the function of the substrate and in many pathologies proteases are 
dysregulated, which can result in non-specific proteases interacting with new substrates 
that they do not normal interact [13]. Furthermore, with the advent of the engineered living 
systems field, with new biomaterials and tissue engineering constructs that combine 
multiple cell types, it is important to consider the role of proteolysis for applications in 
these bioengineering constructs.    
2.1 Cysteine Cathepsins 
 The dynamic state of protein synthesis and degradation of the structural proteins 
has been discovered in the last century [1, 15].  In this time, researchers have concluded 




proteasome system and the lysosomal system [1]. In the ubiquitin-proteasome system 
works intracellularly where substrates to be degraded are tagged by covalent attachment of 
ubiquitin molecules and the subsequence tagged protein is degraded by the proteasome 
[15-17]. In the lysosomal degradation system, extracellular proteins are endocytosed and 
intracellular materials are taken up by autophagy so that hydrolases in the lysosomes can 
degrade these proteins [1, 18]. These so called “suicide bags” carry out this protein 
degradation at an acidic pH and generally the hydrolases have a very broad specificity to 
facilitate their role as recycling enzymes [13, 18, 19].  
 Cysteine cathepsins are a group of these lysosomal proteases that belong to the clan 
CA of cysteine peptidases, more specifically they are members of the C1 family of papain-
like peptidases [1, 20].  There are eleven cysteine cathepsins in this family of potent 
enzymes including cathepsins B, C, F, H, K, L, O, S, V, W, and X [1] and contain the 
powerful human collagenase, cathepsin K, as well as the most powerful human elastase, 
cathepsin V [3, 5, 6, 21-24]. Since cysteine cathepsins are a part of the papain superfamily, 
their structure is highly conserved and like that of papain, as indicated by amino acid 
sequences and crystal structures [1, 25-32]. Cathepsins have two structural domains 
roughly equal size separated by an active site cleft [1, 20, 21]. One domain contains three 
a-helices with the longest element containing 40 residues, including the catalytic Cys25 at 
the N-terminus [20, 21].  The other domain has a b-barrel of five to six strands makes up 
the C-terminus [20, 21]. The two-domain interface forms the active site, which is open at 




Substrates bind in an extended confirmation with its side chains alternating contact 
between the two structural domains [1, 33]. The active site cysteine and histidine form a 
thiolate-imidazolium ion pair, where the SH group of the Cys25 acts at the nucleophile and 
the adjacent imidazole from the His159 removes the proton from the SH group [21, 34]. 
The third member of the catalytic triad is Asn175, which acts as a polarizable acceptor for 
positive charge, stabilizing the thiolate-imidazolium pair for transfer of the imidazolium 
proton to the cleaved substrate [34].  Of interest are cathepsins K, L, S, and V which share 
60% sequence identity and redundancy in target substrate proteins with different catalytic 
activities toward similar matrix substrates [3, 5, 35].  
2.1.1 Cathepsin K 
Cathepsin K is the most potent mammalian collagenase and is the only mammalian 
protease known to cleave in the triple helix of type I collagen at multiple sites [6, 20, 23]. 
It was first detected in rabbit osteoclasts and, since then, have also been found to be 
expressed in ovary, small intestine, colon tissue, endothelial cells, fibroblasts, 
macrophages, and tumor cells [20, 21, 29, 36-41]. Cathepsin K is known to be a critical 
enzyme in bone resorption as an enzyme secreted into an acidic milieu by osteoclasts.  
When individuals have an autosomal recessive genetic mutation resulting in production of 
an inactive form of cathepsin K, a disorder called pycnodysostosis, these individuals have 
unnatural bone turnover and are characterized by having brittle, dense long bones, 
premature closure of long bone growth, and facial hypoplasia [3, 42, 43]. Pathologically, 




many pharmaceutical companies have tried to develop cathepsin K specific inhibitors to 
treat osteoporosis [44-47]. Cathepsin K is also a potent elastase and has been reported to 
contribute to rapid elastin degradation leading to plaque formation in cardiovascular 
disease [3, 48-51]. Cathepsin K’s proteolytic activity has also been implicated in other 
tissue destructive diseases including cancer metastasis, rheumatoid arthritis, and 
endometriosis [36, 38, 52-56]. 
2.1.2 Cathepsin L 
Cathepsin L is one of the ubiquitously expressed cysteine cathepsins (along with 
cathepsins B, C, and H) [18]. Unlike cathepsins K, S, and V, there are two proteolytically 
active forms of cathepsin L, a single-chain form of 28kDa and a heavy chain form of 
24kDa, where a 4kDa light chain has been cleaved [20]. Cathepsin L was first identified in 
rat liver lysosomes and such facilitates a variety of activities both intracellularly and 
extracellularly [20]. In endosomes and lysosomes cathepsin L is involved with invariant 
chain processing and specific antigenic peptides for MHC class II molecules presentation 
to T-cells [20, 57, 58], recycling growth factor and growth factor receptors to the plasma 
membrane [20, 59, 60], and degrading the capsid and underlying proteins of viruses to 
initiate infection [20, 61-67]. In the extracellular space, cathepsin L has been implicated in 
pathologies including atherosclerosis and tumor progression, as well as neovascularization 
by matrix degradation and integration of circulating progenitor cells into ischemic tissue 
[20, 36, 38, 50, 68-71]. In the nucleus, cathepsin L has been reported to play a role in 




accelerating cell cycle progression [20, 72-74].  Some of cathepsin L’s nuclear activities 
have resulted in enhanced proliferation and invasiveness in tumor cells [20, 75].  Finally, 
cathepsin L in the cytoplasm has been reported to be both a pro-apoptotic and anti-
apoptotic enzyme through cleavage of enzymes in the caspase pathway [18, 20, 76, 77].  
2.1.3 Cathepsin S 
Cathepsin S is unique in that it is the only cysteine cathepsin that remains stable 
and active at a neutral pH [3, 20, 21, 74].  Cathepsin S shares 55% sequence identity with 
cathepsin K and has both collagenase and elastase activities [20].  It was first identified in 
bovine lymph nodes and later in the spleen, but cathepsin S is also highly expressed by 
macrophages and in thyroid tissue and is involved with immune response [3, 20, 21]. 
Because of its high expression in lymph nodes and spleen, cathepsin S has been found to 
be involved in immune function including major histocompatibility complex (MHC) class 
II antigen presentation [1, 3, 20, 78].  Cathepsin S’s proteolytic activity has been implicated 
in pathologies including emphysema, Alzheimer’s disease, atherosclerosis, tumor 
progression and other inflammatory diseases as well as obesity [3, 20, 21, 50, 71, 79-83]. 
Interestingly, cathepsin S also plays a role in itch and immune response [84-88].  
2.1.4 Cathepsin V 
The most recently discovered member of the cysteine cathepsin family is cathepsin 
V and it is the most potent mammalian elastase and is about twice as efficient in cleaving 




cathepsin L2, and cathepsin L share 80% sequence identity, however mouse cathepsin L is 
orthologue of human cathepsin V and there is no mouse equivalent orthologue to human 
cathepsin L and hair follicle defect and impaired CD4+ helper cell selection in cathepsin 
L-deficient mice can be restored with cathepsin V-transgenic mice [20, 57, 90, 91].  
Cathepsin V is selectively expressed in the thymus, testis, and cornea [5, 20, 57, 89, 92, 
93].  Like cathepsins L and S, cathepsin V is involved with processing of invariant chains 
[20, 24, 93].  Furthermore, the elastinolytic activities of cathepsin V are increased in 
stenotic valves and atherosclerotic plaque development [20, 41, 94]. Finally, like the other 
three cathepsins, cathepsin V has also been implicated in cancer metastasis and is 
considered potential diagnostic markers for colon tumors [20, 38, 54, 95].  
2.1.5 Cysteine cathepsin mechanisms of regulation 
 Cysteine cathepsins are synthesized as inactive zymogens (procathepsin) with a 
pro-peptide occluding the active site, which must be cleaved to have mature, active enzyme 
[3, 21]. This is one mechanism for how cells prevent erroneous cathepsins catalytically 
activity. Activation of cysteine cathepsins can occur autocatalytically, where the cathepsin 
is in a favorable (acidic) pH where it can cleave its own propeptide [9, 10, 96]. 
Alternatively, other proteases can also cleave the propeptide through intermolecular 
activation [10, 43, 97]. Since most cathepsins also require an acidic and reducing 
environment to be catalytically active towards substrates, it is hypothesized that this acts 




96]. Moreover, the release of the propeptide has also been reported to act as a regulator of 
cathepsin activity and can be potent inhibitors of mature protease [10, 98]. 
 An alternative mechanism for cysteine cathepsin regulation is the concept of 
cathepsin cannibalism, one species of cathepsin can preferentially degrade another, even 
in the presence of substrate matrix protein [7]. In the seminal study by Barry and Platt, 
2012, cathepsin S was found to preferentially degrade cathepsin K, when in the presence 
of collagen and elastin. Furthermore, this cannibalistic relationship can protect against 
substrate degradation, which is important because it could be utilized as a method to 
preserve matrix proteins in disease states or synthetic environments. Figure 2-1A shows 
elastin degradation of cathepsin S (white squares), cathepsin K (white triangles), and both 
together (red circles) on fluorogenic elastin, which fluoresces when cleaved. Initially the 
predicted amount of degraded elastin by the combination of cathepsins was predicted as 
the sum of each cathepsin’s degradation alone on the substrate, however, experimentally, 
the amount of degraded elastin by cathepsin K and S together was only slightly more than 
cathepsin K alone.  Figure 2-1B shows that including cathepsin cannibalism interactions 
and allowing cathepsin S to bind and degrade cathepsin K, in addition to the elastin, one 
could accurately predict the total amount of elastin degradation. Traditionally these 
enzymes are investigated by biochemists in isolation; however, cells secrete many 
proteases simultaneously and there is evidence of protease cooperativity, it is important to 
understand how these proteases interact cooperatively or antagonistically to correct in 





Figure 2-1. Cathepsin cannibalism terms were necessary to predict the target 
substrate degradation by cathepsin K and S. (Figure adapted from Barry and Platt, JBC 
2012) 
2.2 Cathepsin Inhibitors 
 Cells also produce the endogenous inhibitors for cathepsins, cystatin B (stefin B) 
and C, to regulate cathepsin activity intracellularly and extracellularly, respectively [3, 12]. 
These proteins serve as competitive, reversible, but tightly binding inhibitors that prevents 
cathepsins from binding to substrate [1]. E-64 is a small molecule inhibitor that forms a 
covalent bond in the active site of the cathepsin and can be used to inhibit cathepsin activity 
in enzymatic studies, based on yeast analog to cystatin C [99-101].  
 Since cysteine cathepsins are upregulated in many tissue destructive diseases 
including cancer metastasis [1, 36, 38, 52-54, 69-71, 75, 95, 102-115], atherosclerosis [3, 
40, 41, 48, 50, 51, 68, 116-119], osteoporosis [3, 6, 42, 45, 46, 114, 120], rheumatoid 
arthritis [55], endometriosis [56], and tendinopathy [121, 122], pharmaceutical companies 
have identified the need to inhibit these potent proteases in a variety of pathologies. 




not efficacy [47, 110, 120, 123]. Furthermore, attempts to inhibit cathepsins in cellular 
systems, result in non-intuitive responses. For example, during phase I trial of a cathepsin 
S specific inhibitor, resulted in a dose dependent increase in amount of cathepsin S and 
cathepsin S activity [124]. Additionally, in breast cancer cell lines, treatment with E-64 
resulted in a differential cathepsin inhibition, where the amount of active cathepsin L was 
reduced, but the amount of active cathepsin S was increased by 24 hours [71]. Determining 
how these cathepsins interact with each other as a mechanism of proteolysis regulation is 
necessary to effectively dose pharmaceutical inhibitors to mediate cathepsin dysfunction.  
2.3 Biological Machines 
 In the construction of engineered living systems, integrating heterotypic cells into 
non-natural conformations with each other and with polymers or native matrix substrates 
may induce emergent responses of protease secretion. Cell-cell contact, contact with matrix 
substrates, inflammatory cytokines, and fluid shear stresses have all been shown to induce 
protease expression and activity [40, 68, 94]. Their activity can subsequently degrade 
extracellular matrix, alter the structural configuration, and leads to failure of the machines, 
particularly a locomoting machine reliant on the mechanical properties and coupling that 
drive the locomotion. 
The early walking biological machines “bio-bots” consisted of seeding rat cardiac 
cells on a stereo-lithographic 3D printed hydrogel “bimorph” cantilever utilizing 
spontaneous contraction of the cell sheet to actuate the cantilever and produce a power 




matrix solution of C2C12 murine myoblasts that are then differentiated into a muscle strip 
in the presence of insulin-like growth factor, fibrin, collagen, and Matrigel™ on a 
stereolithographic 3D printed polymer solution (Figure 2-2) [126, 127]. The biological 
machines are cultured in growth medium for three days, then switch to differentiation 
medium. Starting on Day 4, the biological machines can be electrically stimulated with 1 
Hz frequency, 50 ms pulse width for 10 min per day to walk [126, 127]. 
 However, without intervention, these biological machines will fail (by losing 
passive tension in the muscle strip and failing to contract or tissue damage in the muscle 
strip preventing contraction) on average after 8 days [126, 128]. Furthermore, histological 
staining for Masson’s Trichrome reveals tissue degradation and loss of structural integrity 
in these biological machines [128]. It is hypothesized that this degradation is due to 
proteases secreted by the muscle strip and must be characterized to design effective 






Figure 2-2. Fabrication of hydrogel structures and formation of 3D muscle strips. (A) 
CAD software was used to design bio-bots with desired dimensions. (B) A 
Stereolithography Apparatus was used to polymerize hydrogel structures. (C) Cell-matrix 
solution consisted of C2C12 skeletal myoblasts, matrix proteins, and MatrigelTM. (D) 
Fabricated bio-bot (i, side) and holder (ii, top). The solution was pipetted into a 
polymerized holder containing the bio-bot structure (iii-iv, side). Cells and matrix 
compacted around the pillars to form a solid muscle strip (v-vi, top) and the device was 
released (vii, side). All scale bars, 1 mm. (Figure and caption from Cvetkovic et al., PNAS 
2014.) 
2.4 Motivation and Research 
 The ultimate goal of this project was to develop a mechanistic model of the 
cathepsin proteolytic network and exploiting the complex cathepsin-cathepsin interactions 
for applications in treatment of tissue destructive diseases and control of survival time of 
biological machines. Cysteine cathepsins are upregulated in a variety of tissue destructive 
diseases and currently researchers have had trouble specifically targeting cathepsin activity 
[38]. From a clinical aspect, all the well-designed cathepsin inhibitors that have been 
developed are effective at reducing target substrate degradation in disease states, but have 




results from this work offers a way to re-examine pharmaceutical inhibitors in the larger 
cathepsin proteolytic network context to adjust the dosing to find a safe dose for patients 
that still achieve the desired therapeutic effect. Using the insights gained in this research, 
scientists and clinicians can develop more-effective strategies at targeting the cathepsin 
activity in these tissue destructive illnesses. 
In order to develop multicellular functional units with the ability to sense, process 
signals, and produce force and motion in response to external stimuli, how cells in 
biological machines interact with each other must first be understood. Specifically, how 
the cells regulate the extracellular matrix environment through proteolysis is crucial for 
designing biological machines that can be used for prolonged activities. Locomoting 
biological machines will only show electrically induced contractility for a limited amount 
of time, approximately 8 days following formation, until the machine fails without any 
additional intervention. As more advance biological machines are constructed, more cell 
types will be incorporated into the machine design to add additional functionality 
(vasculature, neuro-muscular junctions) and this heterotypic contact can change the 
protease signature in non-intuitive ways, which is an important element to consider in 
stable biological machine design and development. These proteolytic activities can be 
controlled as a designed benefit of the biological machines rather than a mechanism to 
wreak havoc on machine stability. 
The research dissertation is innovative because it analyzes cathepsin activity 




cathepsins K, L, S, and V proteolytic network and developing molecular tools to interrupt 
the complex cathepsin-cathepsin interactions. This work can ultimately be applied to 
driving effective targeting strategies for cathepsin-mediated diseases and sustainable 
fabrication of biological machines. Traditionally, cathepsins have been studied 
individually, however, cells secrete multiple cathepsin species at once, in the presence of 
many extracellular matrix substrates. Since these cathepsins degrade each other, the 
dynamics of this complex network must be understood to effectively target cathepsins 
whether they be upregulated in tissues destructive diseases or destabilizing engineered 







CHAPTER 3. PACMANS: A BIOINFORMATICALLY 
INFOMRED ALGORITHM TO PREDICT, DESIGN, AND 
DISRUPT PROTEASE-ON-PROTEASE HYDROLYSIS  
This chapter was adapted from Ferrall-Fairbanks, M.C. et al. (2017). PACMANS: A 
bioinformatically informed algorithm to predict, design, and disrupt protease-on-protease 
hydrolysis. Protein Science, 26(4), 880-890. doi: 10.1002/pro.3113 [129] 
3.1 Introduction 
 Cysteine cathepsins are a group of lysosomal proteases in the papain superfamily 
that are involved in intracellular protein degradation as well as degradation of extracellular 
matrix proteins when secreted by cells [1, 130]. Of particular interest, cathepsins K, L, S, 
and V which share 60% sequence identity and among them, include the most potent 
mammalian collagenase, cathepsin K, and most potent mammalian elastase, cathepsin V 
[3-6]. These four cathepsins have been implicated in many tissue destructive pathologies 
such as cancer metastasis [36, 38, 39, 53, 107, 109], osteoporosis [32, 50, 51], 
atherosclerosis [3, 40, 41, 50, 118, 119], rheumatoid arthritis [55], endometriosis [56], and 
tendinopathy [122]. Consequently, these proteases have redundancy in substrate cleavage 
preferences.  
We recently showed that one cathepsin family member could preferentially degrade 
another, even in the presence of the substrate, which we termed cathepsin cannibalism [7], 




important to note that this mechanism occurred between two mature enzymes, with one 
mature enzyme hydrolyzing the other into inactive fragments, not the well reported 
propeptide activation that occurs between cathepsins [9, 10, 96]. Determining that 
cathepsin S proteolysis of cathepsin K involved substrate degradation assays, 
immunoblotting, zymography, and computational modeling to test hypotheses about the 
cause of the unexpectedly low amount of substrate being degraded when two cathepsins 
were co-incubated.  
 Mass spectrometry can be used to sequence fragments of substrate protein after 
these cannibalistic hydrolysis, however this can be prohibitive due to cost and requirements 
of large amounts of purified protein, to test a hypothesis that may or may not be supported. 
We present here a computer algorithm and program to identify sites where proteases may 
cleave other proteases or substrate proteins, in an unbiased way, using data automatically 
gleaned from the online database of peptidases and their inhibitors, MEROPS 
(https://www.ebi.ac.uk/merops/) [131, 132]. We call this new tool PACMANS: Protease-
Ase Cleavages from MEROPS Analyzed Specificities. PACMANS was validated by 
studying cannibalism between mature cathepsin S, as the “protease-ase,” and cathepsin K, 
as the substrate protease, using this bioinformatically informed site-directed mutagenesis 
of cathepsin K to prevent its cannibalistic cleavage by cathepsin S.  This bioinformatics 
analysis was also applied to inter-familial proteolysis of cathepsins by matrix 





3.2 Materials and Methods 
3.2.1 Algorithm and program workflow 
  Protease-Ase Cleavages from MEROPS ANalyzed Specificities (PACMANS) is 
a program that determines putative cleavage site locations of a dominant protease 
(protease-ase) hydrolyzing a substrate protease. Putative locations were determined by 
point-by-point comparison of a substrate protease’s amino acid sequences with a protease-
ase’s active site specificity matrix (available from the MEROPS online peptidase database) 
to score the frequency each amino acid has been found in subsite P4 through P4’, and  is 
susceptible to cleavage in the protease-ase’s active site [131]. 
PACMANS was developed using a sliding-window approach, where individual 
sub-sequences that fill the P4 to P4’ active site pocket were scored. This pocket slides along 
the length of the substrate amino acid sequence and all possible sub-sequences were scored 
and then sorted by score. This program was implemented using MATLAB. Pseudocode for 
the program flow of PACMANS is given below:  
Main Inputs: sequence (text string of protein under analysis) and  
specmat (protease-ase matrix of specificity values) 
Determine pocket size using starting and end points (testlen) 
Determine the number of 1-8 amino acid sequences to be analyzed (numsequences) 
for i=1:numsequnces 
Determine current sequence (curseq) 




Determine the individual amino acid preference score for the j-th 
amino acid in the current sequences and store these scores in a 
matrix 
Add individual scores together to determine cumulative sequence 
score 
end 
calculate the range and median of individual residue scores as well as 
subsequent fragment size for each sequence 
end 
Scores matrix was then sorted by maximum cumulative score and printed to a file 
 Specialized MATLAB functions utilized in these calculations included 
molweight() [from the Bioinformatics Toolbox], which calculates the molecular weight of 
a given amino acid sequence and quantile() [from the Statistics and Machine Learning 
Toolbox], which returns the quantiles of a dataset, in this case the scores, to determine the 
top five-percent of scores for further analysis. The computational complexity of this 
algorithm is O(n), where n is the number of amino acids in the input sequences.  
 The functionality of PACMANS was further extended when used to compare 
substrate preferences between different protease-ases. The code was modified to calculate 
a normalized score, where the individual residues scores were normalized to the number of 





 The code was packaged into a graphical user interface (GUI) using MATLAB’s 
GUIDE Toolbox to allow use by a broader audience, which will be able to be downloaded 
and run as a MATLAB Application and the code was also re-implemented in PHP to host 
online (platt.gatech.edu/PACMANS). The functionality of the code was also adapted to 
allow users to vary the size of the active site picket, to a subset of the P4 to P4’ used in this 
work.  
3.2.2 Cathepsin K mutagenesis  
pCMVA6 plasmid containing the gene for human cathepsin K was originally 
purchased from OriGene (CTSK (NM_000396) Human cDNA clone). The mutant 
cathepsins were made by site-directed mutagenesis using overlap extension polymerase 
chain reaction (PCR) with mutagenic primers to introduce point-mutations into cathepsin 
K gene (Supplemental Table 1) [133], which was then ligated into pcDNA 4/TO/A plasmid 
(Invitrogen) that contains a C-terminal polyhistidine tag for nickel-column purification. 
Recombined plasmid was amplified in competent bacteria cells (Strain Zymo 5α, Zymo 
Research) and successful mutagenesis was confirmed with DNA sequencing by Genewiz. 
3.2.3 Stable expression and purification of mutant cathepsin K  
 HEK293T cells were stably transfected using Lipofectamine 2000 (Thermo-Fisher 
Scientific) and zeocin (Invivogen) as the selection marker for steady production of mutant 




purified from cell lysates with the ProBond Purification System (Thermo-Fisher 
Scientific). 
3.2.4 Multiplex cathepsin zymography  
 The multiplex cathepsin zymography assay was used to determine the amount of 
active cathepsin by the protocol previously established by our lab [134, 135]. 
3.2.5 Western blotting  
 Western blots were performed on proteins either from cell lysate (extracted using 
modified RIPA buffer) or purified protein in co-incubation experiments to determine levels 
of detectable protein. To test the cannibalism-resistance of cleavage site mutants, purified 
cathepsin mutants were co-incubated with or without 1 pmol of recombinant cathepsin S 
(Enzo) in a phosphate buffer (pH 6.0), 2mM dithiothreitol (DTT), and 1mM 
ethylenediamine tetraaceticacid (EDTA, Fischer Scientific) for two hours at 37°C. The 
reaction was quenched by the additional of a reducing loading dye and then samples were 
boiled for 5 minutes before loading into Western blot gels.  SDS-PAGE was performed 
using a 12.5% SDS polyacrylamide (National Diagnostics) gel and resolved at 150V at 
room temperature to separate proteins by molecular weight and then transferred onto a 
nitrocellulose membrane (Bio-Rad) using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-
Rad). Membranes were blocked for one hour with blocking buffer (Odyssey, diluted 1:1 
with PBS) and incubated over night with either a monoclonal mouse primary cathepsin K 




Proteins were imaged on a LI-COR Odyssey scanner using donkey anti-mouse or anti-goat 
secondary antibodies (Invitrogen) tagged with an infrared fluorophore. Densitometry to 
quantify band intensity (indicating protein amount) was performed using ImageJ (NIH). 
Results are presented with a mean ± standard error of the mean (SEM). Statistical analysis 
performed was a two-tailed, Student’s t-test (Microsoft Excel). 
3.2.6 Fluorescent gelatinase activity assay  
 Five pmol of recombinant cathepsin S (Enzo), MMP2 (Enzo), or MMP9 (Enzo) 
was incubated at 37°C individually or in combinations with 50 µg/ml of DQ gelatin 
(Thermo-Fisher) in phosphate buffer, pH 6.0, 2mM DTT, and 1mM EDTA in a 96-well 
plate.  Changes in fluorescence were measured at an excitation in 485nm and emission of 
525nm with a SpectraMax Plus microplate reader (Molecular Devices). 
3.3 Results 
3.3.1 Development and instructions for PACMANS 
 The design goals for PACMANS included (1) ease of use, (2) algorithmically 
efficient, (3) versatile for protease and substrate sequence input, and (4) automation. With 
these design goals in mind, a program using a sliding-window approach was developed, 
where each 8-residue segment of the amino acid sequence of the substrate protease was 
assessed for likelihood of cleavage in the active site pocket of the protease-ase.  Individual 





Figure 3-1. Using PACMANS to score locations of hydrolysis of the substrate protease 
by the protease-ase. Input the name of hypothesized protease-ase and desired substrate 
protease, specificity matrix for the protease-ase, and amino acid sequence of desired 
substrate protease. The specificity matrix quantifies the likelihood that a given amino acid 
in positions P4 through P4’ will result in a peptide bond cleavage between P1 and P1’ in 
the enzyme’s active site. Using the protease-ase’s specificity matrix and another protease’s 
amino acid sequence as the substrate protease, the potential locations of cleavage were 
scored by the sum of the individual scores that a given residue has been reported to occur 
in each subsite of the active site pocket. These putative sites of cleavage by protease-ase 
were then sorted by score and given to users in text file along with a histogram of all the 
scores. 
matrix for each protease that quantifies the likelihood of cleavage of each residue in each 
subsite of a protease’s active site [131, 132].  The positions on the protease at the active  
site are designated with S, and for the substrate as P, and are numbered outward (typically 
to P4/P4’) from the scissile bond between P1 and P1’ positions [136], where the non-
primed numbers refer to residues on the N-terminal side and the primed numbers refer to 
the C-terminal side of the cleaved bond (Figure 3-1). A cumulative likelihood score was 
Retrieve specificity matrix of 
the protease-ase from 
MEROPS 
(http://merops.sanger.ac.uk/) 
Retrieve amino acid 
sequence of the substrate 
protease








calculated by summing individual residue scores for each set of 8 amino acids being 
analyzed in that sliding window. A higher cumulative likelihood scored sequence would 
indicate higher specificity of that 8-amino acid sequence on the substrate protease for the 
active site in the protease-ase. Lower cumulative likelihood scores represent sequences 
with lower specificity for hydrolysis by the protease-ase for the substrate protease at that 
8-amino acid window. This algorithm was coded and implemented in MATLAB as 
described in the Methods section, and is available as an online application at 
platt.gatech.edu/PACMANS.  
Users are required to input five main pieces of information into PACMANS to 
generate the ranked list of putative cleavage site locations.  
1) User inputs names of the protease-ase and substrate protease, which will be 
used to generate the output file name: “PROTEASEASEonSUBSTRATE.txt” 
(Figure 3-1A). 
2) User defines the sliding window size of up to 8 subsites for analysis, where a 
lower bound of 1 would correspond to the residue in the S4 subsite and an upper 
bound of 8 would correspond to the residue in the S4’ subsite. If these fields are 
left blank, PACMANS will default to the full 8 (S4-S4’), but the option is 
available for a smaller window.  
3) User goes to MEROPS (https://www.ebi.ac.uk/merops/), click on the “Name” 
link under “Peptidase” on the left column on the page. Find the putative 




“MEROPS ID” given in the right column of the table.  Copy the web-address 
of the protease-ase of interest and paste into the link field of PACMANS 
interface (Figure 3-1B). 
4) User inputs the FASTA-formatted amino acid sequence of the substrate 
protease. Amino acid sequences can be obtained from UniProt 
(www.uniprot.org) by searching for substrate protease of interest in the search 
box at the top of the page (Figure 3-1C).  Select the “Entry” number of substrate 
protease of interest and scroll down to find the “Sequence” section. Click link 
to “FASTA” sequence and copy only the amino acid sequence. Be sure to 
remove spaces before inputting into PACMANS.    
5) User clicks “Load Data” and then “Calculate Scores” to generate a text file of 
scores. 
 After execution, PACMANS will return a text file with the substrate protease amino 
acid sequence, molecular weight, and cleavage site analysis (Figure 3-1D).  The cleavage 
site analysis will rank segments by cumulative sum score, and for each segment, list 
specific amino acid sequence being hydrolyzed, individual scores of residues (i.e. S1-P1 
score), the range and median of those individual scores, as well as expected size of the two 
fragments of the hydrolyzed substrate protein, assuming one cleavage site.  The cumulative 
likelihood scores will also be plotted in a histogram for quick viewing of high scoring 





Table 3-1. Top ninety-fifth percentile of cumulative cleavage scores of cathepsin S 
cannibalizing cathepsin K. The table includes the highest-scored regions of where 
cleavage of cathepsin K by cathepsin S is most likely to occur as well as descriptive 
information about the range and median residue scores and a schematic of where cleavage 
was expected to occur within the cathepsin K protein. The pro-region of cathepsin K 
includes residues 1 to 114, which were excluded when determining cathepsin K mutants to 
interrupt cathepsin cannibalism. The ‘/’ in the amino acid sequences indicates the scissile 
bond that would be hydrolyzed by cathepsin S. Schematics in the right column have a blue 
arrow indicating the hydrolysis would occur along with subsequence fragment sizes. 




Amino Acid	Sequence Individual	 Residue	
Specificity Scores
Range Median
1 701 (321) ANLA/SFPK	(328) [16,	244] 75
2 679 (143)	SSVG/ALEG	(150) [31,	172] 74
3 672 (60) HNLE/ASLG	(67) [20,	244] 76.5
4 658 (146)	GALE/BOLK	(153) [23,	244] 60.5
5 658 (277)	AVLA/VGYG (284) [16,	244] 74.5
6 633 (251)	ASLT/SFQF	(258) [12,	244] 60
7 612 (158)	KLLN/LSPQ	(165) [7,	244] 59
8 594 (64) ASLG/VHTY	(71) [10,	244] 48
9 585 (95)	VPLS/HSRS	(102) [8,	244] 51
10 577 (279) LAVG/YGIQ	(286) [13,	172] 58.5
11 576 (243)	GPVS/VAID (250) [21,	172] 64
12 574 (169)	DCVS/ENDG	(176) [20,	172] 69.5
13 554 (202)	PYVG/QEES (209) [14,	172] 46.5
14 550 (76)	NHLG/DMTS	(83) [8,	244] 36
15 546 (20)	EILD/THWE	(27) [8,	244] 49
16 544 (276)	HAVL/AVGY	(283) [10,	172] 57
propeptide
36.38 kDa 0.68 kDa
propeptide
16.91 kDa 20.13 kDa
propeptide
7.78 kDa 29.34 kDa
propeptide
17.22 kDa 19.89 kDa
propeptide
31.49 kDa 5.57 kDa
propeptide
28.54 kDa 8.55 kDa
propeptide
18.53 kDa 18.57 kDa
propeptide
8.11 kDa 28.94 kDa
propeptide
11.55 kDa 25.52 kDa
propeptide
31.64 kDa 5.40 kDa
propeptide
27.76 kDa 9.31 kDa
propeptide
19.69 kDa 17.39 kDa
propeptide
9.47 kDa 27.57 kDa
propeptide
2.65 kDa 34.45 kDa
propeptide
31.42 kDa 5.68 kDa
propeptide
23.29 kDa 13.75 kDa





3.3.2 Application of PACMANS utility: Cathepsin S cannibalism of Cathepsin K  
 PACMANS was used to determine putative locations of protease-on-protease 
cleavage for the cathepsin S-cathepsin K relationship. Cathepsin S was input as the 
protease-ase and cathepsin K as the substrate protease. Top putative hydrolysis sites were 
ranked and output into a text file. PACMANS ranks all possible sequence segments, 
however only the top 5% of highest scoring sequences (16 sites) were further reviewed for 
structural cues that would likely affect protease-ase hydrolysis. In Table 3-1, the amino 
acid sequence segments are presented such that ‘/’ indicates the scissile bond in cathepsin 
K. The range of the lowest and highest Individual scores as well as the median score of 
each 8-residue sequence is also presented. Schematics of cathepsin K with the location of 
hydrolysis and the fragment sizes generated were also added to Table 3-1. Five of the 16 
sites were eliminated because they were in the propeptide region (the first 114 residues of  
 
Figure 3-2. Cathepsin K putative sites of cleavage locations reviewed for accessibility 
to cleavage. A cathepsin K protein data bank (PDB) model was downloaded (PDB ID: 
1ATK) and sequences identified in Table 4-1 were reviewed for external accessibility by a 
protease-ase using Swiss-Pdb Viewer 4.1.0. 
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cathepsin K), which would have already been cleaved off during activation to the mature  
enzyme (numbers 3, 8, 9, 14, and 15 in Table 3-1 with grayed text). The other eleven sites 
were inspected for their accessibility using Swiss-Pdb Viewer 4.1.0 of Cathepsin K (PDB 
ID code: 1ATK) (Figure 3-2): residues on cathepsin K’s surface exposed to the aqueous 
environment and residues in unstructured regions were given higher priority over more 
internal residues because of their accessibility to cleavage by cathepsin S. 
 Sequence #6 ASLT/SFQF and #12 DCVS/ENDG met these criteria.  L253 and 
V171were identified as key locations that fit all criteria and the most probable sites of 
cathepsin K cannibalism by cathepsin S. 
3.3.3 Validation of PACMANS predictions with site-directed mutagenesis   
 To validate that these amino acid residues were important for hydrolysis of 
cathepsin K by cathepsin S, simulated mutations in PACMANS were analyzed. Mutating 
those two positions greatly reduced the overall cumulative score (L253A: 633 to 411; 
L253V: 633 to 561; V171A: 574 to 424) of those sequences. Site-directed mutagenesis at 
L253 and V171 was completed. They were mutated to alanine and valine [137] for small 
residues, whereas mutating to a bulky, charged residue, such as glutamic acid, would 
reduce the PACMANS overall score even more (L253E: 633 to 391), but could be more 
disruptive to protein folding which we wanted to retain.  
Next, mutations were introduced to test the hypothesis that mutating PACMANS 
identified sites (L253, V171) would yield cannibalism-resistant cathepsin K mutants. 





Figure 3-3. Expression of cleavage-site cathepsin K mutants yield full length protein 
and are protected from degradation by cathepsin S. (A) HEK293T cells were stably 
transfected with a plasmid for each of the His-tagged cathepsin K mutants.  Cell pellets 
were collected and lysed and prepared for immunoblotting to determine if protein was 
produced, and cathepsin zymography to test for active cathepsin K with the mutations. (B) 
One picomole of recombinant cathepsin S was co-incubated with purified cathepsin K 
wildtype or cleavage site cathepsin K mutants for 2 hours at 37°C. Cathepsin S degraded 
50% of wildtype (w.t.) cathepsin K (n=3, p<0.05). Mutations at V171 showed partial 
protection of 25% (n=3, p<0.05), but mutations at L253 protected cathepsin K with no 
statistically significant difference, in the presence or absence of cathepsin S (n=3). 
Densitometry is quantified in the graph below. 
a plasmid with six tandem histidine residues (6xHis-tagged) at the C-terminal end of 
cathepsin K, confirmed by sequencing, then transfected into HEK293T cells. Translation 
of full length mutant cathepsin K proteins were verified by immunoblotting (reducing SDS-
PAGE), and cathepsin zymography (a non-reducing SDS-PAGE method) was used to test 
if they were proteolytically active (Figure 3-3A). L253A, V171A, and L253V were 
expressed as full length proteins but, L253V did not yield an enzymatically active protein 
in these studies, but L253A and V171A did, as confirmed by the zymogram (Figure 3-3A). 
 Recombinant cathepsin K mutants were also purified from cell lysates and 









































































degradation. Quantification of immunoblots after two hours of co-incubation with 
cathepsin S indicated a 50% reduction in wildtype (WT) cathepsin K (n=3, p<.02), 
compared to when incubated alone, only a 27% reduction in V171A cathepsin K protein 
(n=3, p<0.02), and no significant reduction in protein for the L253A or the L253V 
cathepsin K mutants (n=3) (Figure 3-3B). This indicates that PACMANS was correctly 
able to identify a putative site of cleavage of cathepsin K by cathepsin S, which could be 
mitigated by bioinformatically informed mutagenesis. 
3.3.4 Inter-familial protease-on-protease interactions: cathepsin S, MMP-2, and  
MMP-9 
In our design of PACMANS, we wanted to provide versatility for protease selection 
of any protease with information in MEROPS, not just cysteine cathepsins. PACMANS 
was applied to study interfamilial proteolysis.  Matrix metalloproteinases (MMPs) are 
another family of proteases implicated in similar tissue destructive diseases as cysteine 
cathepsins, MMP-2 and MMP-9 in particular [4, 138-141], and interfamilial proteolysis 
can impact substrate degradation similarly to intrafamilial proteolysis. We used 
PACMANS to test the hypothesis that cathepsin S could degrade MMP-2 and MMP-9. To 
do so, cathepsin S was input into PACMANS as the protease-ase and either MMP-2 or 
MMP-9 as the substrate protease, the maximum cumulative scores of potential protease-
on-protease interactions between cathepsin S and MMP-2 and 9 were plotted (Figure 
3-4A). This procedure was repeated for MMP-2 (Figure 3-4B) and MMP-9 (Figure 3-4C) 




scores for each protease-ase’s hydrolysis of type 1 collagen and elastin were also analyzed 
by PACMANS to compare with likelihood scores of substrate proteases as a comparative 
metric for likelihood of cleavage.  
The initial intention was to use the PACMANS scores from traditional extracellular 
matrix substrates collagen I and elastin as a normalization strategy to compare between 
 
Figure 3-4. PACMANS predictions and validation of protease-on-protease 
interactions causing a reduction in gelatinase activity of cathepsin S when co-
incubated with MMP-2 or MMP-9. Using cathepsin S, MMP-2, and MMP-9’s specificity 
matrices and the amino acid sequence of other enzymes as the substrate protease, the 
maximum cumulative cleavage likelihood was plotted, specifically focusing on (A) 
cathepsin S, (B) MMP-2, and (C) MMP-9 as the protease-ases of interest.  PACMANS was 
further refined to calculate normalized scores to allow users to make comparisons among 
cathepsin S, MMP-2, and MMP-9 with their collagen scores as markers (D). Fluorogenic 
gelatin was incubated individually and in pairs of cathepsin S (catS), MMP-2, and MMP-
9 (E). Cathepsin S alone degraded the most gelatin, but when co-incubated with equal 
amounts of either MMP-2 or MMP-9, the total gelatin degradation was approximately half 













































































































































































































































































































































































protease-ases, but the magnitude of the scores would have different ranges based on the 
number of papers published on the protease-ase. Maximum score was 840 for cathepsin S, 
4426 for MMP-2, and 749 for MMP-9. The reason for this is that the MEROPS specificity 
matrix contains the frequency that a given residue has been reported in publications for 
each subsite. This was not constant when comparing across different proteases in this 
study; MMP-2, with reports as far back as 1988 [142] have more published substrate 
specificities analyzed and therefore generally have higher frequency values in their 
specificity matrix than other proteases such as cathepsin V, first reported in 1998 and have 
less known substrate preferences published [89]. As a result, the magnitude of the 
cumulative score was greater for proteases with a greater number of known substrates and 
preferences. To enable comparisons across protease-ases, an effective normalization 
strategy was developed. By dividing the individual likelihood score for a position by the 
total possible score of that subsite for all amino acids;	𝑆𝑀$,&'()*, the normalized score for a 





where 𝑖 is amino acid (row), 𝑗 is subsite (column), and 𝑆𝑀 is specificity matrix. Norm 
means normalized. The sum of the normalized scores,	𝑆𝑀$,&'()*, can be used to more 
accurately compare cleavage potential across multiple protease-ases, as shown below.    
Using normalized scores, cathepsin S hydrolysis of MMP-2 (score of 0.97) scored 
higher than cathepsin K (score of 0.95), which was higher than MMP-9 (score of 0.93). 




MMP-9 (score of 0.88) (Figure 3-4D). This suggested that MMP-2 would preferentially 
hydrolyze cathepsin S more than vice versa and that co-incubation would reduce cathepsin 
S’s degradation ability. PACMANS-based hypotheses were then tested experimentally by 
co-incubating cathepsin S with MMP-2 or MMP-9 and monitoring cleavage of a 
fluorescently quenched gelatin substrate; increased fluorescence indicates substrate 
degradation. By itself, cathepsin S degraded more gelatin than the other proteases with 
MMP-2 degrading 10.3% as much and MMP-9 degrading 46.0% as much gelatin as 
cathepsin S alone (Figure 3-4E). When co-incubating with cathepsin S, only 65.2% of total 
gelatin was degraded with MMP-2, and only 60.5% with MMP-9 compared to cathepsin S 
alone (100%), even though there was initially twice the molar amount of proteases in the 
system (Figure 3-4E). If no interactive proteolysis was occurring, then the results from co-
incubation would be expected to be the sum of each individual protease’s activity. This 
suggests that MMP-2 and MMP-9 were reducing the amount of active cathepsin S in the 
system by cleaving it, or were distracting cathepsin S from degrading the gelatin serving 
as an alternative substrate for cathepsin S to bind, or both, which supports the hypothesis 
from PACMANS that MMP-2 and MMP-9 could cleave cathepsin S when co-incubated, 
and to some degree, vice versa.  
3.4 Discussion  
 PACMANS uses a bioinformatics approach to analyze the primary structure of a 
protease (substrate protease) and determines possible locations that could be vulnerable to 




compared to other putative site cleavage programs, by allowing users to define the protease 
of interest, and utilizing the specificity matrix from MEROPS to rank the most likely 
locations of cleavage. Although this program was initially conceived to analyze proteases 
cleaving other proteases, which could be bidirectional, it can also be used for traditional, 
non-protease substrate proteins, as well as short peptide sequences.  Putative sites on 
cathepsin K susceptible to cleavage by cathepsin S were identified by PACMANS, 
confirming its ability to score sites based on protease-ase preferences. Cathepsin S prefers 
moderately-sized, branched hydrophobic residue (such as leucine in L253) in the P2 [143-
145], and these were detected in the top 5% of putative sites on cathepsin K. Introducing 
mutations into cathepsin K at sites L253 and V171, protected cathepsin K from cleavage 
by cathepsin S (Figure 3-3). This validated PACMANS as a useful tool for predicting 
locations of protease-on-protease interactions and cleavage. Taken together, this confirms 
cathepsin cannibalism between cathepsin S and cathepsin K and that its outcomes can be 
modified by mutational analysis and application.  
 Other protease families may undergo similar proteolytic interactions between 
family members, but we also used PACMANS to demonstrate the possibility of inter-
familial regulation of proteases using cathepsin S/MMP-2,-9 studies. PACMANS 
predicted interactions and preferential hydrolysis directions between cathepsin S vs. MMP-
2 and MMP-9 (which are both gelatinases), were then tested experimentally by monitoring 
gelatinase activity of these proteases in isolation, in concert, or against each other. 
PACMANS analysis indicates that both MMP-2 and -9 have greater preference for 




experimentally that cathepsin S gelatinase activity was reduced when co-incubated with 
MMP-2 or MMP-9 compared to its incubation by itself indicating interactions between 
MMP-2 and cathepsin S and of MMP-9 with cathepsin S were reducing cathepsin S 
activity.  Cathepsin S could be acting as a decoy or distraction for MMPs, causing them to 
bind to and hydrolyze cathepsin S preferentially over the gelatin substrate, reducing the 
amount of gelatin being degraded over the same unit time.  If MMP-2/-9 are cleaving 
cathepsin S, there is the additional consequence of inactivating a fraction of cathepsin S, 
preventing that amount of active enzyme from degrading gelatin resulting in a net reduction 
in total gelatinase activity. This reduced gelatinase activity observed occurred even when 
there was twice the molar amount of active protease present since equimolar amounts were 
added for each of the experimental conditions (Figure 3-4E). 
Expanding PACMANS to test inter-familial protease relationships between 
cathepsin S and MMP-2/MMP-9, it became clear that the initial scores calculated from 
MEROPS were not comparable across protease-ases. The protease-ase scores clustered 
depending on the magnitude of scores in the MEROPS specificity matrices, rather than just 
biological preference.  For example, MMP-9 is known to be a strong collagenase [4], 
however, based solely on the scores, MMP-2 preference for collagen, elastin, as well as 
cathepsin S, MMP-2, and MMP-9 was greater than MMP-9’s score for degrading collagen.  
To compare across cathepsin S, MMP-2, and MMP-9, a normalized score was developed, 
which normalized the specificity matrix by the total number of substrates used to generate 
it. After normalization, protease-ase preferences could be more directly compared and 




the strongest collagenase (score 2.05) followed by MMP-2 (score 1.20) and cathepsin S 
(score 1.10), which better approximates published comparisons [4].  
PACMANS customizability allows users to input amino acid sequences and 
proteases of interest. Other programs developed to determine proteolytic cleavage sites, 
more commonly have a predefined, set list of proteases available for analysis.  PROSPER 
[146] and PeptideCutter [147] are two programs that differ from PACMANS in that they 
analyze a set list of enzymes to cleave the amino acid sequence, while PACMANS’s only 
limit is that the protease must have a specificity matrix characterized in MEROPS (which 
as of the time of this submission is 263). PeptideCutter did not have any of the cysteine 
cathepsins, and PROSPER only included cathepsin K.  
Prediction of Protease Specificity (PoPS) is a robust program similar to 
PACMANS, but users must manually type each subsite’s specificities for each amino acid 
by hand (which can be error-prone) [148] instead of directly linking to MEROPS like 
PACMANS. Furthermore, PoPS has the user choose between scaling methods.  
PACMANS normalizes the specificity matrix and computes a normalized score for 
comparison. PoPS gave similar results to PACMANS with the sequence (143) SSVG/ALEG 
(150) having a maximum score of 17.83, which was the second entry in PACMANS results 
(Table 3-1). However, the sequences containing L253 (rank 9, score: 9.28) and V171 (rank 
19, score: 5.85) in the P2 locations were lower ranked in the top scores from PoPS and 
were shown from the PACMANS identified sites as key locations for interrupting 




 In summary, PACMANS is now added to other tools that can be used to test basic 
scientific questions for proteolysis, as well as design interventions in tissue-destructive 
diseases.  PACMANS also can be used to design mutant proteins that can be therapeutically 
resistant or enhanced for protease-on-protease interactions. For example, if design goals 
were for cathepsin K to be degraded quickly for some biotechnology application or for 
some biologic manufacturing tasks, then instead of expressing  L253A mutants resistant to 
cannibalism, one could express T254G or Q257P; both of these mutants would increase 
likelihood scores to enhance its degradation by cathepsin S. Understanding protease-on-
protease interactions can also allow for accurate dosing of protease inhibitors, considering 
the activities of protease-on-protease interactions that can generate off-target side effects 
caused by miscalculations of protease concentrations in pharmacological analyses. 
PACMANS offers an inexpensive in silico method to perform first pass analyses prior to 






CHAPTER 4. COMPUTATIONAL PREDICTIONS OF 
CYSTEINE CATHEPSIN-MEDIATED FIBRINOGEN 
DEGRADATION  
This chapter was adapted from Ferrall-Fairbanks, M.C.*, West, D. M.*, et al. 
Computational predictions of cysteine cathepsin-mediated fibrinogen degradation. 
Manuscript submitted.  
4.1 Introduction 
Fibrin networks form the basis of a blood clot in response to injury to the 
endothelial lining of blood vessels to prevent blood loss and maintain homeostasis. 
Maladies in this wound healing response can results in an increased risk unnecessary clot 
formation and thrombotic complications, such as those found in individuals with sickle cell 
disease, diabetes, and rheumatoid arthritis [149, 150]. Fibrinogen, the fibrin precursor, is a 
340kDa protein that circulates in the blood at high concentrations [151-154] in preparation 
for an injury event. It is a hexameric protein, composed of two subunits, each with three 
polypeptide chains (a, b, and g), held together by disulfide bonds, with a flexible region 
(E-domain) and with large globular regions (D-domain) on the ends [155]. It is within the 
E-domain that thrombin, a serine protease, binds and cleaves N-terminal fibrinopeptides A 
and B, producing disulfide linkages. In the presence of Factor XIIIa, fibrinogen monomers 
are converted into an insoluble fibrin network, which at the site of an injury, traps red blood 




Fibrin-based scaffolds have emerged for a wide variety of tissue engineering 
constructs from hydrogels to synthetic applications in muscle strips of biological machines 
[128, 151, 153, 156-158], microphysiological systems [159, 160], and regenerative 
medicine applications as sealants during procedures and hemostatic agents in surgery 
[126], and perfusable microvascular networks (MVNs) [161]. Despite enhanced 
angiogenesis, networks destabilize within six days [159]. Plasmin is the endogenous 
enzyme that degrades fibrin during resolution of blood clots [159], yet even with the 
inhibitors of plasmin-mediated fibrin degradation, these fibrin-based constructs are being 
destabilized in an uncontrolled manner, indicating other proteases produced by cells may 
be fibrinolytic agents.  
Non-plasmin fibrinolytic pathways must be considered to explain fibrin matrix 
destabilization. While thrombin and plasmin are known proteases involved in the 
coagulation cascade to cleave fibrinogen and degrade fibrin, we hypothesize that there are 
other proteases with similar capabilities that have been overlooked due to physiological 
constraints that are no longer applicable in engineered biological systems. One such 
candidate are cysteine cathepsins, a family of proteases that are known to degrade 
extracellular matrix proteins, including collagen and elastin, as well as themselves [3, 102, 
130]. These enzymes are implicated in various types of tissue destructive diseases [1, 7, 
130] and their substrate redundancy has been well documented [36, 38, 39, 53, 107, 109]. 




130]; however, very little work has been done exploring cysteine cathepsins’ potential to 
hydrolyze fibrinogen and fibrin.  
 Here, we use computational methods of possible molecular docking interactions 
combined with bioinformatics substrate specificity analysis to analyze the proteolytic 
interactions between fibrinogen a, b, and g chains and cathepsins K, L, and S. Using these 
two independent computational techniques to implicate regions of fibrinogen susceptible 
to hydrolysis by cysteine cathepsins could provide a mechanistic understanding of how 
these cysteine cathepsins play a role in destabilizing biomaterials, tissue engineered 
constructs, and microphysiological systems. 
4.2 Materials and Methods 
4.2.1 Molecular docking simulation 
Molecular docking was accomplished using the web server ClusPro 2.0 [3-6]. The 
atomic co-ordinates of human fibrinogen (PDB ID: 3GHG), cathepsins K (PDB ID: 4N79), 
cathepsin L (PDB ID: 5F02), and cathepsin S (PDB ID: 4P6E) were downloaded from the 
Protein Data Bank [162-166]. Briefly, the crystal structure of cathepsins were stripped of 
all water molecules and ligands, then uploaded to the server as a ligand. Human fibrinogen, 
the much larger molecule, was uploaded as a receptor. For the study of individual fibrin 
chains, the role of ligand and receptor remained constant, with specific chains selected 
during the upload of the fibrinogen model. Using ClusPro allows for selection of binding 




and Van der Waals interactions. The simulations for this work were performed with a 
balanced approached, meaning an unbiased binding method acknowledging all bonding 
interactions when developing docking models. The structures were rotated and translated 
in three dimensions, simulating 109 possible binding interactions. The docking simulations 
followed a balanced approach, producing 103 energetically indistinguishable 
conformations, all representative of a possible binding motif. With these conformations, 
models in which one atom of the ligand was within 1 nm of one receptor atom were selected 
for clustering. Following selection, the distance between the a-carbons of the 
corresponding residues of the selected ligands were calculated. Ligands with a carbon-
carbon bond distance within a 9-Å interface RMSD radius [166] between the ligand and 
macromolecule were clustered into groups, and the ligand with the most neighboring 
molecules were chosen as the representative model for the cluster. The models were 
visualized using the PyMol molecular viewer (PyMOL Molecular Graphics System; 
DeLano Scientific: San Carlos, CA, 2002). Although crystal structures do not capture all 
the different confirmations that may be observed in solution, we focused on models in 
which the active site of the ligand was facing the receptor, and discarded possible allosteric 
alternate binding modes as well as overlapping structures [167].  From the crystal structure 
of fibrinogen, only a portion of the overall structure was captured and further investigated, 
for the a chain region included was A46 through Q219, for the b chain region included 





4.2.2 Putative cleavage site determination with PACMANS 
PACMANS (Protease-Ase Cleavages from MEROPS ANalyzed Specificities) 
[168, 169] developed by us (and available online: platt.gatech.edu/PACMANS) is an 
algorithm for  users to input a URL link to the MEROPS specificity matrix of a protease 
(here cathepsin K, L, and S) and the amino acid sequence of a substrate (here fibrinogen 
a, b, and g chains), and returns a ranked list scoring hydrolysis of each eight amino acid 
sequence in the substrate sequences. Using a sliding window approach, the program scores 
the likelihood of hydrolysis occurring between the P1/P1’ scissile bond when a given 8 
amino acid segment of the substrate was in the S4 through S4’ subsites of the protease’s 
active site using the protease’s specificity matrix characterized by MEROPS. The top 5% 
of scores are then further analyzed for accessibility by the protease and compared with 
molecular docking results. 
4.2.3 Fibrinogenolysis experiment 
Human fibrinogen (FIB 3 Plasminogen, von Willebrand Factor and Fibronectin 
Depleted; Enzyme Research Laboratories) was co-incubated with recombinant human 
cathepsins K, L, or S (Enzo) in assay buffer (0.1M sodium phosphate buffer, pH 6.0, 1mM 
EDTA) with 2mM dithiothreitol (DTT) for 24 hours at 37°C. The samples were centrifuged 
at 7012g and the supernatant was saved. The pellet was prepped in 50mM Tris-
HCl/100mM NaCl with 25% betamercaptoethanol (OmniPur) and sonicated. Samples were 




50% glycerol, 25% betamercaptoethanol) and run on 10% SDS-PAGE gels and stained 
with Coomassie stain (10% acetic acid, 25% isopropanol, 4.5% Coomassie blue), followed 
by destaining (10% isopropanol and 10% acetic acid) and imaged with an ImageQuant 
LAS 4000 (GE Healthcare), and densitometry performed with ImageJ (NIH) to quantify 
fibrin(ogen) polypeptide chains. 
4.3 Results 
4.3.1 Molecular docking predicts primary cathepsin binding sites and PACMANS ranks 
likelihood of cleavage by cathepsins 
ClusPro molecular docking was used to calculate and visualize putative cathepsin-
fibrinogen interactions based on energetically favourable binding confirmations. Our goal 
was to determine specific residues on fibrinogen with high probability of binding of 
cathepsin K, L, and S active sites. The active sites of papain family cysteine cathepsins are 
highly conserved [129] with a cysteine (C), histidine (H), and asparagine (N) to form the 
catalytic triad. For cathepsin K, its catalytic triad is formed of residues C25, H162 and 
N182 [170], for cathepsin L, residues C25, H163 and N187 [1], and for cathepsin S, 
residues C25, H164, and N184 [1]. ClusPro generated models with similar conformations 
closely clustered together to produce a single model representative of the group. The 
structures provided by ClusPro were all energetically favorable and unique (see Materials 





To investigate the potential for cathepsin-mediated hydrolysis of fibrinogen (a, b, 
and g) chains, the top 5% of scored PACMANS sequences were further investigated and 
compared against the molecular docking results. The full top 5% of scored sequences of a 
cathepsin on individual fibrinogen chains for cathepsins K, L, and S are in Appendix A.3.  
Locations that were independently identified by these two methods, molecular docking and 
specificity preference from PACMANS, were further analyzed to determine mechanistic 
interactions. 
With correlation between putative cleavage sites and molecular docking binding 
sites, the next step focused on what possible molecular interactions that would make these 
sites favorable for catalysis. The top scoring sequences from each fibrinogen chain was 
further analyzed to determine possible interactions between amino acid residues of 
cathepsins K, L, and S and the cleavage site of each fibrinogen chain. For this study, 
correlating binding regions on structured, helical portions of the subunits was preferable to 
binding in the globular regions between cathepsins would have easier access for 
fibrinogenolysis at these locations in solution. 
4.3.2 Cathepsins binding to fibrinogen 
The binding of cathepsins appeared to be distributed along the length of the 
fibrinogen monomer, binding to all three chains, and included models with binding at both 
the E- and D-domains. This was a similar binding conformation in the crystal structure of 




fibrinogen subunit, an advantageous conformation for cleavage. Additional models also 
revealed docking of cathepsin K around the D-domain of fibrinogen, regions where the 
fibrinogenolytic and fibrinolytic enzymes thrombin and plasmin, respectively, are known 
to bind for cleavage events. The helical domain of the fibrinogen subunit was where 
cathepsins K, L, and S hydrolysis of fibrinogen was most likely to occur. This contrasts 
with thrombin, where primary fibrinolysis is proposed to occur specifically in the E domain 
to generate fibrin monomers. The roles of thrombin, plasmin, and cathepsin as proteases 
associated with tissue formation implies that they can share similar binding and cleavage 
tendencies, indicated by their comparative interactions with fibrinogen. However, with 
differing amino acid compositions and substrate redundancy, cathepsins K, L, and S can 
display accessory roles in fibrinogen degradation or even fibrin generation. 
4.3.3  Cathepsin K cleavage likely in a and g chains of fibrinogen 
Simulated docking showed the active site of cathepsin K directly interacting with 
the helical subunits in the models, binding in regions that directly correlate to the predicted 
cleavage sites from PACMANS (Figure 4-1). For cathepsin K (Figure 4-1B), there were 
five top ranked PACMANS sequences in the a chain with corresponding molecular 
docking models and four top ranked PACMANS sequences in the b and g chain. From 
PACMANS, the greater the score, the more likely cleavage occurs and the normalized 
scoring allowed for comparison between cathepsins on each fibrinogen chain. Based on the 
culled PACMANS scoring information, the a chain in the helical region at residues #111-




score of 0.91). The next top scoring sequences was at residues #90-97 IQLT/YNPD in the 
g chain (score of 0.90), #202-209 KQLE/QVIA in the a chain (score of 0.87), and #179-
186 HQLY/IDET in the b chain (score of 0.85). Also, interestingly, the top scoring 
cleavage sequence in the g chain by cathepsin K, #90-97 IQLT/YNPD (score of 0.90), was 
five residues shifted from a known plasmin cleavage site on fibrin (QLIK/AIQL) [171].  
We focused on highest scoring PACMANS region that correlated with a docking 
site. For the a chain of fibrinogen (Figure 4-1A), there was only cathepsin K binding in the 
helical region. Within the sequence EILR/GDFS, hydrolysis was predicted between R95 
and G96, in an amphipathic cleavage site (Figure 4-2A). There appeared to be a possible 
electrostatic interaction between E111 sidechains of catK and R114 in the cleavage site, 
(Figure 4-2A) and this interaction could lock these residues in an extended conformation, 
exposing the main chain of arginine and glycine for cleavage by the catalytic triad.  
Similar trends were also seen in the b and g chains (Figure 4-2B-C). In the b chain, 
there was a possible electrostatic interaction between T186 and the backbone of Y182 of 
the fibrinogen cleavage site HQLY/IDET. Cleavage for this site was predicted between 
Y182 and I183 and the cleaved isoleucine would be able to form a hydrogen bond with 
Q180. While the current distance was 4.4 Å, the binding of fibrinogen b chain could 
promote a conformational change placing these residues within a distance suitable for 
molecular bonding.  




to bind with D97 within a hydrogen bonding distance of 2.9 Å, anchoring this fibrinogen 
cleavage site (Figure 4-2C). The ability for both intra- and inter-molecular bonding events 
to stabilize predicted cleavage sites was an interesting finding that can serve as a molecular 
basis for cathepsin K fibrinogenolysis.  
 
Figure 4-1. Top scored locations for cathepsin K binding and cleavage of fibrinogen. 
(A) Molecular docking of cathepsin K on fibrinogen monomer with the a chain is in red, 
the b	chain is in green, and the g chain is in blue. Cathepsin K bind in various formations 
and each color indicates a different docking model (note there is some overlap with the 
model found in cluster location B and E). Structures used were PDB ID 3GHG (fibrinogen) 
and 4N79 (cathepsin K). (B) Predicted fibrinogen cleavage sites by cathepsin K from 
PACMANS and molecular docking models. 





(111) EILR/GDFS (118) α 155 0.91 C
(202) KQLE/QVIA (209) α 152 0.87 B/E
(132) EDLR/SRIE (139) α 139 0.81 B
(73) LIDE/VNQD (80) α 135 0.83 D
(90) NSLF/EYQK (97) α 128 0.75 C
(179) HQLY/IDET (186) β 141 0.85 B
(105) LCPT/GCQL (112) β 137 0.84 D
(200) SILE/NLRS (207) β 144 0.83 B
(203) ENLR/SKIQ (210) β 133 0.78 B
(90) IQLT/YNPD (97) γ 154 0.90 C
(155) AQLE/AQCQ (162) γ 147 0.85 B
(114) KMLE/EIMK (121) γ 148 0.84 E






















Figure 4-2. Proposed binding interfaces of cathepsin K on each fibrinogen chain. 
Amino acid sequences of predicted cleavage sites for cathepsin K on fibrinogen (A) a 
chain, (B)  b chain, and (C) g chain were visualized in the docking models. The close up is 































(A) FIBRINOGEN ALPHA CHAIN
(B) FIBRINOGEN BETA CHAIN

















4.3.4 Cathepsin L has highest scored cleavage location in the a chain and greatest 
number of scored sequences in the b chain 
Cathepsin L docking sites multiple at cluster D where α, β, and γ cleavage as for E. 
A, B, and C docking sites did not have matching high PACMANS scores (Figure 4-3A). 
For cathepsin L (Figure 4-3B), the highest scoring sequence was found in the a chain at 
#111-118 EILR/GDFS (score of 0.82), and the top scoring site for cathepsin K cleavage as 
well (Figure 4-2A), followed by #185-192 ETVN/SNIP in the b chain (score of 0.80) and 
SILT/HDSS (score of 0.80) in the g chain. IQLT/YNPD (score of 0.75) in the fibrinogen γ 
chain was another likely cleavage site for cathepsin L and was a predicted cathepsin K 
cleavage site also.  
When cathepsin L binds to the a chain to sequence EILR/GDFS (Figure 4-4A), the 
flexible R114 can be stabilized by two cathepsin aspartates, D137 and D160, both within 
molecular bonding distance to the arginine amino groups, 2.8 and 2.9 Å respectively. An 
electrostatic interaction could ablate the flexibility of arginine, exposing the scissile bond 
for successful fibrinogen cleavage. This was a similar stabilizing mechanism when 
cathepsin L was bound to the b chain (Figure 4-4B), with E185 in proximity to N188 and 
S189 in the cleavage site of sequence ETVN/SNIP.  For the g chain (Figure 4-4C), the 
cleavage sites do not involve amino acids with flexible side chains, and therefore does not 
appear to be an amino acid in an advantageous position available for bond stabilization. 
However, T128 in the cleavage sequence SILT/HDSS is 5.2 Å from S125 and could 





Figure 4-3. Top scored locations for cathepsin L binding and cleavage of fibrinogen. 
(A) Molecular docking of cathepsin L on fibrinogen monomer with the a	chain is in red, 
the b  chain is in green, and the g chain is in blue. Cathepsin L binds in various formations 
and each color indicates a different docking model (note there is some overlap with the 
model found in cluster location B and D). Structures used were PDB ID 3GHG (fibrinogen) 
and 5F02 (cathepsin L). (B) Predicted fibrinogen cleavage sites by cathepsin L from 
PACMANS and molecular docking models. 





(111) EILR/GDFS (118) α 863 0.82 B/D
(132) EDLR/SRIE (139) α 789 0.75 E
(185) ETVN/SNIP (192) β 839 0.80 E
(196) RVLR/SILE (203) β 813 0.76 E
(135) EAVS/QTSS (142) β 776 0.74 B/D
(200) SILE/NLRS (207) β 750 0.71 E
(125) SILT/HDSS (132) γ 840 0.80 E
(90) IQLT/YNPD (97) γ 801 0.75 B/D




















Figure 4-4. Proposed binding interfaces of cathepsin L on each fibrinogen chain. 
Amino acid sequences of predicted cleavage sites for cathepsin L on fibrinogen (A) a chain, 
(B)  b chain, and (C) g chain were visualized in the docking models. The close up is rotate 












(A) FIBRINOGEN ALPHA CHAIN
(B) FIBRINOGEN BETA CHAIN






























4.3.5 Cathepsin S has highly scored locations of cleavage in the g and b chains in the 
helical region 
For cathepsin S, clusters B, D, and E had the most probable sites of binding (Figure 
4-5A). There were the most top ranked sequences from PACMANS and molecular docking 
models in the b chain of fibrinogen and the highest scoring sequence occurring in the g 
chain at AQLE/AQCQ (with a score of 0.86), same as for cathepsins K and L. The next 
highly scored sequence occurred in the b chain at EAVS/QTSS (score of 0.84) and in the 
a chain at EILR/GDFS (both with scores of 0.81). In the b chain, the sequence 
ENLR/SKIQ was also predicted as a cleavage site for both cathepsin S (0.78) and cathepsin 
K (0.78). 
The intramolecular interactions stabilizing cathepsin S when bound to fibrinogen 
were similar to those of cathepsins K and L. When cathepsin S binds to the a chain at 
sequence EILR/GDFS (Figure 4-6A), the same binding sequence of cathepsin K and 
cathepsin L with the highest PACMANS score, R114 is stabilized by a hydrogen bond with 
E111, identical to cathepsin K.  For the b sequence EAVS/QTSS (Figure 4-6B) and g 
sequence AQLE/AQCQ (Figure 4-6C), the scissile bond does not involve flexible side 
chains, however with the current rigid conformation Q139 can form a hydrogen bond with 
S143 in the b sequence. In the g chain, E158 can form a possible hydrogen bond with Q162 
in the cleavage sequence (Figure 4-6C). The availability of charged polar amino acids for 
intramolecular stabilization of flexible scissile bonds, and not necessarily for cleavage sites 




cathepsins can occur with intra-molecular bonding as a mechanism to facilitate successful 
cleavage of flexible scissile bonds. 
 
Figure 4-5. Top scored locations for cathepsin S binding and cleavage of fibrinogen. 
(A) Molecular docking of cathepsin S on fibrinogen monomer with the	a	chain is in red, 
the b chain is in green, and the gchain is in blue. Cathepsin S binds in various formations 
and each color indicates a different docking model (note there is some overlap with the 
model found in cluster location B and E). Structures used were PDB ID 3GHG (fibrinogen) 
and 4P6E (cathepsin S). (B) Predicted fibrinogen cleavage sites by cathepsin S from 
PACMANS and molecular docking models. 
  





(111) EILR/GDFS (118) α 592 0.81 D
(132) EDLR/SRIE (139) α 576 0.78 B/E
(135) EAVS/QTSS (142) β 614 0.84 D
(203) ENLR/SKIQ (210) β 572 0.78 B/E
(185) ETVN/SNIP (192) β 571 0.78 B/E
(196) RVLR/SILE (203) β 575 0.77 B/E
(132) NNVE/AVSQ (139) β 563 0.75 D
(200) SILE/NLRS (207) β 552 0.75 B/E
(128) DELN/NNVE (135) β 540 0.73 D
(155) AQLE/AQCQ (162) γ 632 0.86 B/E
(125) SILT/HDSS (132) γ 584 0.79 B/E


























Figure 4-6. Proposed binding interfaces of cathepsin S on each fibrinogen chain. 
Amino acid sequences of predicted cleavage sites for cathepsin S on fibrinogen (A) a chain, 
(B)  b chain, and (C) g chain were visualized in the docking models. The close up is rotate 





































(A) FIBRINOGEN ALPHA CHAIN
(B) FIBRINOGEN BETA CHAIN





Figure 4-7. Experimental validation of cleavage of fibrinogen by cathepsins K, L, and 
S. Fibrinogen was co-incubated with cathepsins K, L, and S for 24 hours at 37°C. Samples 
were resolved in a reduced 10% SDS-PAGE (A). Cathepsins K and L cleave fibrinogen in 
a similar manner to thrombin. However, cathepsin S degrades most of the Aα and Bβ 
polypeptide chains of fibrinogen releasing lower molecular weight fragments.  (B) 
Densitometry was used to quantify the 64kDa A(a) chain band, 56kDa B(β) chain band, 
and 47kDa γ chain band and revealed that all groups (fibrin, Cat L, Cat K, and Cat S) were 
statistically significantly less compared to fibrinogen (pH 6). #p<.0002, *p<.0001, 
&p<.005, n=3.  
4.3.6 Cathepsins K, L, and S cleave all three fibrinogen chains 
To experimentally confirm if cathepsins K, L, or S could cleave fibrinogen, equal 
amounts of fibrinogen was incubated separately with cathepsins K, L, or S for 24 hours at 
37°C (Figure 4-7A) followed by reducing SDS-PAGE. a, β, and γ bands are visible in the 
control lane and quantification of the amount of fibrinogen remaining after incubation was 
done with densitometry and normalized to that of the no enzyme control. There was a 
significant decrease (p<0.005) after fibrinogen was co-incubated with each cathepsin, but 










































the banding pattern of degradation was different for each enzyme. The most reduction 
occurring in the a chain by all three cathepsins (CatK a: 0.15 ± 0.03-fold, CatL a: 0.09 ± 
0.01-fold, CatS a: 0.06 ± 0.02-fold) (Figure 4-7B). Additionally, cathepsin S had the 
greatest reduction in all three fibrinogen chains (a: 0.06 ± 0.02-fold, b: 0.09 ± 0.03-fold,g: 
0.20 ± 0.11-fold) compared to cathepsins K and L. Cathepsin L showed the second most 
fibrinogenolysis activity (a: 0.09 ± 0.01-fold, b: 0.11 ± 0.03-fold, g: 0.16 ± 0.02-fold).  The 
g chain had the most amount intact after co-incubation with cathepsins and cathepsin L 
hydrolyzed the g chain the most (CatK g: 0.25 ± 0.05-fold, CatL g: 0.16 ± 0.02-fold, CatS 
g: 0.20 ± 0.11-fold). Cathepsin K showed the least amount of hydrolyzed fibrinogen overall 
(a: 0.15 ± 0.03-fold, b: 0.23 ± 0.06-fold, g: 0.25 ± 0.05-fold).   
4.4 Discussion 
 Human cysteine cathepsins have experimentally been shown to degrade fibrinogen 
(Figure 4-7) and cathepsins K, L, and S appear to do so differently, generating unique 
cleavage profiles. We computationally assessed where fibrinogen cleavage by cathepsin K, 
L, and S could be occurring by combining molecular docking and putative bioinformatics 
cleavage site predictions as two unbiased approaches to objectively determine putative sites 
based on electrostatics and defined amino acids that were preferred sites fitting into the 
protease active site cleft. We used molecular modeling to study possible electrostatic 
interactions between fibrinogen and cathepsins. We visualized the binding interactions of 
each cathepsin on each fibrinogen chain as well as predicted putative cleavage sites based 




predicted cleavage sites allowed for the discovery of alternative mechanisms of cathepsin-
mediated fibrinogen degradation. 
Much like fibrinogenolytic enzymes thrombin and plasmin, cysteine cathepsins 
studied here showed a preference for binding to the E-domain and the helical region (Figure 
4-1A, Figure 4-3A, Figure 4-5A), the same region where hydrolytic events causing fibrin 
formation (thrombin) and fibrin degradation (plasmin) occurs. The binding conformation 
was such that the active site of the cathepsin was facing the fibrinogen subunit, indicating 
that the active site had a high affinity for this region. We were limited by the crystal 
structure of fibrinogen, which does not include portions of the fibrinogen subunit due to 
either resolution or flexibility, however the molecular docking proposed binding sites in 
the range of the amino acid sequence visualized by the crystal structure were in high 
agreement with top ranked predicted cleavage sites from PACMANS. The preference for 
the E-domain, indicated by high PACMANS scores and docking models, provides specific 
amino acid locations for cathepsin binding and fibrinogen cleavage. The loops that 
compose the E-domain indicate a highly flexible region prone to cleavage and cathepsins 
may bind here and initiate cleavage on its composed chains. The b chain, which forms 
much of the globular region of the D-domain, has a binding site directly adjacent to this 
portion of the protein, which was also proximal to the region where crosslinking occurs for 
fibrin polymerization [172, 173], as well as a known cleavage site of plasmin cleavage.  
The binding regions on the a, b, and g chains of the fibrinogen subunit showed a 
high correlation with the predicted cleavage sites on fibrinogen by PACMANS. Taking all 




sites by cathepsin highlight the redundancy in substrate specificities of cathepsins with two 
a chain sequences, EILR/GDFS (catK score 0.91, catL score 0.82, catS score 0.81) and 
EDLR/SRIE (catK score 0.81, catL score 0.75, catS score 0.78), and one b chain sequence, 
SILE/NLRS (catK score 0.83, catL score 0.71, catS score 0.75), that were highly ranked 
cleavage sites by all three cathepsins and molecular docking models showed these as 
possible interactions. The redundancy in hydrolysis sites by cathepsins K, L, and S mirrors 
the redundancy also seen with tradition substrates [1], and the conserved nature of their 
active sites with the rest of protein having 60% sequence identity with this substrate and 
cathepsins. Cathepsins K and L were predicted to hydrolyze the fibrinogen g chain more 
similarly than cathepsin S with both having a cleavage sequence, IQLT/YNPD, a few 
amino acids away from a known plasmin cleavage of fibrinogen. Cathepsin K had thirteen 
predicted cleavage sites that also had supporting molecular docking models near those 
sequences, while cathepsin S had twelve sequences and cathepsin L had nine sequences.  
Cathepsin K also had a much greater potential for cleaving multiple locations in the a 
chain, with five cleavages sequences with corroborating molecular docking models 
compared to the two cleavage sequences for cathepsins L and S.  Likewise, cathepsin S 
had the greatest potential for cleaving in the b chain, with seven cleavage sequences with 
supporting molecular docking models compared to the four cleavage sequences for 
cathepsins K and L. Cathepsins S and L have a number of overlapping docking models that 
indicate cleaving in the b chain EAVS/QTSS (cathepsin S score 0.84, cathepsin L score 




(cathepsin S score 0.77, cathepsin L score 0.76) and in the g chain at SILT/HDSS (cathepsin 
L score 0.80, cathepsin S score 0.79). Also, it is interesting to note that although there was 
far more congruence in the number of b chain cleavage sequences (4), there was only one 
sequence found to be a top ranked PACMANS sequence for hydrolysis and had molecular 
docking models supporting binding at that location for cathepsins K, L, and S, whereas in 
the a chain, the overlap was for two cleavage sequences, which were both highly ranked 
cleavage locations for all three cathepsins.   
The docking models and predicted cleavage sites provide computational evidence 
of where cathepsins K, L, and S can bind and cleave fibrinogen. Further study of cathepsins 
bound to individual fibrinogen chains illustrated mechanisms of intra-molecular 
stabilization based on the cathepsins binding to cleavage sites predicted by PACMANS 
(Figure 4-2, Figure 4-4, Figure 4-6).  Whether the scissile bond involved a flexible or rigid 
side chain, the presence of nearby polar residues capable of molecular bonding portrayed 
fibrinogen as an easily accessible cleavage target for these cysteine cathepsins. While these 
models deal with rigid structures, the polarity of these residues supports the hypothesis that 
these residues and cleavage sites would be readily accessible for cleavage in a cellular 
environment.  Indeed, cathepsin expression by endothelial cells, fibroblasts, osteoclasts, 
and immune cells degrade intracellular proteins and complicated insoluble 
macromolecules like type I collagen and elastin. 
 Defining cysteine cathepsin-mediated fibrinolysis has many benefits. As novel 
fibrin-based tissue engineering constructs are being used exposing fibrin to novel cellular 




can be remodeled. We have recently demonstrated upregulation of cysteine cathepsins 
during the lifetime of a self-locomoting biological machine [128]. Further experimentation 
is needed to confirm the binding and cleavage sites identified by our computational 
techniques, however, this report, experimentally confirming cysteine cathepsin K, L, and 
S degradation of fibrinogen provides molecular docking evidence of its feasibility and 
stabilization of the intermediates and final products. Understanding this mechanism is 
important for regenerative medicine applications, especially when using fibrinogen 
polymerized gels as biocompatible, natural substrates and constructs implanted with cells, 





CHAPTER 5. INVESTIGATING THE LIFE EXPECTANCY AND 
PROTEOLYTIC DEGRADATION OF ENGINEERED SKELETAL 
MUSCLE BIOLOGICAL MACHINES 
This chapter was adapted from Cvetkovic, C.*, Ferrall-Fairbanks, M. C.*, et al. (2017). 
Investigating the life expectancy and proteolytic degradation of engineered skeletal muscle 
biological machines. Scientific Reports, 7:3775. doi:10.1038/s41598-017-03723-8 [128]  
5.1 Introduction 
The modular and scalable architecture of skeletal muscle tissue makes it an ideal 
power supply for producing force and locomotion – on a range of forces and time scales – 
in engineered living systems and biological actuators. Skeletal muscle is the primary 
actuating source for mammals, which are evolutionarily considered to be the highest life 
forms and capable of many complex behaviors and high-level functionalities [174-176]. A 
combination of techniques from the fields of 3D printing, tissue engineering, and 
biomaterials has recently yielded a new class of millimeter-to-centimeter scale skeletal 
muscle-powered biological robots (‘bio-bots’) capable of dynamic and adaptive responses, 
reliable force production, and untethered locomotion upon applied electrical [126] or 
optical [127, 177] signals. This forward-engineered biomaterial-muscle platform is ideal 
for introducing different cell types and biomaterials, and permits control over physical, 




 In vivo, skeletal muscle is supported by a basal lamina containing layers of 
connective tissue that provide a barrier from physical stress and damage [178, 179]. A 
combination of extracellular matrix (ECM) proteins, including the natural hydrogel of 
fibrin, acts as a bioinspired basement membrane mimic that provides cues and physical 
support to the cells in the engineered solid muscle strip of the bio-bots [126]. Though 
synthetic polymers have been used in the fabrication of some skeletal muscle constructs, 
the viscoelastic mechanical properties of natural proteins, such as fibrin, can be tuned to 
those of native connective tissue or skeletal muscle, rendering it a useful scaffold material 
for engineering a myriad of tissue types [180, 181]. However, maintaining consistent 
results becomes challenging when sustaining a living cellular system in vitro for weeks or 
months. Skeletal muscle must be preserved in a differentiated state at environmental 
conditions [175]. Moreover, the system is subject to degradation by cell-secreted proteases 
that can break down the mechanical integrity of the ECM in tissue and thus eventually lead 
to device failure, despite the presence of some protease inhibitors [126].  
The polymerization of fibrin into a 3D branching network is actively and equally 
opposed in a physiological equilibrium by fibrinolysis; despite cross-linking, the protein is 
extremely susceptible to degradation by cell-secreted enzymatic proteases [182, 183] 
(Figure 5-1). Plasmin is a serine protease secreted by many different cells to rapidly 
degrade fibrin [184, 185]. In skeletal muscle, inhibition of plasmin can result in fibrin build 
up and reduced myoblast fusion, differentiation, and regeneration [186]. Furthermore, 





Figure 5-1. Polymerization and Degradation of Fibrin. Fibrinogen is cleaved by 
thrombin to yield fibrin monomers that can be polymerized into protofibrils. The addition 
of the protease plasmin can lead to hydrolysis of the fibrin branching network, yielding 
degradation products. However, the anti-fibrinolytic inhibitor aminocaproic acid (ACA) 
can be added to prevent plasmin from becoming its active form. ACA binds to the lysine 
binding sites present on both plasmin and its activating agent plasminogen, which can be 
produced by C2C12s. ACA prevents plasmin from being activated and binding to (and 
subsequently degrading) fibrin by competitive and stoichiometric inhibition. 
matrix metalloproteinases (MMPs) must also be considered as contributors to fibrin 
network destabilization [187-189]. Cysteine cathepsins are powerful lysosomal proteases 
that degrade intracellular and extracellular matrix proteins and include the most powerful 
mammalian collagenase and elastase [1, 3, 5, 21, 130]; their upregulation during myogenic 
differentiation has been documented [187]. MMPs are another group of ECM-degrading 
enzymes involved in remodeling and maintenance of the ECM in both normal and 
pathological states [188, 189]. Specifically, MMP-2 and MMP-9 have been seen to be 
involved with skeletal muscle ECM remodeling in muscle satellite cell migration and 
differentiation, and are differentially regulated by cytokines and growth factors during 
these processes. While MMP-9 has been implicated in pre-fusion migration and in the early 





 Here we examine the life expectancy and breakdown of engineered skeletal muscle 
bio-bots by loss of form and function, as a result of degradation by three major classes of 
proteases: plasmin, cathepsin L (CatL), and MMPs (including MMP-2 and MMP-9). We 
first examined the effect of adding a serine protease inhibitor, aminocaproic acid (ACA), 
on the maintenance of machine life expectancy and structural integrity. We also 
demonstrate the use of gelatin zymography, a substrate gel electrophoresis technique, to 
determine the effects of differentiation time, inhibitor concentration, and electrical 
stimulation on temporal cysteine cathepsin and MMP expression within muscle strips. An 
experimental window under two weeks allowed for an increased understanding of the 
system on a shorter time scale. Finally, we demonstrate the ability to measure CatL and 
MMP activity while modifying certain design parameters involved in bio-bot fabrication. 
With this understanding of proteases secreted by these cells and concomitant matrix 
degradation, we are poised to design the next generation of machines with controllable gain 
and loss of function. Our studies can also have important applications in skeletal muscle 
based tissue engineering, muscles-on-a-chip, and related fields of studies. 
5.2 Materials and Methods 
5.2.1 Design and 3D Printing of Bio-Bot Skeleton 
Bio-bot skeletons and holders were fabricated using a commercial 
Stereolithography apparatus (SLA 250/50, 3D Systems) [126]. Briefly, parts were designed 
in CAD software (AutoCAD), exported in .STL format for slicing into layers (3D Lightyear 




modified as previously described [192, 193]. To print hydrogel beams with varying 
stiffness profiles, the polymerization energy of the SLA was changed by controlling two 
parameters according to a characterized Working Curve Equation [194, 195]. Bio-bot beam 
skeletons were polymerized with energy doses that ranged from 108.7 to 233.3 mJ cm-2 in 
order to obtain elastic moduli of 214 to 489 kPa, as detailed earlier [126]. The liquid 
hydrogel formulation was not altered. A skeleton beam of 319 kPa was used unless 
otherwise noted. 
Liquid pre-polymer hydrogel solutions were composed of bio-inert and 
biocompatible 20% poly(ethylene glycol) diacrylate of MW 700 g mol-1 (PEGDA 700, 
Sigma-Aldrich) or poly(ethylene glycol) dimethacrylate of MW 1000 g mol-1 (PEGDMA 
1000, Polysciences, Inc.) [126, 177]. After fabrication, skeletons and holders were rinsed 
in PBS, sterilized in 70% EtOH, and stored in sterile PBS until use.  
5.2.2 Cell Culture and Seeding 
C2C12 murine myoblasts were proliferated in growth medium (GM) and passaged 
before confluence. For optogenetic bio-bots, ChR2-C2C12s were used, as previously 
described [177, 196]. GM consisted of Dulbecco’s Modified Eagle Medium (DMEM, 
Corning Cellgro) with 10% (v/v) fetal bovine serum (FBS, VWR) and 1% (v/v) each of L-
glutamine and penicillin-streptomycin (both Corning Cellgro). For the seeding of muscle 
strips, bio-bot skeletons were placed in polymerized holders and aspirated of excess liquid. 
5 x 106 cells ml-1 (final concentration of myoblasts in cell-gel solution, unless otherwise 




(30% of total volume, Corning), fibrinogen (4 mg ml-1, Sigma-Aldrich), and thrombin from 
bovine plasma (0.5 U mg-1 fibrinogen, Sigma-Aldrich). The cell-gel solution was added to 
each holder (day 0) and incubated for 1.5 hr before adding warm GM. All cells and cultures 
were maintained at 37 ºC and 5% CO2. 
 
Figure 5-2. Timeline of Bio-Bot Development and Analysis. Skeletal muscle bio-bots 
were fabricated and seeded on day 0. On day 3, DM was added to induce differentiation 
of skeletal muscle. Electrical or optical stimulation was applied on days 4-12, as noted. 
Samples were snap frozen for gelatin zymography on days 3, 6, 8, and 12. 
5.2.3 Skeletal Muscle Differentiation and Stimulation 
After 3 days in GM, bio-bots were released from the holders and switched to 
differentiation media (DM), consisting of DMEM with 10% (v/v) heat-inactivated horse 
serum (HS, Gibco), 1% (v/v) each of L-glutamine and penicillin-streptomycin, 50 ng ml-1 
of insulin-like growth factor (IGF-1, Sigma-Aldrich), and ACA as noted: 0 mg ml-1 (0x 
ACA), 1 mg ml-1 (1x ACA), or 3 mg ml-1 (3x ACA). Media was changed daily. Electrical 
stimulation was applied using a custom-built setup [126, 197] starting on day 4 (Figure 
5-2). Bio-bots were placed in warm DMEM between two sterilized Pt electrodes and a 
current was applied perpendicular to the longitudinal axis of the muscle strip with the 




total stimulation per day. Optical stimulation of ChR2-C2C12 optogenetic bio-bots was 
applied as previously described [177], starting on day 4, at 1 Hz frequency for 10 min total 
stimulation per day. 
5.2.4 Force and Diameter Measurements 
Images of the bio-bots were taken using a stereomicroscope (MZ FL III, Leica 
Microsystems) with a digital camera (Flex, SPOT Imaging Solutions). The Measure Tool 
in ImageJ software (National Institutes of Health) was used to measure muscle strip 
dimensions from top-view (diameter) and side-view (passive tension) images. The passive 
tension force of the muscle strip was calculated using an equation derived from Euler-
Bernoulli linear beam theory: 𝐹3 = (8𝐸𝐼/𝑙𝐿.	)𝛿*=>, where E is the elastic modulus (319 
kPa [126], unless otherwise noted), I is the moment of inertia of the bio-bot beam, L is the 
beam length, l is the moment arm between the beam and muscle strip, and 𝛿*=> is the beam 
deflection. 
5.2.5 Viability Assays  
Cell viability was quantitatively determined using a metabolic colorimetric assay 
by incubating muscle strips in CellTiter 96 AQueous One Solution (MTS, Promega) and 
DMEM without phenol red (LifeTechnologies) in a 5:1 (v/v) ratio in the dark at 37 ºC. 
After 4 h, absorbance was measured at 490 nm using a microplate reader (Synergy HT, 
BioTek). The absorbance of a blank sample without cells was subtracted from each reading, 




5.2.6 Immunofluorescence and Histology 
Muscle strips were removed from bio-bot skeletons and rinsed in PBS. For 
fluorescent staining, tissues were fixed in 4% paraformaldehyde (Electron Microscopy 
Services) for 30 min and permeabilized with 0.25% Triton X-100 (Sigma-Aldrich) for 10 
min. After blocking in Image-iT® FX (Molecular Probes) overnight at 4ºC, muscle strips 
were incubated with MF-20 (1:400, Developmental Studies Hybridoma Bank, The 
University of Iowa) and anti-sarcomeric α-actinin primary antibodies (1:400, Abcam) 
overnight at 4ºC, rinsed 3x with PBS, and incubated with Alexa Fluor® 488 goat anti-
mouse and Alexa Fluor® 568 goat anti-rabbit (both 1:400, ThermoFisher) overnight at 4ºC 
in the dark. Muscle strips were rinsed 3x with PBS, incubated with 4’,6-diamindino-2-
phenylindole (DAPI, 1:5,000 in sterile DI water, Sigma-Aldrich) for 10 min, rinsed, and 
imaged with a confocal microscope (LSM 710, Zeiss). For histology, frozen muscle strips 
were embedded in OCT compound (TissueTek), cut into 14 µm sections using a cryostat 
(CM3050, Leica), mounted on glass slides, stained with a Masson’s Trichrome kit 
(Polysciences, Inc.), and imaged using a digital pathology slide scanner (C9600, 
NanoZoomer). 
5.2.7 Muscle Strip Nucleic Acid Extraction and Assay 
Muscle strips were removed from bio-bot skeletons, snap frozen in liquid nitrogen, 
and stored at -80 ºC until use. Before RNA isolation, tissues were lysed using a rotor-stator 
homogenizer (TissueRuptor, Qiagen). Total RNA was then extracted using an RNeasy 




isolate total genomic DNA from muscle strips. The concentration of DNA or RNA was 
measured at 260 nm with a spectrophotometer (NanoDrop 1000).  
5.2.8 Muscle Strip Protein Extraction and Assay  
Muscle strips were snap frozen in liquid nitrogen and stored at -80 ºC until use. 
Upon thawing, muscle strip cells were digested in lysis buffer with freshly added 0.1mM 
leupeptin (Calbiochem) for zymography and Western blotting, or RIPA buffer (Thermo 
Scientific) for total protein measurements and muscle creatine kinase (MCK) assays. Lysis 
buffer consisted of 20 nM Tris–HCl at pH 7.5, 5 mM ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (Sigma-Aldrich), 20 mM β-glycerolphosphate 
(Alfa Aesar), 150 mM NaCl (BDH), 1 mM sodium orthovanadate (Sigma-Aldrich), 10 mM 
NaF (Sigma-Aldrich), 1% Triton X-100 (EMD Chemicals), and 0.1% Tween-20 (Fisher 
Scientific) [135]. After sonication and centrifugation, the protein extract supernatant was 
collected. Using a Pierce BCA Protein Assay Kit (Thermo Scientific), total muscle strip 
protein content was measured at 562 nm with a spectrophotometer. Extracted protein 
supernatant was used to determine MCK production using a Liquid Creatine Kinase 
Reagent Set (Pointe Scientific), and absorbance was measured at 340 nm with a microplate 
reader. 
5.2.9 Cathepsin and MMP Zymography 
Protocols for multiplex zymography to detect mature cathepsins K, L, S, and V 




detection of pro- and mature forms of MMP-2 and MMP-9 [198]. For gelatin zymography, 
SDS-PAGE gels (12.5% for cathepsins, 10% for MMPs) were impregnated with 5 mg ml-
1 soluble gelatin substrate. Samples were prepared with a non-reducing loading dye (5× − 
0.05% bromophenol blue, 10% SDS, 1.5 M Tris, 50% glycerol) and separated by 
electrophoresis resolved at 200V for 1 h at 4°C. Gels were washed in renaturing buffer and 
then incubated in assay buffer overnight, specific to proteases being probed. Renaturing 
buffer contained 65 mM Tris buffer at pH 7.4 with 20% glycerol for cathepsins, and 2.5% 
Triton-X 100 for MMPs. Assay buffer contained 0.1 M sodium acetate buffer at pH 4.0, 1 
mM EDTA, and freshly added 2 mM dithiothreitol for cathepsins, and 50 mM Tris-HCl at 
pH 7.4, 10 mM CaCl2, 50 mM NaCl, and 0.05% Triton X-100 for MMPs. After overnight 
incubation, gels were stained for 2 h in 4.5% Coomassie blue stain (Sigma-Aldrich) with 
10% acetic acid and 25% isopropanol. Gels were then destained with 10% isopropanol and 
10% acetic acid, and imaged with an ImageQuant LAS 4000 (GE Healthcare). 
Densitometry quantification of white band intensity (indicating active protease) was 
preformed using ImageJ, and all results were normalized to day 3 (the start of muscle 
differentiation). In all results, one representative gel image is shown for each experiment. 
5.2.10 Western Blots 
Muscle strip protein extracts were prepared with loading dye with the additional of 
β-mercaptoethanol, boiled for 5 min, and loaded into a 12.5% SDS-PAGE gel. Proteins 
were separated by molecular weight under electrophoresis resolved at 150V and then 




(Bio-Rad) at 10V for 30 min. Membranes were blocked for at least 1 h in Odyssey Blocking 
Buffer (LI-COR Bioscience) diluted 1:2 in PBS, then incubated with primary antibodies 
(1:1000) for goat polyclonal mouse cathepsin L (R&D Systems), or rabbit polyclonal 
cystatin C (Millipore) overnight at 4°C with constant agitation. Proteins were detected with 
a LI-COR Odyssey scanner using anti-goat or anti-rabbit secondary antibodies (1:5000 
with 0.1% Tween, Invitrogen) tagged with an infrared fluorophore. Densitometry was 
preformed using ImageJ, and results were normalized to day 3. 
5.2.11 Statistical Analysis  
Results are presented as mean ± standard error of the mean (SEM) as noted in figure 
captions. Statistical analyses included tests for significance (one-way ANOVA followed 
by Tukey’s Multiple Comparison Test, performed using OriginPro software, or two-tailed 
t-tests, performed using Microsoft Excel) and survival (Kaplan-Meier analysis, performed 
using OriginPro software). For muscle strip life expectancy and survival analysis, outliers 
were calculated using the Interquartile Range Rule. Any data points outside of 1.5 × IQR 
(interquartile range) from the 1st or 3rd quartiles were omitted.  
5.3 Results 
5.3.1 Development and Maturation of Skeletal Muscle Bio-Bots 
The freestanding skeletal bio-bot consisted of an engineered muscle strip coupled 
to a fabricated hydrogel skeleton, or a scaffold consisting of a flexible beam connected by 




in which the force from a contractile muscle is transmitted to a bone through an adjoining 
tendon4. We used stereolithographic 3D printing, a rapid manufacturing technique that 
prints a structure with customizable geometric and mechanical parameters in a layer-by- 
layer fashion [194, 195, 199-201], to polymerize the bio-bot skeleton from a synthetic 
biocompatible hydrogel. 
C2C12 myoblasts at a density of 5 x 106 cells ml-1 were mixed with ECM proteins 
including fibrinogen, thrombin, and MatrigelTM; the liquid suspension was added to a 3D 
printed holder and began to cross-link into a gel. The cells applied traction forces to 
compact the tissue into a solid muscle strip around the pillars of the hydrogel skeleton. 
After three days in proliferation media, the bio-bot (consisting of the hydrogel skeleton and  
attached muscle strip) was released as a freestanding biological machine. Myoblasts were 
then induced to differentiate with the addition of horse serum and insulin-like growth factor 
(IGF-1) [202]. Striated, multinucleated myotubes were visible throughout the muscle strip 
(Figure 5-3A).  
Over the course of the experiment, the total DNA present in the muscle strips 
increased over ten-fold, from 2.1 ± 0.8 on day 3 to 23.8 ± 3.4 µg on day 12. The total 
protein content per muscle strip increased as well, and was significantly amplified on day 
12 (356.8 ± 33.5 µg) compared to day 3 (235.7 ± 44.7 µg, Figure 5-3B). The activity of 
muscle creatine kinase (MCK), which is expressed in mature skeletal muscle only after 
differentiation [203] and thus served as a quantitative gauge of myogenesis, was 
significantly increased as early as day 6 and reached a maximum output of 560.4 ± 44 U 





Figure 5-3. Development and Differentiation of Skeletal Muscle Bio-Bots. (A) Modular 
bio-bots were assembled and differentiated in a stepwise manner. (i) A Stereolithography 
apparatus (SLA) was used to 3D print a millimeter-scale hydrogel skeleton and holder. (ii) 
C2C12s were mixed with a liquid solution of ECM proteins that included fibrinogen, 
thrombin, and Matrigel. (iii) When added to the holder, the cell-gel solution compacted to 
form a solid muscle strip. Scale bar, 2 mm. (iv) The freestanding bio-bot (consisting of the 
muscle strip coupled to the hydrogel skeleton) could be released from the holder and 
subjected to electrical or optical stimulation. (v) Immunostaining revealed the presence of 
striated and multinucleated myotubes (α-actinin, red; MF-20 myosin, green; DAPI nuclear 
stain, blue). Scale bar, 50 µm. (B) Total DNA and protein levels increased over the time 
course of the experiment (n = 3-4 muscle strips per time point). There was no statistically 
significant difference in protein/DNA ratios between days 8 (17 ± 2.8 µg protein µg DNA-
1) and 12 (15.7 ± 2.5 µg protein µg DNA-1). (C) Muscle creatine kinase (MCK) activity was 
significantly increased as early as day 6, and reached a maximum output on day 12 (n = 3 
muscle strips per time point). The rate of increased MCK activity slowed between days 8 
and 12, confirming that this was a relevant stopping point for the experiments. All plots 
represent mean ± SEM. * indicates significance (p < 0.05) between conditions at the same 
time point; ^ indicates significance compared to initial time point.  
5.3.2 Cathepsin and MMP Zymography without ACA 
Multiplex zymography was used to examine the activity of cell-secreted or cell-
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various time points (Figure 5-4A). Polyacrylamide gels were impregnated with gelatin to 
create a substrate that could be degraded by active proteases. Muscle strips were lysed and 
loaded for zymography. After protein separation by electrophoresis, gels were washed in a 
renaturing buffer that allowed proteins to re-fold into their native conformation, and then 
incubated in assay buffer overnight for optimal enzyme activity to degrade the substrate. 
Both renaturing and assay buffers were specific to the proteases examined. Gels were 
stained with Coomassie Blue stain, which stains all proteins, and then destained; areas of 
white bands indicated proteolytic activity. On the cathepsin zymogram, bands were 
identified for Cathepsin L, both unbound (CatL, 25-37 kDa) and bound to matrix proteins 
in the muscle strip tissue (CatL+tissue, 75 kDa; Figure 5-4B). On the MMP zymogram, 
bands were identified at 62-72 and 82-92 kDa, pertaining to MMP-2/pro-MMP-2 and 
MMP-9/pro-MMP-9, respectively (Figure 5-4C). 
In the absence of any anti-fibrinolytic treatment (0x ACA), muscle strips produced 
active cathepsins and MMPs, and the amount of active enzyme increased over the course 
of 12 days. The activity of each protease was quantified by densitometry and normalized 
to the beginning of skeletal muscle differentiation on day 3. On day 12, the amount of 
active CatL displayed a significant (3.9 ± 1.1-fold) change, and amount of active 
CatL+tissue increased by 2.8 ± 0.9-fold. Electrical stimulation of muscle strips 
significantly increased the expression of both active CatL and CatL+tissue (5.5 ± 1.1 and 
3.5 ± 0.7-fold compared to day 3, respectively; Figure 5-4B). Additionally, the amount of 





Figure 5-4. Gelatin Zymography of Cathepsins and MMPs without ACA. (A) Muscle 
strip zymography process flow. (i) Degrading muscle strips were removed from hydrogel 
skeletons. (ii) Muscle strips could be fixed and stained for further analysis. (iii) Tissues 
were digested in lysis buffer. Isolated proteins were run through gel electrophoresis. (iv) 
Gels were incubated in renaturing and assay buffers. (v) Gels were stained with Coomassie 
Blue; bright bands indicated the activity of specific proteases, which were separated by 
molecular weight. (B) Cathepsin zymography identified the activity of CatL and 
CatL+tissue at days 3, 6, 8, and 12, in the presence or absence of electrical stimulation (n 
= 3-5 muscle strips per condition). (C) MMP zymography identified the activity of MMP-
2 and MMP-9 at days 3, 6, 8, and 12, in the presence or absence of electrical stimulation 
(n = 3-5 muscle strips per condition). For MMP zymograms, upper bands reflect inactive 
enzyme (proMMP) and lower bands reflect active enzyme. (D) Western blotting confirmed 
the presence of cathepsins and related proteins, such as CysC (n = 3-5 muscle strips per 
condition). All plots represent mean ± SEM. ^ indicates significance (p < 0.05) compared 
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and 1.3 ± 0.5-fold) and without electrical stimulation (1.6 ± 0.4 and 1.6 ± 0.7-fold; Figure 
5-4C). Western blotting confirmed the identity of two mature isoforms of the cysteine 
protease CatL (including heavy chain [204] CatL), as well as the presence of cystatin C 
(CysC), an endogenous cysteine protease inhibitor. Pro-forms of both MMPs and CatL 
were also present (Figure 5-4D). 
5.3.3 Muscle Strip Life Expectancy 
Breakdown of the muscle strip was defined as detachment from the hydrogel 
skeleton (Figure 5-4A), rendering the bio-bot non-functional. In the absence of any anti-
fibrinolytic treatment (0x ACA), muscle strips demonstrated an average life expectancy of  
 
Figure 5-5. Bio-Bot Life Expectancy. (A) In the absence of any anti-fibrinolytic treatment 
(0x ACA), muscle strips demonstrated an average life expectancy of 8.2 ± 0.5 days until 
rupture. However, incubation in medium with the serine protease inhibitor ACA 
lengthened the life expectancy of the muscle strips. Box plots represent 25th, 50th, and 75th 
percentiles, with average values marked as (x) and whiskers representing ± SEM. Data are 
presented to the left of the boxes (n = 6-13 muscle strips per condition, excluding outliers). 
* indicates significance (p < 0.05) between time points. (B) Kaplan-Meier survival analysis 
provided an additional method of comparison by plotting survival fraction of each 








































































8.2 ± 0.5 days until rupture (Figure 5-5A). However, incubation of the serine protease 
inhibitor ACA in medium lengthened the life expectancy of the muscle strips; addition of 
1 mg ml-1 (1x) and 3 mg ml-1 (3x) ACA significantly increased the averages to 17 ± 3.9 
and 94 ± 31.9 days until rupture, respectively. Kaplan-Meier survival analysis provided an 
additional method of comparison between treatment groups (Figure 5-5B). For those 
muscle strips which remained unruptured on the order of months, passive tension remained 
statistically unchanged on day 140 (4.6 months) compared to early values; furthermore, 
some muscle strips treated with 3x ACA continued to contract spontaneously and in 
response to electrical stimulation after 210 days (7 months). Finally, increasing the 
concentration of ACA did not significantly alter cellular viability in the muscle strips 
(126.6 ± 15% for 1x ACA and 139 ± 7.8% for 3x ACA on day 12 normalized to day 3).  
5.3.4 Loss of Tissue Structure and Mechanical Integrity 
Over the time course of the experiment, muscle strips began to degrade (most 
notably, in the middle region of the tissue) in the absence of anti-fibrinolytic treatment 
(Figure 5-6A). Five days after cell seeding, 0x ACA muscle strips displayed cross-sectional 
diameters already significantly reduced from those treated with the inhibitor (2.1 ± 0.08 
versus 2.4 ± 0.06 mm for 3x ACA). On day 12, the diameters of all groups were 
significantly reduced (a range of 73.1 ± 6.8 to 78.4 ± 7% from their day 5 values). The 0x 
ACA muscle strips displayed a lower passive tension and faster decrease in static force 
over time compared to both 1x and 3x ACA treated muscle strips. As early as day 8, the 





Figure 5-6. Loss of Tissue Structure and Mechanical Integrity. (A) Muscle strips began 
to degrade (most notably, in the middle region of the tissue), as shown in top-view images. 
Though the diameters of all groups on day 12 were reduced, the addition of 3x ACA helped 
to maintain the integrity of the tissue longer (n = 2-9 muscle strips per condition). Scale 
bar, 1 mm. (B) Muscle strips cultured without ACA displayed a lower passive tension and 
faster decrease in static force over time. After day 8, the passive tension was significantly 
lower for 0x muscle strips (n = 4-7 per time point) compared to both 1x (n = 5-6 per time 
point) and 3x ACA (n = 5-7 per time point). Scale bar, 1 mm. All plots represent mean ± 
SEM. * indicates significance (p < 0.05) between conditions at the same time point; ^ 
indicates significance compared to initial time point. (C) Histological staining for 
Masson’s Trichrome indicated that the addition of ACA helped to maintain the ECM in 
muscle strips. Scale bar, 200 µm. 
247.1 µN, compared to 1327.6 ± 86 and 1509.5 ± 106.7 µN for 1x and 3x ACA, 
respectively (Figure 5-6B). Neither application of daily electrical stimulation nor 
increasing the concentration of ACA beyond 1x caused any statistical difference in average 
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Trichrome, a connective tissue stain, indicated that the addition of ACA helped to maintain 
the presence of ECM proteins supporting the differentiated myotubes (Figure 5-6C). 
5.3.5 Cathepsin and MMP Zymography with 1x and 3x ACA  
In the presence of a serine protease inhibitor, muscle strips cultured with 1x and 3x 
ACA continued to produce active cathepsins and MMPs. On day 12, the amount of active 
CatL displayed a 0.9 ± 0.2-fold change with 1x ACA and a 0.7 ± 0.3-fold change with 3x 
ACA compared to day 3. The amount of active CatL+tissue displayed a 1.2 ± 0.2-fold 
change with 1x ACA and a 2.3 ± 0.1-fold change with 3x ACA, significantly increased 
from day 3 (Figure 5-7A). Both the amount of active MMP-2 and MMP-9 increased by 
day 6, but decreased below day 3 levels on day 8. On day 12, MMP-2 was again 
upregulated (1.1 ± 0.3-fold and 1.3 ± 0.5-fold change for muscle strips cultured with 1x 
and 3x ACA), while levels of active MMP-9 continued to decrease significantly compared 
to day 3 levels (0.5 ± 0.2-fold and 0.5 ± 0.2-fold change for muscle strips cultured with 1x 
and 3x ACA) (Figure 5-7B). 
However, when comparing muscle strips cultured with 0x ACA to those cultured 
in 1x and 3x ACA after 12 days, we observed a reduction in the amount of active protease 
that was statistically significant for CatL (0.9 ± 0.2-fold and 0.7 ± 0.3-fold, compared to 
3.9 ± 1.1-fold for 0x), but not significant for MMP-2 or MMP-9 (Figure 5-8). Increasing 
the ACA concentration beyond 1x did not further enhance this reduction in active CatL, 
and electrical stimulation did not significantly alter the expression of any of the cathepsins 





Figure 5-7. Gelatin Zymography of Cathepsins and MMPs with 1x and 3x ACA. (A) 
Cathepsin zymography identified the amount of active CatL and CatL+tissue at days 3, 6, 
8, and 12, in the presence or absence of electrical stimulation, for 1x and 3x ACA (n = 3-
6 muscle strips per condition). (B) MMP zymography identified the amount of active MMP-
2 and MMP-9 at days 3, 6, 8, and 12, in the presence or absence of electrical stimulation, 
for 1x and 3x ACA (n = 4-7 muscle strips per condition). All plots represent mean ± SEM. 
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Figure 5-8. Comparison of Active Cathepsins and MMPs in 0x, 1x, and 3x ACA 
Cultured Muscle Strips. (A) Cathepsin zymography identified the amount of active CatL 
and CatL+tissue and (B) MMP zymography identified the amount of active MMP-2, and 
MMP-9, with and without electrical stimulation, for day 12 conditions compared to the 
initial time point of day 3. (C) ACA prolonged the lifetime and reduced the amount of active 
CatL in locomoting biological machines. All plots represent mean ± SEM. * indicates 
significance (p < 0.05) between conditions at the same time point; ^ indicates significance 
compared to initial time point. 
pro-form of CatL, as well as the presence of CysC (Figure 5-9).  
5.3.6 Varying Hydrogel Skeleton Stiffness and Cell Seeding Density 
The hydrogel-muscle platform was modified to introduce tunable variations in the 
muscle strip as well as the 3D printed skeleton [126]. First, to test the hypothesis that 
concentration of cells within the muscle strip affected the amount of active proteases 
produced, muscle strips seeded at a density of 5 x 106 cells ml-1 were compared to those  
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Figure 5-9. Western Blotting of CatL in Muscle Strips with ACA. (A) Western blotting 
confirmed the presence of cathepsins and related proteins in muscle strips cultured with 
1x and 3x ACA over time. (B) Western blotting of CatL, with and without electrical 
stimulation, for day 12 conditions compared to the initial time point of day 3 (n = 4-7 
muscle strips per condition). All plots represent mean ± SEM. * indicates significance (p 
< 0.05) between conditions at the same time point; ^ indicates significance compared to 
initial time point. 
with 2.5 and 10 x 106 cells ml-1. On day 12, though a decreased cell density caused a 
significant increase in CatL, other measurements of active CatL and CatL+tissue showed 
no significant change compared to muscle strips with 2.5 or 10 x 106 cells ml-1 cultured in 





Figure 5-10. Gelatin Zymography of Cathepsins and MMPs in Muscle Strips Varying 
Cell Density. (A) For day 12 muscle strips cultured with 1x ACA and fabricated with 
varying cell densities (2.5, 5, or 10 x 106 cells ml-1), cathepsin zymography identified the 
amount of active CatL and CatL+tissue and (B) MMP zymography identified the amount 
of active MMP-2 and MMP-9. Zymogram signal for n = 3-4 muscle strips per condition 
was quantified for active cathepsins (C) and MMPs (D). All plots represent mean ± SEM. 
* indicates significance (p < 0.05) between conditions at the same time point; ^ indicates 
significance compared to initial time point. 
change compared to muscle strips with 2.5 or 10 x 106 cells ml-1 cultured in 1x ACA (Figure 
5-10B, D). 
Next, to assess whether cells in the muscle strip responded differently when 
subjected to a varying degree of static force, we altered the mechanical microenvironment 
felt by the myotubes during differentiation by 3D printing hydrogel skeletons with varying 
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Figure 5-11. Gelatin Zymography of Cathepsins and MMPs in Muscle Strips Varying 
Hydrogel Stiffness. (A) For day 12 muscle strips cultured with 1x ACA with a hydrogel 
skeleton stiffness of 214, 319, or 489 kPa, cathepsin zymography identified the amount of 
active CatL and CatL+tissue and MMP zymography identified the amount of active MMP-
2 and MMP-9. Zymogram signal for n = 3-4 muscle strips per condition was quantified for 
active cathepsins (B) and MMPs (C). (D) Western blotting confirmed the presence of 
cathepsins in muscle strips with varying hydrogel stiffness, for day 12 conditions compared 
to the initial time point of day 3. All plots represent mean ± SEM. * indicates significance 
(p < 0.05) between conditions at the same time point; ^ indicates significance compared to 
initial time point. 
strips coupled to hydrogel beams with a modulus of 319 kPa (an optimal stiffness used in 
previous bio-bot demonstrations that combined a robust mechanical structure with 
sufficiently high deflection necessary for locomotion [126, 177]) had retained their passive 
tension over time (Figure 5-6C). Muscle strips cultured in 1x ACA for 12 days in higher 
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significant change in the amount of active CatL or CatL+tissue compared to those on 
skeletons with a stiffness of 319 kPa (Figure 5-11A-B). Though MMP-2 showed a 
downward trend with increasing tension, there was no significant change for either MMP-
2 or MMP-9 in an environment of higher or lower tension (Figure 5-11A, C). Western 
blotting corroborated the presence of the pro-form of CatL as well as CysC in these muscle 
strips (Figure 5-11D). 
5.3.7 Optical Stimulation of ChR2-C2C12 Muscle Strips 
To test if dynamic optical stimulation of muscle strips contributed to an increase in 
protease activity, bio-bots were fabricated using ChR2-C2C12s (myoblasts infected to 
express an optogenetic ion channel [177]). ChR2-C2C12 optogenetic bio-bots were 
cultured in 1x ACA and subjected to daily optical stimulation by an external blue light 
pulse that depolarized the cells to produce contraction. The muscle strips from ChR2-
C2C12 optogenetic bio-bots were collected on day 6 (to compare to non-optogenetic bio-
bots) and on day 12 (to compare to both non-optogenetic bio-bots as well as ChR2-C2C12 
bio-bots without optogenetic stimulation) for zymography (Figure 5-12A). Just as daily 
electrical stimulation had not altered the expression of CatL or MMP-2 over 12 days, the 
application of daily optical stimulation for ChR2-C2C12 optogenetic bio-bots did not have 
a significant impact on the amount of active CatL, CatL+tissue, MMP-2 or MMP-9 (Figure 
5-13). Finally, there was no fundamental difference between ChR2-C2C12 and non-
optogenetic muscle strips with regards to the amount of active cathepsins or MMPs at either 





Figure 5-12. Gelatin Zymography of Cathepsins and MMPs in Muscle Strips Varying 
Applied Stimulation. (A) Cathepsin zymography identified the amount of active CatL and 
CatL+tissue and (B) MMP zymography identified the amount of active MMP-2, and MMP-
9, with and without electrical or optical stimulation. (C) Amount of active CatL, 
CatL+tissue, (D) MMP-2, and MMP-9 on days 6 and 12, for both non-optogenetic bio-
bots as well as ChR2-C2C12 bio-bots without optogenetic stimulation. (E) Amount of 
active CatL, CatL+tissue, (F) MMP-2, and MMP-9 on day 12, for both non-optogenetic 
bio-bots subjected to electrical stimulation and ChR2-C2C12 bio-bots subjected to optical 
stimulation. 3 (G) Western blotting confirmed the presence of cathepsins in ChR2-C2C12 
muscle strips on days 6 and 12, with and without optical stimulation (n=3 muscle strips 
per condition). All plots represent mean ± SEM. ^ indicates significance (p < 0.05) 





Figure 5-13. ChR2-C2C12 Optogenetic Bio-Bots. (A) For ChR2-C2C12 optogenetic 
muscle strips, cathepsin zymography identified the amount of active CatL and CatL+tissue 
at days 6 and 12, and (B) MMP zymography identified the amount of active MMP-2 and 
MMP-9 at days 6 and 12, in the presence or absence of optogenetic stimulation (n=3 
muscle strips per condition). All plots represent mean ± SEM. * indicates significance (p 
< 0.05) between conditions at the same time point; ^ indicates significance compared to 
initial time point (day 6). 
trends in active CatL, CatL+tissue, MMP-2 and MMP-9 expression as electrical 
stimulation (Figure 5-12C-F). Western blotting confirmed the presence for pro-form of 
CatL and CysC in the ChR2-C2C12 optogenetic bio-bots (Figure 5-12G). 
5.4 Discussion 
The role of the basal lamina is of critical importance in providing necessary 
elasticity and strength, as well as key binding sites for sequestration of myogenic growth 
factors, during muscle development. Laminin-2, collagen IV, and proteoglycans are 
present in abundance in skeletal basal lamina. In the hydrogel-muscle platform of the 
skeletal muscle bio-bots, natural ECM proteins comprise a bioinspired engineered system 
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physiological arrangement. After myoblasts withdraw from the cell growth cycle and 
commit to a myogenic lineage during differentiation, they migrate to (and then physically 
fuse with) other myoblasts to create multinucleated myotubes with one cytoplasm, and 
increase expression of muscle-specific genes in adult muscle fibers [187, 202, 205]. The 
cells in the muscle strips exhibited these morphological and genetic changes, observable 
by immunostaining (Figure 5-3A) and the presence of mature muscle proteins (Figure 
5-3C). During injury, a similar process of migration and fusion is observed by quiescent 
satellite cells, or myoblast progenitors, present in the basal lamina [206]. 
In vivo, protease activity is regulated by a strict balance between expression, 
activation, and inhibition; this balance plays a major role in the degree of matrix 
degradation and resulting cellular processes [190]. In vitro, degradation and resulting 
instability are drawbacks to tissue engineering with fibrin, and an inhibitor such as the anti-
fibrinolytic agent ACA [184] must be incorporated to prevent indiscriminate matrix 
digestion in systems lasting longer than a few hours. Incubation with increasing 
concentrations of ACA helped to preserve the structural integrity of the fibrin muscle strips 
and significantly increased the lifetime before rupture (Figure 5-5). Though the serine 
protease inhibitor aided in the maintenance of passive tension in the muscle strips over 
time and slowed the degradation of muscle strips at earlier time points, it did not 
significantly reduce tissue loss by day 12 (Figure 5-6); thus, the need for an investigation 
of the other protease families, including cysteine cathepsins and MMPs, was apparent. 
In gel zymography is a versatile method used to determine protease activity by 




antibodies, is relatively inexpensive, and allows for visual confirmation of enzyme identity 
(and determination of active quantity) by molecular weight separation, zymography is 
useful in the study of both cathepsins and MMPs [134, 135] across a number of tissue types 
[56, 122, 207, 208]. Using a well-characterized technique wherein electrophoresis 
separated proteases of interest from muscle strip lysate [134, 135], we temporally 
quantified the amount of active cathepsins as well as MMPs in various culture conditions 
(Figure 5-4B, Figure 5-7, Figure 5-8, Figure 5-13). Cathepsins are implicated in a number 
of tissue-destructive disease states as well as mechanisms of normal tissue physiology, 
including myogenic differentiation [36, 39, 94, 134, 208, 209]. CatL has been recognized 
as a major player in muscle atrophy and wasting [187, 205]. We observed that the amount 
of active CatL present in the muscle strips increased steadily over time, and was most 
highly expressed in the absence of ACA. Its activity on day 12 was significantly higher in 
all 0x muscle strips compared to 1x and 3x ACA, both with and without electrical 
stimulation (Figure 5-8C), indicating that the presence of ACA may prevent some 
processes associated with physiological muscular breakdown and potentially reduce the 
expression of CatL. There is also prior evidence suggesting ACA may inhibit proteolytic 
activity by lysosomal cysteine cathepsins [210, 211]. These hypotheses could explain the 
extended lifetime observed in the presence of ACA and why this process is independent of 
electrical stimulation. 
MMPs comprise a range of proteases capable of degrading all ECM proteins. Like 
cathepsins, they are also involved in many normal mammalian cell processes (such as 




pathologies. Their role in myogenic differentiation, development, and injury is primarily 
extracellular, and they have been shown to interact with specific ECM proteins over varied 
timelines [212]. Cellular alignment, differentiation of adult myofibers, or remodeling of 
muscle tissue architecture is a direct result of MMPs degrading ECM proteins, which may 
hinder myoblast migration and fusion [189, 206]. They can also be activated (directly or 
indirectly) by other proteolytic enzymes including plasmin and plasminogen [191], which 
are present in our system. Both MMP-2 and MMP-9 can act on various collagen substrates, 
some of which are localized in our engineered muscle strips due to the presence of 
MatrigelTM [189]. 
Expression of MMP-9 has been shown to be upregulated in C2C12 myoblast 
cultures during migration and before cell fusion [188, 206]. The processes concerning 
mature myotube formation then witness a decrease in expression over time. We observed 
a decline in amount of active MMP-9 at later time points in muscle strips cultured with 1x 
and 3x ACA (Figure 5-7B, Figure 5-12D, F, Figure 5-13B). Since upregulation of MMP-
9 is also associated with early acute inflammation and initiation of muscle regeneration in 
proliferating and migrating satellite cells [206], it is likely that only the earlier stages of 
muscle strip compaction and differentiation involve processes that resemble the 
recruitment (and subsequent fusion) of satellite myoblasts after injury. 
MMP-2, which is secreted by C2C12s, is constitutively produced in lower levels in 
healthy adult muscle and does not play a large role in myoblast migration or fusion. It is 
involved more heavily in later stages of C2C12 myofiber differentiation [188, 190, 206]. 




5-7B, Figure 5-8C), suggesting that while myogenic differentiation was observed, the 
complete extracellular remodeling of matrix proteins that accompany later stages of 
muscular maturation may not have been visible during this experimental timeline. Though 
a short-term investigation proved relevant for this application of biological machines, an 
investigation on a longer time scale would provide more detailed temporal data on 
expression of specific MMPs as well as cathepsins. Additionally, levels of MMP-2 (which 
can be secreted by satellite cells) increase gradually during later stages of injury, then return 
to baseline levels, suggesting an important role in repair and regeneration of new muscle 
fibers [188, 190]. The introduction of deliberate inflammation or injury to the muscle strips 
could test this hypothesis in future studies. 
The fabrication of skeletal muscle bio-bots offers flexibility in varying almost any 
parameter in the system. We also investigated the effect of altering certain variables whose 
effects on bio-bot functionality we have previously reported: cell density, hydrogel 
stiffness [126], and dynamic optogenetic stimulation [177]. Varying these conditions 
revealed that the amount of active cathepsin and MMP was largely independent of these 
environmental changes or applied stimuli. When the cell seeding density for muscle strip 
formation was varied, the amount of active cathepsin and MMP was statistically unchanged 
(Figure 5-10). MMP-2 increased slightly as the cell concentration was increased to 10 x 
106 cells ml-1, though not significantly; it is possible that the increase in initial myoblast 
density accelerated the fusion and differentiation process. MMP-2 has been shown to 




When muscle strips were differentiated under higher static tension, the amount of 
active cathepsin L decreased, although again not significantly (Figure 5-11). Interestingly, 
the amount of active MMP-2 and MMP-9 both decreased in the presence of higher static 
tension (Figure 5-11C), despite an extracellular presence in a condition that favors higher 
degrees of myofiber alignment and differentiation. This may indicate reduced myotube 
formation in these bio-bots under higher tension.  
Finally, when ChR2-C2C12 optogenetic bio-bots were subjected to optical 
stimulation, we observed no change in the amount of active CatL or MMPs (Figure 5-12, 
Figure 5-13). Though electrical stimulation is a useful tool because it allows for the global 
and coordinated stimulation of all excitable cells within the muscle strip, optical 
stimulation provides a less invasive and more specific alternative by increasing 
spatiotemporal control over contraction and locomotion [177, 213]. These results indicate 
that neither the use of optogenetic cells nor optical stimulation altered proteolytic 
expression profiles associated with myogenic differentiation or injury, and confirm that the 
electrical stimulation is not responsible for the observed proteolytic activity by cathepsins 
and MMPs.  
In engineered living systems, biological building blocks – different cell types or 
tissues in an instructive environment – can be assembled to promote the emergence of 
cellular systems with well-defined functionality, allowing for the realization of dynamic 
cellular machines with the ability to interface with the environment and other living 




critical to design systems with a specific life expectancy and exhibit greater consistency. 
Forward engineering of biological and mechanical properties, along with knowledge of 
how these factors affect protease activity, can dictate a system’s sustainability. A machine 
designed to ‘fail’ or ‘break’ within a certain time frame (after performing a specific task, 
for example), could be programmed to upregulate expression of proteases through 
inflammatory cytokines such as TNF-α, which are known to accelerate overexpression or 
activation of some proteases [94, 188]. On the other hand, the addition of a protease 
inhibitor (such as the strong-binding endogenous cysC [4, 71, 134], the broad-spectrum 
cathepsin inhibitor E-64 [71, 94, 134], or tissue inhibitors of metalloproteinases (TIMPs) 
[189, 214]) could aid in prolonging the machine’s lifespan by lowering the amount of active 
proteases. Most likely, the majority of future engineered living systems will require an 
intricate balance between the activity and inhibition of serine and cysteine proteases as they 
exist and function together in a complex, inter-connected proteolytic network [215, 216]. 
The ratio between proteases and their inhibitors (such as the important equilibrium required 
between MMPs and TIMPs in skeletal muscle [188, 189, 191, 206]) is critical to 
maintaining a balanced state. 
Looking forward, as neuromuscular control and vascularization are introduced into 
engineered living systems, it will be critical that we understand what proteases are involved 
in these processes and how the cells may adapt to the new environment. Proteolysis of the 
basal lamina is critical in angiogenesis, and MMP-2 and membrane-type 1 (MT1) MMP 
involvement has been seen in capillary growth [188]. Furthermore, MMP-2, MMP-7, and 




together, these highlight the importance of recognizing that the proteases that appear to be 
involved in normal muscle strip development will also be involved in these other cellular 
processes, and must be accounted for in future development of engineered living systems.  
Finally, because skeletal muscle cathepsins can also hydrolyze myogenic proteins such 
as myosin, troponin T, and tropomyosin [205, 217], it may also be worth examining 
whether the activity of these proteases in intracellular degradation (and subsequent 
breakdown or atrophy of muscle fibers) contributes in any way to failure of the engineered 
muscle system. Lastly, increased expression and regulation of cathepsins [205, 218] and 
MMPs [36] has been observed in dystrophic muscles; therefore this platform could also be 
used for the study of disease-specific models and treatments of diseases such as muscular 





CHAPTER 6. ENGINEERING BIOLOGICAL MACHINE 
LIFESPAN THROUGH PROTEOLYTIC DEGRADATION  
6.1 Introduction 
 Locomoting biological machines powered by skeletal muscle strips produce 
increasing amounts of cathepsin L over a 12 day timeline [128].  As described in Chapter 
5, modifying different biological machine design parameters (cell seeding density, 
hydrogel stiffness, electrical stimulation, and optogenetic stimulation) does not alter the 
cysteine cathepsin protease activity of these bio-bots. Biological treatment with 
aminocaproic acid (ACA), which prevents plasmin, the known fibrin degrading protease, 
from becoming its active form (Figure 5-1) can prolong the life expectancy of the 
biological machines. At a low concentration of ACA (1X), the average time until bio-bot 
breaking went from 8.2 ± 0.5 days to 17 ± 3.8 days and at a high concentration of ACA 
(3X), the average time of breaking is prolonged until 105.5 ± 31.1 days (Figure 5-5). While 
ACA lengthens expected survival time of these biological machines, the large variability 
in when the bio-bots break currently cannot be controlled.    
 Here we examined the life expectancy of these engineered living systems to 
determine ways to control the time until failure. We demonstrated that specifically 
inhibiting the cysteine cathepsin activity of these muscle strips reduces the cathepsin bound 
to muscle strip matrix, without affecting overall muscle strip viability and passive tension.  




function commonly used to model lifetime distributions in reliability engineering, to 
describe the functional lifetime distributions of biological machines. Using the protease 
activity of these machines, we developed a model to predict the life expectancy of these 
engineered living systems, which can be used to design interventions to control the time 
until bio-bot failure.    
6.2 Materials and Methods 
6.2.1 Zymography   
In-gel zymography was used to detect active cysteine cathepsins in bio-bot muscle 
strip samples.  This modified SDS-PAGE used a gel impregnated with either 5 mg ml-1 
soluble gelatin substrate or 5 mg ml-1 soluble fibrinogen substrate. Samples were prepared 
in a non-reducing loading dye and separated by electrophoresis at 4°C. Gels were washed 
in a renaturing buffer to refold enzymes and then incubated in assay buffer overnight at 
37°C for optimal protease activity. The following morning gels were stained with 
Coomassie blue and destained with white bands indicative of protease activity. Gels were 
imaged with an ImageQuant LAS 4000 (GE Healthcare) and densitometry using ImageJ 
(NIH) was used to quantified the intensity of the white bands and is reported as the average 
value ± the standard error of the mean (SEM).     
6.2.2 Biological machine muscle strip parameter evaluation  
Biological machine cell culture development was the same as described in the 




from growth media to differentiation media of DMEM with 10% (v/v) heat-inactivated 
horse serum (HS, Gibco), 1% (v/v) each of L-glutamine and penicillin-streptomycin, 50 ng 
ml-1 of insulin-like growth factor (IGF-1, Sigma-Aldrich). E-64, the cysteine cathepsin, 
broad spectrum, small molecular inhibitor was added to differentiation media at 5 µM and 
10 µM concentrations. Media was changed daily. Bio-bot muscle strips samples were 
collected at day 3, day 12, day 30, and day 90. 
The passive tension force of the muscle strip was calculated using an equation 
derived from Euler-Bernoulli linear beam theory as described in Section 8.2.4. The elastic 
modulus for these bio-bots were 319 kPa.  Cell viability was compared between day 3 and 
day 12 samples using a metabolic colorimetric assay described in Section 8.2.5. Muscle 
creatine kinase (MCK), a marker of muscle cell differentiation, was assayed using Liquid 
Creatine Kinase Reagent Set (Pointe Scientific) as described in Section 8.2.8.  
6.2.3 Using Weibull distribution to describe biological machine survival  
Previously, the biological machine survival was determined and reported as a Kaplan 
Meier survival function, which converted the “age” of which individual bio-bots failed to 
a survival function. Kaplan Meier is popularly used because it can handle cases where 
participants “drop-out” and cannot be followed over the entire course of a study. However, 
we can track all the biological machines until they break, which opens additional methods 




Weibull frequency distribution was implemented in MATLAB and the probability density 
function can be described by:  






𝑒E >/= G (2) 
where 𝑎 was the scale parameter, 𝑏 was the shape parameter (also called the Weibull slope), 
and 𝑥 was the time until failure. The Weibull frequency distribution is often used to model 
the breaking strength of materials and other reliability engineering lifetime distributions. 
Weibull distribution parameters were determined for the 0X, 1X, and 3X biological 
machine time until failure data. All code associated with determining the Weibull 
parameters for these datasets is included in Appendix D.     
6.2.4 Biological machine survival model development 
A percolation theory model was developed using MATLAB to predict the bio-bot 
lifespan based on reported survival functions. This two-compartment model has (1) a 
muscle strip compartment and (2) a protease compartment.  The muscle strip compartment 
was composed of a 2D grid representing fibrin(ogen)/extracellular matrix at each time step 
cycling through each node in the network, the protease compartment generates an amount 
of cathepsin, which if less than the Pcleavage threshold results in a cleavage edge. At the end 
of the time step, the number of connected edges was calculated and if it is below a certain 
probability of broken, the muscle strip was broken and that time of failure was recorded. If 




survives to the next time point. The protease compartment was composed of linear models 
of increasing cysteine cathepsin activity extrapolated form the protease characterization 
described in Chapter 8.  The two main parameters of this model were the Pcleavage and Pbroken 
thresholds, which were estimated based on the Weibull distribution for the biological 
machines. The code describing this model is included in Appendix D.  
6.3 Results 
6.3.1 E-64 treated biological machines reduced cathepsin bound to matrix 
Chapter 8 characterizes the cysteine cathepsin and MMP proteolytic activity of 
these biological machines [128]. Cysteine cathepsins and MMPs have known 
collagenase/gelatinase activity [2, 3, 21, 170, 220, 221], however the major matrix protein 
in these bio-bot muscle strips was fibrin [126-128].  Cysteine cathepsins are not well 
established in the literature as fibrinogenolytic proteases, however Chapter 6 explored and 
confirmed the proteolytic potential for cysteine cathepsin hydrolysis of fibrin(ogen). Since 
biological machines secrete cathepsin L, we adapted the multiplex cathepsin gelatin 
zymography protocol to use a fibrinogen substrate, instead of gelatin substrate, to verify 






Figure 6-1. Fibrinogen zymography confirms fibrinogenolysis by bio-bot cathepsin L. 
Bio-bot cathepsins have increasing fibrinogenolysis over time.  
 
 
Figure 6-2. Gelatin zymography of E-64 cultured muscle strips. (A-B) Cathepsin 
zymography identified a dose dependent decrease in the amount of CatL+tissue and (C-D) 
MMP zymography identified an increase in the amount of active MMP-2, for day 12 
conditions compared to the initial time point of day 3. All plots represent mean ± SEM. * 
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Once confirming that the cathepsins secreted by the bio-bots can degrade 
fibrinogen, we explored the effects of specifically inhibiting the cysteine cathepsin in these 
biological machines. E-64, the broad spectrum, small molecule cysteine cathepsin inhibitor 
[99-101], was added to the bio-bot differentiation media starting on day 3 and the 
proteolytic activity of these machines was assayed by gelatin zymography on day 12 when 
treated with a low (5 µM) and high (10 µM) concentration of E-64 (Figure 6-2). The 
cathepsin L bound to muscle strip tissue (75kDa, catL+tissue) at Day 12 of E-64 was 
significantly reduced in a dose-dependent manner compared to Day 12 1X ACA bio-bots 
from 3.80 ± 0.34 to 2.67 ± 0.12-fold at a low concentration of E-64 and 2.24 ± 0.13-fold at 
a high concentration of E-64 (Figure 6-2A, B). Furthermore, there was a concurrent 
increase in total MMP-2 with the E-64 treatment compared to the Day 12 1X ACA bio-
bots from 1.08 ± 0.05 to 4.51 ±  1.20-fold at a low concentration of E-64 and 5.43 ± 2.06-
fold at a high concentration of E-64 (Figure 6-2C, D). This increase in active MMP may 
be a result of a shift in the muscle strip’s proteolytic network through cysteine cathepsin 
inhibition.   
6.3.2 E-64 does not negatively impact biological machine key metrics 
 The cell viability of muscle strip cells was quantified by incubating the muscle strip 
with a metabolic colorimetric solution (CellTiter 96 AQueous One Solution, MTS, 
Promega) in the dark at 37°C for 4h, then absorbance was measured at 490 nm using a 
microplate reader. Muscle strips showed increased in percentage of viable cells at day 12 




12 with increasing concentrations of E-64 (Figure 6-3A). Furthermore, muscle creatine 
kinase (MCK) is a marker of mature skeletal muscle, expressed after differentiation [203].  
Previously, muscle strips reached a maximum MCK activity output by day 12, which was 
also seen with the E-64 treated bio-bots.  There was no significant difference between the 
MCK activity of muscle strips with increasing concentrations of E-64 at day 12 (Figure 
6-3B).  
 E-64 treatment did not affect the functional output, muscle strip passive tension, of 
biological machines.  Figure 6-3C compares the passive tension in the muscle strips by day 
12 and there was no significant difference between the treatment conditions.  Furthermore, 
there was no difference between adding 1X ACA or low dose (5 µM) of E-64.  Long-term 
passive tension also did not show any significant difference due to treatment conditions 
(Figure 6-3D).  Increasing E-64 from the low to high concentration did not greatly increase 
passive tension, but combination of E-64 and ACA treatments appeared to have a greater 
impact.  
 Preliminary data for the impact of E-64 on life expectancy of the biological 
machines was very encouraging. Table 6-1 records the known days at which bio-bots have 
broken with one of three treatments: (1) 5 µM and 0X ACA, (2) 5 µM and 1X ACA, or (3) 
10 µM and 1X ACA. Treatment condition (1), which had comparable passive tension to 
1X ACA treated bio-bots previously described, had at least a 3.5-fold increase in life 
expectancy (an average of 59.3 days with 5 µM E-64 only treated compared to 17 days 




bio-bots (as of 5/20/2017) for each of the conditions. It was important and encouraging to 
note that both the combination treatments of E-64 and ACA treated biological machines 
have multiple bio-bots still functioning by day 121. If we assumed that all the remaining 
bio-bots were to break on 5/20/2017, the average life expectancies of each E-64 treatment 
condition would be 2.6 to 3.8-fold improved compared to the 1X ACA treated bio-bots 
(treatment condition 1 would be 44.6 ± 10.6 days, treatment condition 2 would be 62.9 ± 
22.6 days, and treatment condition 3 would be 64.6 ± 17.3 days).  
 
 
Figure 6-3. E-64 does not impact cell viability, MCK activity, and passive tension in 
E-64 cultured muscle strips. 
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Table 6-1. Life expectancy of E-64 cultured muscle strips. 
 
6.3.3 Weibull distribution describes biological machine lifespan  
 The Weibull distribution is a function used in reliability engineering and used 
to model lifetime distributions for properties such as breaking strength of materials. 
Here we applied the Weibull distribution to model the life expectancy of biological 
machines and determine unique scale and shape parameters for each ACA 
concentration ( 
Table 6-2, Figure 6-4). While there were very different Weibull parameters for each of the 
three distributions, there appeared to be a relationship between the two Weibull parameters 
and the treatment concentration of ACA. Figure 6-5 shows the value of the scale parameter 
and shape parameter plotted as a function of ACA concentration. Equation 3 describes the 
relationship between the scale parameter (a) and ACA with an R2 value of 1:  
𝑎 = 8.8946 ∗ 𝑒/.MNON∗[QRQ] (3) 
Equation 4 describes the relationship between the shape parameter (b) and ACA with an 
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𝑏 = 4.8667 ∗ 𝑒E/.UV.∗[QRQ} (4) 
While there were currently only three data points, this trend seemed encouraging.  This 
relationship may also extend to predicting the life expectancy of E-64 treated bio-bots, if 
we assumed that 1X ACA = 5 µM of E-64, then for 10 µM of E-64, the expected Weibull 
parameters would be: a = 42.21 and b = 1.582, which would be an average life expectancy 
of 37.9 days.  
 
Figure 6-4. Fitted Weibull Distribution of Bio-Bot Life Expectancy. The blue curve 
represents the empirical cumulative distribution function of 0X, 1X, and 3X ACA cultured 
bio-bots. The red curve represents the fitted Weibull distribution and the dotted red curves 
represent the 95% confidence bounds of the estimated Weibull distribution parameters. 
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Figure 6-5. Weibull parameters represented as a function of ACA concentration. 
Weibull Parameter Confidence Interval 
0X Life Expectancy
a = 8.800 [7.931, 9.765]
b = 5.552 [3.712, 8.303]
1X Life Expectancy
a = 19.29 [13.27, 28.06]
b = 2.227 [1.289, 4.024]
3X Life Expectancy
a = 92.42 [46.78, 182.6] 
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Figure 6-6. Schematic of Bio-Bot Life Expectancy Model. 
6.3.4 Developing model to predict biological machine lifespan 
 Figure 6-6 illustrates a schematic representation of the biological machine life 
expectancy model and all the MATLAB code for model implementation is documented in 
Appendix D. There were two main compartments, the protease compartment, which output 
an amount of protease that was input into the muscle strip compartment, where the protease 
amount determines if cleavage of the matrix would occur in the fibrin(ogen)/ECM grid. 
The protease compartment was extrapolated from the known increases of cysteine 
cathepsin over time, where the fold-change increases determine in Chapter 5 were related 
to a physical amount of recombinant cathepsin as demonstrated in Figure 6-7.  The protease 
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simulations resulting in more protease than the 1X and 3X ACA models, like the 
relationship depicted in Figure 5-8.   
 
Figure 6-7. Quantified amount of active cathepsin was used to information the life 
expectancy model's protease compartment. 
 In the muscle strip compartment, a 2D lattice graph was created, where the edges 
represent the cleavable fibrin(ogen)/ECM matrix.  This graph had post locations removed 
to recapitulate an approximate geometry of the bio-bot muscle strip.  At each time point, 
cycling through each node, a protease amount was generated from the protease 
compartment dependent upon the current time and ACA concentration. If that amount was 
less than the Pcleavage threshold, then one of the edges of that node was selected uniformly 
at random within the neighborhood of the selected node.  The Pcleavage was weighted by the 
number of edges for the node being analyzed, because it was expected that matrix 
degradation exhibits spatiotemporal locality.  At the end of the time point, the fraction of 
the graph’s nodes contained in the largest connected component was compared to the Pbroken 
threshold. If the largest connected component contained at least Pbroken of the nodes in the 
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considered to have failed and that functional lifetime was collected for cumulative 
distribution function and Weibull distribution parameter estimation after all model 
simulations were completed. The Pcleavage and Pbroken each had ±25% variability in attempts 
to account of the large variability seen in the life expectancy of the biological machines. 
 Then a grid search was run to determine if there was a combination of Pcleavage and 
Pbroken, using this model construct, that could give the Weibull distribution parameters to 
describe the 0X, 1X, and 3X life expectancies.  The results of the grid search are 
represented in Figure 6-8. The top panels describe Weibull distribution scale parameter (a, 
left) and shape parameter (b, right) for 0X ACA cultured bio-bots. The middle panels 
describe Weibull distribution parameters for 1X ACA cultured bio-bots and the bottom 
panels describe the parameters for 3X ACA cultured bio-bots. The relative error was 





where the 𝑡𝑟𝑢𝑒	𝑣𝑎𝑙𝑢𝑒 was the point-estimate of the parameters described in  
Table 6-2 and the 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑	𝑣𝑎𝑙𝑢𝑒 was the estimated Weibull distribution parameter for 
the given Pcleavage and Pbroken pair determined after 200 muscle strip simulations. The shape 
parameters (b) are related to the inverse variance of the lifetimes, thus there were some 
parameters with large values of b, including cases of b=infinity, when all simulated bio-




 Unfortunately, using only these two thresholds as the model parameters and the 
protease compartment, as currently constructed, was not sufficient to recapitulate the 
Weibull distribution parameters estimated for the 0X, 1X, and 3X bio-bot life expectancies 
in  
Table 6-2. However, various ranges of Pcleavage provided the best estimates for the 
two different Weibull distribution parameters. The scale parameter (a) appeared to be 
tightly bounded to a Pcleavage of 0.1 to 0.2 and increasing concentrations of ACA appeared 
to become independent of Pbroken.  Across the three ACA concentrations, if we only needed 
to accurately describe the scale parameter, then a Pcleavage of 0.1 and Pbroken on 0.25 fit the 
best across the life expectancies (Figure 6-9A). The shape parameter (b) had the smallest 
errors at larger Pcleavage thresholds (0.25 to 0.40).  The shape parameter also appeared to be 
independent of Pbroken thresholds.  Across the three ACA concentrations, if we only needed 
to (1) accurately describe the shape parameter, and (2) minimize the Pcleavage to 
accommodate the scale parameter, then a Pcleavage of 0.25 and Pbroken on 0.25 fit the best 
across the life expectancies (Figure 6-9B).  Comparing these solutions, the best fitting scale 





Figure 6-8. Compiled grid search results of the relative error for different 
combinations of Pcleavage and Pbroken on the Weibull distribution parameters for the life 
expectancy of 0X, 1X, and 3X cultured biological machines. 
































































































Figure 6-9. Best fit Pcleavage and Pbroken threshold pairs compared to biological machine 
life expectancies. The blue curve represents the empirical cumulative distribution function 
of 0X, 1X, and 3X ACA cultured bio-bots. The dotted red curve represents the 95% 
confidence interval empirical cumulative distribution function. The purple curve 
represents the Weibull distribution based on the best Pcleavage and Pbroken threshold pair for 
(A) the scale parameter and (B) the shape parameter. 
6.4 Discussion 
Currently, most of the locomoting biological machines will only show electrically 
induced contractility for 8 days following formation, without any intervention. As more 
advance biological machines are constructed, more cell types will be in contact with each 
other and may alter the machine’s proteolytic profile. Therefore, protease interactions with 

























3X ACA Weibull Distribution vs Model Fit 

























1X ACA Weibull Distribution vs Model Fit 

























0X ACA Weibull Distribution vs Model Fit 
Best Scale Parameter (a) found at Pcleavage = 0.1 and Pbroken = 0.25 






































3X ACA Weibull Distribution vs Model Fit 

























1X ACA Weibull Distribution vs Model Fit 
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the machine’s matrix and how they interact with each other are important in the design of 
stable biological machines. Then these proteolytic activities can be commandeered as a 
designed benefit of the biological machines rather than a destructive mechanism to wreak 
havoc on machine stability. 
Previously we have characterized the protease activity of these biological machines 
(described in detail in Chapter 5), which produce an increasing amount of cathepsin L over 
time, independent of electrical stimulus and modulating of bio-bot design parameters 
(initial cell seeding density, backbone hydrogel stiffness, and optogenetic stimulus). Here 
we show that the cathepsin L secreted by these biological machines had fibrinogenolytic 
activity (Figure 6-1) as detected by a fibrinogen zymography protocol adapted from the 
well-established multiplex cathepsin zymography. Furthermore, culturing these biological 
machines with E-64, the small molecule cathepsin inhibitor, resulted in a dose-dependent, 
significant reduction in amount of active cathepsin L bound the muscle strip matrix proteins 
(Figure 6-2). Culturing biological machines with E-64 did not affect cell viability, MCK 
activity, and passive tension in muscle strips (Figure 6-3) and showed an increase in 
average lifespan of bio-bots from 8.2 days to 59.3 days, which was 3.5-fold greater than 
bio-bots cultured with 1X ACA, which functioned for an average of 17 days.  These results 
further support that cathepsin L proteolysis destabilizes the bio-bot muscle strips. Here, 
along with some modeling described in Chapter 4, we underscore cathepsin L as an 




living systems, where fibrin-based constructs are now being exposed to non-traditional 
proteolytic environments.  
In addition to lengthening functional time of these biological machines through 
inhibiting cysteine cathepsin proteolysis, we also investigated other survival analyses that 
would better describe life expectancies of biological machines over the Kaplan Meier 
analysis described in Section 5.3.3. The Weibull distribution is commonly used in 
reliability engineering to model lifetime distribution of different materials. Applying the 
Weibull distribution, we determined the Weibull parameters (a, scale parameter and b, 
shape parameter) for the life expectancy of biological machines cultured in 0X, 1X, and 
3X ACA (Figure 6-5). For Weibull distributions, the scale parameter, a, is considered an 
approximation of the mean time to failure. The shape parameter, b, gives insight into the 
type of failure, where for b > 1 indicates an increasing failure rate over time, b = 1 indicates 
a constant failure rate, and b < 1 indicates a decreasing failure rate over time.  From the 
biological machines’ Weibull distributions, the shape parameter 0X and 1X ACA cultured 
muscle strips were 5.552 and 2.227, respectively, which suggested that these muscle strips 
had an increasing failure rate over time, or “wear-out” failures.  However, the 3X ACA 
cultured muscle strips had a shape parameter of 0.96, which indicated a constant failure 
rate or random failures. Upon further analysis, it appeared that there was a relationship 
between Weibull parameters and ACA concentration. While there were only three 
concentrations of ACA studied and more would be need to better define this relationship, 




relationship could be used to engineer the average lifetime and mechanism of failure of 
future biological machines. Furthermore, this relationship may also be applied to E-64 
culture biological machines, since functional biological machine output appear equivalent 
for 1X ACA cultured and 5 µM E-64 cultured bio-bots.   
Finally, a two-compartment percolation theory model, informed by the proteolytic 
activity described in Chapter 5 was developed to see if we could re-capitulate the Weibull 
distribution life expectancies for 0X, 1X, and 3X cultured bio-bots. The two main 
parameters of the model were Pcleavage and Pbroken thresholds.  The model created a 2D graph, 
where the edges represented the matrix to be cleaved, and at each time point a protease 
amount was determined at each node. If that protease amount was below the Pcleavage 
threshold, one of the edges of that node was randomly removed.  After cycling through all 
the nodes, the fraction of nodes still connected was computed, if this fraction was above 
the Pbroken threshold, the muscle strip went into the next time step, otherwise the failure data 
was recorded. Two hundred muscle strips were simulated at each Pcleavage-Pbroken threshold 
pair and the Weibull distribution parameters were computed.  
A grid search through various Pcleavage and Pbroken thresholds was performed to 
determine if there was a combination that would recapitulate the Weibull distributions that 
describe the bio-bot life expectancies (Figure 6-8). While this grid search did not return 
accurately predict the bio-bot life expectancies, there were some valuable insights learned 
that can be applied to future iterations of the model.  First, the scale parameter (a) was an 




The scale parameter was also tightly constrained by the Pcleavage between 0.1 and 0.2 giving 
the best fits (Figure 6-9A). Both the scale parameter and the shape parameter (b) appeared 
to be mostly independent of the Pbroken, which suggest that this should be held constant in 
future model iterations.  Higher Pcleavage thresholds resulted in reduced error for the shape 
parameter, however qualitatively the fits to the bio-bot life expectancy data was far worse 
(Figure 6-9B). This model was only informed by the proteolytic activity of these bio-bots, 
which was based off a 12-day time frame, however, many of these bio-bots (especially 
when cultured with 1X and 3X ACA) survive much longer and we currently don’t have 
any information on how the protease activity changes on that time scale. During bovine 
muscle development, there is a drop in cathepsin L activity from day 85 to day 200 [222], 
which approximated based on comparison of cow and mouse gestation period, would 
indicated a drop in bio-bot muscle strip cathepsin L activity from day 6 to day 14, just 
outside 12 day time frame we have characterized. Furthermore, mechanical forces and 
stresses may play an important role in the lifetime distribution and is another avenue that 
can be explored in later iterations of this model. 
In summary, inhibiting cysteine cathepsin proteolytic activity can lengthen life 
expectancy of biological machines without negatively effecting cell viability and muscle 
strip passive tension. We have shown here that cathepsin L produced by these muscle strips 
has fibrinogenolytic activity, which further supported that cathepsin L destabilized muscle 
strip integrity. Our findings demonstrate that a Weibull distribution accurately models the 




relationship between Weibull parameters and ACA concentration, which can be used to 
predict biological machine life expectancy for intermediate concentrations of ACA a 





CHAPTER 7. CATHEPSIN CANNIBALISM: A REGULATORY 
MECHANISM OF CATHEPSIN PROTEOLYSIS  
This chapter was adapted from Ferrall-Fairbanks, M.C., Kieslich, C.A., and Platt, M.O. 
Cathepsin cannibalism: A regulatory mechanism of cathepsin proteolysis. Manuscript in 
preparation. 
7.1 Introduction 
 Traditionally enzymes are investigated by biochemists in isolation and assumed to 
be inert to the reaction it is catalyzing. However, cells secrete many proteases 
simultaneously during normal function and disease progression. It is difficult to analyze 
how these proteases interact cooperatively or antagonistically and researchers have only 
recently started to investigate these types of interactions [7, 129, 215, 216]. Cysteine 
cathepsins are a potent group of lysosomal proteases that belong to the papain superfamily 
of peptidases that are optimally active in acidic and reducing environment with cathepsin 
K and V being most powerful human collagenase and elastase, respectively [3, 5, 6, 21-
24]. Cysteine cathepsins are secreted as procathepsins, with a pro-peptide occluding the 
active site, which must be cleaved to have mature, active enzyme [3, 21]. Pro-peptide 
cleavage has been reported to occur through autocatalysis as well as through cleavage by 
another protease [5, 9, 10, 96].  
Of interest are cathepsins K, L, S and V, which share 60% sequence identity and 




matrix substrates [3, 5, 35]. These cathepsins are upregulated in tissue destructive diseases 
and reliably predicting perturbations to individual cathepsins on the overall cathepsin 
proteolytic network is critical to treatment of many of these diseases. Pharmaceutical 
companies have identified this need and have well-designed cathepsin inhibitors that have 
proven effective at reducing target substrate degradation. However, all sixteen inhibitors 
that have made it to phase II and III clinical trials have failed due to side effects, not efficacy 
in stopping target substrate degradation [42, 120, 223, 224]. A complete network of how 
these cysteine cathepsins interact with each other, in addition to matrix proteins, is 
necessary to dose pharmaceutical inhibitors effectively to modulate cysteine cathepsin 
proteolysis in disease states.   
Previously, we have shown that when cathepsins K and S are co-incubated together, 
the total amount of substrate degradation from the equimolar amounts of cathepsins was 
less than the sum of the individual cathepsins’ proteolytic activity [7]. Computational 
modeling was used to test hypothetical interactions that could result in reduced substrate 
degradation. A “cathepsin cannibalism” interaction of cathepsin S preferentially binding 
and degrading cathepsin K over the substrate was introduced and could accurately capture 
the amount of substrate degradation [7].  
To expand upon our knowledge of the cathepsin proteolytic network, here we 
developed a mechanistic, ordinary differential equation model characterizing the cathepsin 
K, L, S, and V proteolytic network with elastin and gelatin substrates. Using a systematic 
approach to first characterize the kinetics of individual cathepsin on elastin or gelatin, then 




proteolytic network.  With this cathepsin proteolytic network model, we predicted substrate 
degradation a priori of all four cathepsins at once.  
7.2 Materials and Methods 
7.2.1 Recombinant cathepsin and procathepsin activation  
 Recombinant cathepsins K, L, S, and V were used in substrate degradation studies. 
Mature, active recombinant cathepsin K, L, and S (Enzo) were thawed from -80°C frozen 
stock. Procathepsin V (Enzo) was purchased with the propeptide intact, which must be 
cleaved to activate before use. Procathepsin V was activated for 40 minutes at room 
temperature in 0.1 M sodium acetate buffer at pH 4.0, 1 mM EDTA, and freshly added 2 
mM dithiothreitol before use in the time course studies.  
7.2.2 Fluorogenic protein degradation  
 Kinetic studies of fluorogenic substrate degradation, where the substrate fluoresces 
when cleaved, with different combinations of recombinant cathepsins K, L, S, and V were 
performed to determine time series substrate degradation over 120 minutes (Figure 7-1). 
EnzChek® Gelatinase Assay Kit (Invitrogen) was performed in a 96-well plate with each 
well receiving 50µL of 150µg/mL DQ-gelatin, 5 picomoles of each enzyme, and cathepsin 
assay buffer (0.1 M sodium phosphate buffer, pH 6.0, 1 mM EDTA, and 2 mM 
dithiothreitol) used to fill each well to 150µL. Four co-incubation scenarios were examined 
and compared to the control of substrate only: (1) each cathepsin’s gelatinase activity 




S, S and L, etc.), (3) gelatinase activity by three cathepsins at once, and (4) gelatinase 
activity by all four cathepsins at once. These cases were used to determine kinetic rates in 
the development of the cathepsin proteolytic computational model to determine substrate 
degradation attributed to each cathepsin. The enzymes were added last to the reaction and 
then incubated at 37°C in a plate reader. The fluorescence intensity was measured every 5 
minutes for 2 hours, yielding 24 measurements, with the digested products having 
absorption maxima at 495 nm and fluorescence emission maxima at 515nm. This 
experiment was also repeated using DQ-elastin, since each cathepsin has a different 
preference for each extracellular matrix component [3, 6, 24].  
 
 
Figure 7-1. Cathepsins K, L, S, and V working in concert do not degrade the most 
elastin and gelatin. Kinetic study fluorescence data of cathepsin individuals, pairs, groups 
of three, and all four together on DQ-elastin and DQ-gelatin. Fluorescence was indicative 





7.2.3 Kinetic model development 
An ordinary differential equation model was developed and implemented with 
COPASI using general mass action kinetics to mechanistically describe the cathepsin-
substrate and cathepsin-cathepsin interactions [225]. The canonical form of general mass 
action kinetics are described by differential equations of the form shown in Equation 6:  







where n is the number of dependent variables, m is the number of independent variables, 
Ti is the number of terms in the ith equation. For individual cathepsins, mass action kinetics 














where 𝐸 represents the enzyme (cathepsin) and 𝑆 was the substrate (gelatin or elastin). 𝐸𝑆 
was the complex that forms between the enzyme and substrate, which was catalyzed to free 
enzyme, 𝐸, and product formation (degraded substrate), 𝑃.  There was also a rate at which 
the enzyme was inactivated over time (𝑘rst). For example, using gelatin (𝐺) as the 






𝑑𝑡 = −𝑘(' 𝑆 𝐺 + 𝑘(ee 𝑆𝐺 + 𝑘v=w 𝑆𝐺 − 𝑘rst 𝐺  
(9) 
𝑑𝐺
𝑑𝑡 = −𝑘(' 𝑆 𝐺 + 𝑘(ee 𝑆𝐺  
(10) 
𝑑𝑆𝐺
𝑑𝑡 = 𝑘(' 𝑆 𝐺 − 𝑘(ee 𝑆𝐺 − 𝑘v=w 𝑆𝐺  
(11) 
𝑑𝑃
𝑑𝑡 = 𝑘v=w 𝑆𝐺  
(12) 
𝑑𝑆rst
𝑑𝑡 = 𝑘rst 𝑆  
(13) 
This set of differential equations was completed for each cathepsin (K, L, S, and V) on 
gelatin and elastin substrates. The kinetic parameters (𝑘(', 𝑘(ee, 𝑘v=w, 𝑘rst) were 
estimated using the dataset gathered in Section 7.2.2, with the methodology described in 
Section 7.2.4. The initial conditions for the systems were 25 nM of active and 8nM of 
inactive enzyme co-incubated with 2.5 µM of substrate.  
 Once kinetics for each individual cathepsin on each substrate were determined, 
cathepsin cannibalism interaction terms were introduced with the addition of an equimolar 
amount of a different cathepsin. Mass action kinetics describe this interaction as shown in 

















Appropriate terms were included with the differential equations and the cannibalistic rates 
(four parameters in total for each pair) were fit to the paired cathepsin substrate degradation 
data. For example, between cathepsins S and K, the cannibalism interactions added terms 
to the differential equations describing the mature and inactive cathepsin S pools as 
described as follows in Equations 16 and 17:  
𝑑𝑆
𝑑𝑡 = −𝑘(' 𝑆 𝐺 + 𝑘(ee 𝑆𝐺 + 𝑘v=w 𝑆𝐺 − 𝑘rst 𝐺 − 𝑘('z{|| 𝐾 𝑆
+ 𝑘(eez{|| 𝑆𝐾 + 𝑘v=wz{||~ 𝑆𝐾  
(16) 
𝑑𝑆rst
𝑑𝑡 = 𝑘rst 𝑆 + 𝑘v=wz{||~ 𝑆𝐾  
(17) 
Similar terms were included in the differential equations for the mature and inactive 
cathepsin K pools.  Once the individual kinetics and paired cannibalism kinetic rates have 
been determined, elastin and gelatin substrate degradations for all four cathepsins at once 
could be predicted a priori.  
7.2.4 Parameter estimation 
The kinetic parameters of each cathepsin were initially fit using COPASI’s genetic 
algorithm with a population of 50,000 for 500 generations, to the time series data of 
substrate degradation by individual cathepsins, which is an iterative procedure. Starting 




model. Parameter values were constrained to be within the reported ranges of 𝐾 and 𝑘v=w 
values [226].  Furthermore, the on-rate upper bound was set by diffusion limit [226] and 
the off-rate lower bound was based on biotin-streptavidin affinity, which is the strongest 
non-covalent biological interaction known [227, 228]. 
 10EV𝑠E1𝑝𝑀E1 ≤ 𝑘(' ≤ 10EO𝑠E1𝑝𝑀E1 (18) 
 10EU𝑠E1 ≤ 𝑘(ee ≤ 10.𝑠E1 (19) 
 0 ≤ 𝑘v=w ≤ 10O𝑠E1 (20) 
Once solutions were determined from the genetic algorithm, parameters were further 
refined and fit across both substrates simultaneously using a surrogate based optimization 
method [229] to find parameters that fit both elastin and gelatin data comparably.  The 

















where exp is the experimental amount of substrate degradation (either degraded elastin or 
gelatin) and pred is the predicted amount of substrate degradation. Then, the cannibalistic 
terms were fit to the paired combinations of cathepsins. The cases with three and four 
cathepsins allowed for a priori confirmation of these cannibalistic relationships. Additional 
in silico scenarios were created by the computational model and the predictions were 




One challenge in parameter estimation and optimization is that it is difficult to 
confirm the solution returned is the true global minimum of the objective function and best 
solution. To guide the parameter estimation to find the optimal parameter set, the cathepsin 
proteolytic network parameters were fit systematically, compared with experimental data, 
and the parameters were validated with a priori predictions. Furthermore, bounds grounded 
by the best known binding affinity for biotin-streptavidin, reported ranges for 𝐾 and 𝑘v=w, 
and the diffusion limit were used to constrain the parameter space and a two-step 
optimization approach was implemented with a genetic algorithm first sweeping the 
parameter space followed by a surrogate-based optimization to converge on an optimal 
solution. Parameters for cathepsin-cathepsin interactions were also constrained to agree 
across substrates. These cathepsin-cathepsin interactions were assumed to be inherent 
binding affinities of the enzymes.  
The cathepsin-substrate binding and catalysis rates determine to what extent these 
cathepsin-cathepsin (cannibalism) interactions modulate the amount of active enzyme in 
the system.  If the cathepsin-substrate affinities were greater than the cathepsin cannibalism 
interactions, then the cannibalism interactions were not play a large role. If the cathepsin-
substrate affinities were less than the cannibalism interactions, then the cathepsin 
cannibalism interactions play a larger role in reducing the amount of cathepsin with 







7.3.1 Stepwise determination of cathepsin K, L, and S reaction kinetics  
 Mass action kinetics are the basis for mathematical models of individual cathepsins 
K, L, and S degradation of elastin and collagen, two major mammalian extracellular matrix 
proteins. Gelatin is a denatured form of collagen and was used here to represent collagen 
in proteolytic network development. To develop a mechanistic model of the cathepsin 
proteolytic network, parameters were systematically estimated for a traditional Michaelis-
Menten enzyme kinetics system with one enzyme and one substrate as described by 
Equation 7. Kinetic rates were estimated first by using a genetic algorithm with parameters 
bound by known physical and biology limits as described in Equations 18-20. Using 
cathepsin S as a model cathepsin, Michaelis-Menten kinetics alone (Model 1) could not 
accurately predict substrate degradation of an individual cathepsin on elastin or gelatin 
(Figure 7-2A, B, C; Model 1 predictions).   
 Michaelis-Menten kinetics alone over-predicted the proteolytic activity of 
cathepsins, so an inactivation rate was introduced as described by the reaction in Equation 
8. Again, the kinetic rates were first estimated independently using a genetic algorithm, 
then further refined using a surrogate-based optimization technique, where the inactivation 
rate was held constant over the two substrates. The inactivation rate was fit as power law 






𝑑𝑡 = 𝑘rst 𝑐𝑎𝑡ℎ𝑒𝑝𝑠𝑖𝑛
t (22) 
The model with Michaelis-Menten kinetics and an inactivation rate (Model 2) reduced the 
objective normalized error for cathepsin S 28.5-fold (from 5.80×10E. to 2.04×10EO; 
Figure 7-2A, B, C; Model 2 prediction) compared to the Michaelis-Menten kinetics only 
case (Model 1). However, the prediction of Model 2 for the amount of inactivated cathepsin 
S was that 95% of the cathepsin S was inactivated within the first five minutes (Figure 
7-2D; Module 2 prediction), which was not biologically reasonable. Cathepsin S activity 
has been reported to be dependent on pH, however varying from a pH 5.0 to 7.5, still have 
active cathepsin S after five minutes [96]. Furthermore, intracellularly, mature cathepsin S 
has been reported to have a half-life of 16-18 hours [11], which would also suggest 
cathepsin S would remain active for more than five minutes. This suggested that there may 
be another interaction to explain that cathepsin S did not immediately bind to substrate. 
We hypothesized a distraction interaction, defined as cathepsins reversibly binding to an 
inactive cathepsins; this is described by the reaction for cathepsin S reversibly binding to 
inactive cathepsin S (𝑆rst) in Equation 23, which adjusted the cathepsin S differential 










𝑑𝑡 = −𝑘(' 𝑆 𝐺 + 𝑘(ee 𝑆𝐺 + 𝑘v=w 𝑆𝐺 − 𝑘rst 𝐺 − 𝑘('f|{z 𝑆 𝑆rst
+ 𝑘(eef|{z 𝑆𝑆rst  
(24) 
Incorporating these distraction terms into Model 3 further reduced the normalized error 
2.9-fold (from 2.04×10EO to 6.99×10E; Figure 7-2A, B, C; Model 3 prediction) for 
substrate degradation by cathepsin S and reduced the amount of inactive cathepsin S 
(Figure 7-2D; Model 2 to Model 3 prediction). This model structure also best describes 
cathepsins K and L on elastin and gelatin. The full list of equations with parameters for all 
three cathepsins on both substrates were reported in reactions 1 through 18 in Table 7-1 







Figure 7-2. Enzyme kinetics alone was not enough to predict substrate degradation. 
(A) Three model structures were evaluated to describe cathepsin S degradation of 
substrate. Model 1 used Michaelis-Menten kinetics only to describe substrate degradation, 
Model 2 included an inactivation rate of cathepsin S, and Model 3 included a distraction 
term of active cathepsin S reversible binding to inactive cathepsin S. Using cathepsin S as 
the model enzyme, the black solid points indicate the experimental degraded elastin (B) or 
degraded gelatin (C) over 120 minutes. Model 1 prediction (red solid line) indicates 
predicted substrate degradation of a Michaelis-Menten model of cathepsin S and substrate. 
Model 2 (green solid line) indicates the predicted substrate degradation of Michaelis-
Menten kinetics model with addition of an enzyme inactivation rate. Model 3 (blue solid 
line) indicates a Michaelis-Menten kinetics model with an enzyme inactivation rate and a 
“distraction” for free enzyme to bind and un-bind to inactive enzyme. (D) In the Michaelis-
Menten plus inactivation model (Model 2, green), the cathepsin S is almost all inactivated 
more quickly than would be expected biologically.  With the addition of the distraction 
terms, allowing free enzyme to bind to the inactive form, (Model 3, blue), active cathepsin 




































































































 Once the individual cathepsin kinetics were established, a second cathepsin was 
incorporated into the proteolytic network model. Using cathepsins S and K, Model 1 
described the superposition of each individual cathepsin’s proteolytic activity (Figure 
7-3A, B; Model 1 prediction) and predicted substrate degradation was 1.4-fold greater than 
the experimental data (Figure 7-3A, B; distinct points). This led to the hypothesis that there 
must be some interaction that reduced the amount of active enzyme available to bind to 
substrate. First, we introduced cathepsin-cathepsin (cathepsin cannibalism) interactions 
with the model, since this concept had been previously established, described by reactions 
in Equations 16 and 17. Cross-distraction interactions were also included in the model, 
defined here for the cathepsins S and K example, where cathepsin K can bind to inactive 
cathepsin S (𝑆rst	) and cathepsin S can bind to inactive cathepsin K (𝐾rst	). Parameter 
estimation was performed in the same two-step fashion as described above and all the rates 
were considered inherent binding affinity of the cathepsins and held constant across 
substrates. Incorporating these cathepsin cannibalism interactions reduced the normalized 
error compared to the case predicted by superposition (Figure 7-3A, B; Model 1 compared 





Figure 7-3. Cathepsin-cathepsin cannibalism interactions accurately described 
paired cathepsin substrate degradation.	(A) Two model structures were used to describe 
two cathepsins degrading substrate. Model 1 assumed superposition of individual 
cathepsin kinetics using the structure defined in Figure 7-2 and Model 2 incorporated 
cathepsin-cathepsin interactions (cathepsin cannibalism and cross-distractions). Using 
the cathepsin K (catK) and S (catS) as the model paired interaction, the black solid points 
indicate experimental data for degraded elastin (B) or degraded gelatin (C) over 120 
minutes. Model 1 prediction (gray dashed line) indicated the expected substrate 
degradation assuming superposition of catK and S individual kinetics, which over 
predicted the experimental data for catK and S degrading substrate. Model 2 prediction 
(black model line) indicated the substrate degradation when the model included cathepsin 
cannibalism interactions between catK and S.  Model 2 substrate degradation contribution 
by catK (blue) and catS (red) indicated the contribution of each cathepsin to the total 
substrate degradation model (black). (D) Total amount of inactive catK (blue) and catS 



















































































































Model 2 prediction by CatK
Model 2 prediction by CatS
Model 2 Prediction by CatKdeg
Model 2 Prediction by CatSdeg
Model 1 Prediction by CatKdeg





Table 7-1. Cathepsin cannibalism reactions, rate laws, and kinetic constant values. 
 
Name Reaction Rate	Law Parameters No.




CatK	catalyzing	elastin 8: → 8 + :IJK Mass	action kcat =	6.362e-3 2
CatK	inactivation 8 → 8OPQRS Mass	action kdeg =	0.792 3




CatK	catalyzing	gelatin 8V → 8 +VIJK Mass	action kcat =	4.592e-4 5








CatL	catalyzing	elastin Y: → Y + :IJK Mass	action kcat =	3.604e-4 8










CatL	catalyzing	gelatin YV → Y + VIJK Mass	action kcat =	9.961e-5 11








CatS	catalyzing	elastin \: → \ + :IJK Mass	action kcat =	6.013e-3 14
CatS	inactivation \ → \OPQRS Mass	action kdeg =	0.861 15




CatS	catalyzing	gelatin \V → \ + VIJK Mass	action kcat =	3.357e-4 17








CatK	catalyzing	CatL	 8Y → 8+ YIJK Mass	action kcat =	500 20
CatL	catalyzing	CatK 8Y → Y + 8IJK Mass	action kcat =	336.16 21












CatK	catalyzing	CatS 8\ → 8 +\IJK Mass	action kcat =	710.24 25
CatS	catalyzing	CatK 8\ → \ + 8IJK Mass	action kcat =	288 26












CatL	catalyzing	CatS Y\ → Y + \IJK Mass	action kcat =	500 30
CatS	catalyzing	CatL Y\ → \ +YIJK Mass	action kcat =	500 31











Table 7-2. Parameter estimation kinetic constant value errors. 
 
7.3.2 Cathepsin cannibalism results in a priori determination of substrate degradation 
Once paired cathepsin cannibalism interactions have been established, combining 
the individual kinetics and paired interactions for cathepsins K, L, and S predicted the 
substrate degradation of all three cathepsins in combination (Figure 7-4). For elastin, the 
error (calculated as described by Equation 21) was reduced from 1.840×10E1 for Model 
1 with only the individual cathepsin kinetics, to 3.334×10EO with the inclusion of 
Name	 Reactions	 Parameters	Fit	 Error	
CatK	only	reactions	
5 + 7	 ↔ 57 → 5 + 7:;<	
5 + =	 ↔ 5= → 5 + =:;<	
5 → 5>?@AB	




M + 7	 ↔ M7 → M + 7:;<	
M + =	 ↔ M= → M + =:;<	
M → M>?@AB	




Q + 7	 ↔ Q7 → Q + 7:;<	
Q + =	 ↔ Q= → Q + =:;<	
Q → Q>?@AB	




5 + M	 ↔ 5M	
5M → 5 + M:;<	
5M → M + 5:;<	
5 + M:;< 	↔ 5M:;<	




5 + Q	 ↔ 5Q	
5Q → 5 + Q:;<	
5Q → Q + 5:;<	
5 + Q:;< 	↔ 5Q:;<	




M + Q	 ↔ MQ	
MQ → M + Q:;<	
MQ → Q + M:;<	
M + Q:;< 	↔ MQ:;<	







cathepsin cannibalism interactions in Model 2, a 55-fold reduction in the error (Figure 
7-4A). Gelatin had a similar reduction in error from 2.426×10E1	to 2.114×10E., an 11.5-
fold reduction in error (Figure 7-4B).  
 
Figure 7-4. Cathepsin-cathepsin cannibalism a priori predicted substrate degradation 
by cathepsins K, L, and S. Inclusion of cathepsin-cannibalism terms in the model 
predicted substrate degradation a priori. Two model structures were used to describe two 
cathepsins degrading substrate as described in Figure 7-3A. Model 1 assumed 
superposition of individual cathepsin kinetics and Model 2 incorporated cathepsin-
cathepsin interactions (cathepsin cannibalism and cross-distractions). The black solid 
points indicated experimental data of degraded elastin (A) or degraded gelatin (B) over 
120 minutes. Model 1 (gray dashed curve) indicated the expected substrate degradation 
assuming superposition of cathepsin K, L, and S individual kinetics (with no cannibalism 
interactions), which over-predicts the amount of substrate degradation by the three 
cathepsins. Model 2 (black solid curve) indicated substrate degradation when the model 
included cathepsin cannibalism interactions between pairs of cathepsins K, L, and S. The 
Model 2 degraded substrate contribution from cathepsin K (blue), cathepsin L (green), and 












































7.3.3 Procathepsin V activation was necessary for determining amount of active enzyme 
Unlike cathepsins K, L, and S, recombinant cathepsin V is only available for 
purchase as the inactive procathepsin form. Five picomoles of procathepsin V was 
activated for 40 minutes in a pH 4.0 sodium acetate buffer prior to use in DQ-substrate 
kinetic studies. Attempts to fit individual cathepsin V kinetics on elastin and gelatin were 
unsuccessful within parameter bounds when assuming all the procathepsin had been 
activated. However, assuming a mixed population of mature, active cathepsin V and 
procathepsin V that would continue to activate in the pH 6.0 kinetic study, drastically 
improved the individual kinetic rate fits, but the ratio of pro- to mature cathepsin V must 
be determined as well as activation rates. A procathepsin V activation kinetic study was 
run to determine (1) the distribution of mature, procathepsin, and degraded cathepsins and 
(2) activation rates for cathepsin V at pH 4.0 and pH 6.0 (Figure 7-5A). This kinetic study 
was performed with DQ-elastin as the substrate to determine the activation rates at both 














Both autocatalytic and bimolecular activation occur during cathepsin activation, so both 




only autocatalytic or only biomolecular activation, had larger errors compared to the model 
with both autocatalytic and bimolecular activation. Once rates were determined, a 
simulation of pro- to mature cathepsin V activation at pH 4.0 in the absence of substrate 
was run to determine the initial conditions for the cathepsin V samples from the larger 
KLSV experiment. Surprisingly, in the absence of substrate during activation of cathepsin 
V, the simulation had 10-fold less mature, active cathepsin V. Using an initial amount of 
225 pM of free, mature cathepsin V, 2400 pM mature cathepsin V bound to procathepsin 
V, 4 pM of procathepsin V, and 30,371 pM of inactive cathepsin V as well as the activation 
rates for procathepsin V at pH 6 and the model structure established by cathepsins K, L, 
and S, the individual kinetics for cathepsin V on elastin and gelatin were determined 








Figure 7-5. Procathepsin V activation was necessary to predict substrate degradation. 
Procathepsin V activation rates were determined and compared between pH 4.0 and pH 
6.0 buffers. (A) Procathepsin V activation was performed in the presence of DQ-elastin 
and showed that more cathepsin V was activated at pH 4.0, compared to pH 6.0, as 
reported by the total amount of elastin degraded after 120 minutes. After activation rates 
were determined, a simulation without substrate was run to determine the initial 
concentration of procathepsin V, mature cathepsin V, inactive cathepsin V, and complexes 
with cathepsin V. With these initial conditions and allowing procathepsin V to activate 
during the pH 6.0 experimental, individual cathepsin V kinetics were determined as 
demonstrated with the degradation of elastin (B) and gelatin (C) over 120 minutes, where 
the black solid points indicated experimental data and the black curve indicated the model 
predicted cathepsin V substrate degradation. Note: All cathepsin V parameter estimation 
was completed using a genetic algorithm with a population size of 10,000 and parameters 












































































Table 7-3. Cathepsin V reactions, rate laws, and kinetic constant values. 
 
 
Name	 Reaction	 Rate	Law	 Parameters	 No.	
CatV	autoactivation	 6789 → 9	 Mass	action	 kact	=	1.347e-5	 34	
CatV	binding	proV	 6789 + 9	↔ 96789	 Mass	action	
kon	=	6.664e-4	
koff	=	0.01764	 35	
CatV	activating	proV	 96789 → 9 + 9	 Mass	action	 kact	=	0.01871	 36	
CatV	binding	elastin	 9 + O	 ↔ 9O	 Mass	action	 kon	=	9.033e-6	koff	=	0.007425	
37	
CatV	catalyzing	elastin	 9O → 9 + OTUV	 Mass	action	 kcat	=	0.001607	 38	
CatV	binding	gelatin	 9 + W	 ↔ 9W	 Mass	action	 kon	=	1e-6	koff	=	1e-5	 39	
CatV	catalyzing	gelatin	 9W → 9 + WTUV	 Mass	action	 kcat	=	1.119e-4	 40	




CatL	binding	proV	 Y + 6789	 ↔ Y6789	 Mass	action	 kon	=	0.001	koff	=	2.508e-4	
42	
CatL	activating	proV	 Y6789 → Y + 9	 Mass	action	 kact	=	43.60		 43	
CatV	and	CatL	
complexing	 9 + Y	 ↔ 9Y	 Mass	action	
kon	=	0.001	
koff	=	4.182	 44	
CatV	catalyzing	CatL	 9Y → 9 + YTUV	 Mass	action	 kcat	=	0	 45	
CatL	catalyzing	CatV	 9Y → Y + 9TUV	 Mass	action	 kcat	=	0	 46	
Inactive	CatL	distraction	








complexing	 9 + \	 ↔ 9\	 Mass	action	
kon	=	9.095e-4	
koff	=	4.597e-5	 49	
CatV	catalyzing	CatK	 9\ → 9 + \TUV	 Mass	action	 kcat	=	1.653	 50	
CatK	catalyzing	CatV	 9\ → \ + 9TUV	 Mass	action	 kcat	=	0	 51	
Inactive	CatK	distraction	








complexing	 9 + ^	 ↔ 9^	 Mass	action	
kon	=	0.001	
koff	=	6.186e-5	 54	
CatV	catalyzing	CatS	 9^ → 9 + ^TUV	 Mass	action	 kcat	=	0.1448	 55	
CatS	catalyzing	CatV	 9^ → ^ + 9TUV	 Mass	action	 kcat	=	0	 56	
Inactive	CatS	distraction	











Table 7-4. Cathepsin V parameter estimation kinetic constant values errors. 
 
 Similarly, to the pairs of cathepsins K, L, and S, the paired cathepsin cannibalism 
interactions with cathepsin V were determined, while holding the individual cathepsin 
kinetic rates (degradation, catalysis, inactivation, and distraction) constant. The sum of 
each cathepsin’s individual proteolytic activity (Figure 7-6A, B; Model 1 prediction) was 
slightly greater than the experimental data (Figure 7-6A, B; experimental data). However, 
the difference in the substrate degradation between the superposition model (Model 1) and 
experimental data with the cathepsin V pairs was less than those for cathepsins K, L, and 
S pairs. Compared to the other cathepsin pairs, this reduced difference between 
superposition model and experimental data was most likely because cathepsin V had only 
Name	 Reactions	 Parameters	Fit	 Error	
CatV	only	reactions	
5 + 7	 ↔ 57 → 5 + 7:;<	
5 + =	 ↔ 5= → 5 + =:;<	
5 + 5:;< 	↔ 55:;<	






5 + M	 ↔ 5M	
5M → 5 + M:;<	
5M → M + 5:;<	
5 + M:;< 	↔ 5M:;<	
M + 5:;< 	↔ M5:;<	
M + >?@5	 ↔ M>?@5





5 + O ↔ 5O	
5O → 5 + O:;<	
5O → O + 5:;<	
5 + O:;< 	↔ 5O:;<	





5 + T	 ↔ 5T	
5T → 5 + T:;<	
5T → T + 5:;<	
5 + T:;< 	↔ 5T:;<	








about 10% the total active amount of enzyme, compared to the other cathepsins. In all 
cases, the superposition model over-predicts the substrate degradation compared to those 
models including cathepsin-cathepsin interactions. Parameter estimation was performed in 
the two-step fashion as described above and all the rates, except for individual substrate 
kinetics, were held constant across the two substrates. The model incorporating these 
cathepsin cannibalism and cross-distraction interactions (allowing active cathepsin to bind 
to the inactive form) reduced the normalized error (Equation 21) compared to the 
superposition predicted case (Figure 7-6A, B; Model 1 to Model 2 prediction) 4.5-fold for 
the example of cathepsin V and S pair (other cathepsin V paired errors are recorded in 
Table 7-4). 
 
Figure 7-6. Cathepsin V cannibalism interactions predicted paired substrate 
degradation. Using the cathepsin V and S as the model paired interaction, the black solid 
points indicated experimental data of degraded elastin (A) or degraded gelatin (B) over 
120 minutes. Model 1 (gray dashed curve) indicated the predicted substrate degradation 







































substrate degradation, which was most evident on the gelatin substrate. Model 2 (black 
curve) indicated the predicted substrate degradation when the model included cathepsin 
cannibalism interactions between cathepsin V and S. The cathepsin V (purple) and 
cathepsin S (red) contribution to the total substrate degradation predicted by Model 2 
(black curve). Most the substrate degradation was predicted to be due to cathepsin S 
catalytic activity, which may be because there was initially 10-fold more active cathepsin 
S compared to cathepsin V.  
 
Figure 7-7. Cathepsin L also activated procathepsin V in paired interactions.	
Cathepsin V and L paired interaction behaves differently compared to other cathepsin 
pairs, as depicted by the experimental data (black solid points) of degraded elastin (A) or 
degraded gelatin (B) over 120 minutes. The increasing nature of the data lead to the 
inclusion of cathepsin L activation of procathepsin V, ultimately reducing the error 
between the model system and the data. Two model structures were used to describe two 
cathepsins degrading substrate. Model 1 (gray dashed curve) assumed superposition of 
individual cathepsin kinetics using the structure defined in Figure 7-2 and Model 2 (black 
solid curve) incorporated cathepsin-cathepsin interactions (cathepsin cannibalism and 
cross-distractions) as well as cathepsin L reversible binding and activating procathepsin 
V.  Inclusion of cathepsin L activation of procathepsin V activation (Model 2), improved 
the fit 1.52-fold compared to the superposition model (Model 1). The contributions of 
cathepsin V (purple) and cathepsin L (green) to the total substrate degradation predicted 
by Model 2 (black). These contributions differed compared to other paired interactions 
because here both cathepsins were hypothesized to continue degradation additional 










































 The cathepsin V and L pair data displayed different dynamics compared to all the 
other cathepsin pairs. While most cathepsin pairs show a saturation of substrate degradation 
prior to 120 minutes, the cathepsins V and L pair continued to degrade substrate past the 
120 minute observation time point (Figure 7-7; experimental data). With inclusion of 
cannibalism and cross-distraction interactions, the error of the superposition case, 
4.278×10E1 was reduced to 3.116×10E1 (1.36-fold). This error was further improved by 








→ 𝐿 + 𝑉	 (27) 
This additional model interaction reduced the error of the superposition case, 4.278×10E1, 
to 2.820×10E1, a 1.52-fold improvement. Procathepsin V activation was also included in 
the paired model with cathepsin K, since the model under-predicted total elastin 
degradation by 5.5%. However, this addition increased the overall error of the cannibalism 
and cross distraction interactions.  
7.3.4 A priori prediction of cathepsins K, L, S, and V substrate degradation 
Accounting for the cathepsin V individual kinetics and cathepsin-cathepsin 
interactions, the cathepsin proteolytic network model improves model performance for 
predicting the elastin and gelatin degradation of four cathepsins K, L, S, and V in 




interactions (Fig. 3-7A, B; Model 1 prediction), the prediction accuracy in terms of 
degraded elastin was 30-fold (error of 7.191×10EO	compared to 2.131×10E1) for the 
model including the cathepsin-cathepsin interactions (Figure 7-8A, B; Model 2 prediction) 
and for degraded gelatin was 16-fold better than the model with cathepsin-cathepsin 
interactions (error of 3.049×10E. compared to 4.823×10E1). For both elastin and gelatin, 
cathepsin S degraded the most substrate (Figure 7-8A, B; Model 2 prediction by CatS). 
Cathepsin K (Figure 7-8A, B; Model 2 prediction by CatK). When tracking the amount of 
active enzyme, there were substrate specific differences in the predicted amount of 
cathepsin still active at the end of the experiment (Figure 7-8C, D). Interestingly, there was 
on average 1.64-fold more total amount of active cathepsin present in the model including 
cathepsin-cathepsin interactions compared to the model relying only on the individual 
cathepsin kinetics to determine substrate degradation (Figure 7-8C, D).  This was because 
through the addition of the cathepsin-cathepsin interactions, each cathepsin could bind to 
other cathepsins rather than substrate, effectively decreasing the amount of cathepsin 






Figure 7-8. Cathepsin V cannibalism interactions a priori predicted substrate 
degradation of four cathepsins. Inclusion of cathepsin-cannibalism terms in the model 
predicted substrate degradation a priori of cathepsins (cat) K, L, S, and V. Experimental 
data (black solid points) indicated degraded elastin (A) or degraded gelatin (B) over 120 
minutes. Model 1 (gray dashed curve) predicted substrate degradation assuming 
superposition of catK, L, and S individual kinetics (with no cannibalism interactions) over-
predicts total substrate degradation. Model 2 (black curve) indicated predicted substrate 
degradation when the model includes cathepsin cannibalism interactions between pairs of 
cathepsins. The contribution of catK (blue), catL (green), catS (red), and catV (purple) to 
the total substrate degradation predicted by Model 2 (black curve). (C, D) The total amount 
of active catK (blue), catL (green), catS (red), and catV (purple) can be compared between 
the model with cannibalism (solid line) and without cannibalism (dashed line) and how the 











































































 These studies demonstrate that cathepsin cannibalism occurs between cathepsins 
K, L, S, and V, which suppresses active enzyme in the system and protects against substrate 
degradation. Using a systematic approach, a cathepsin proteolytic network model of 
cathepsins K, L, S, and V degrading elastin and gelatin was constructed by first determining 
the individual substrate kinetics for each cathepsin on each substrate. In the initial layer of 
the model, the need for an inactivation rate was evident in addition to the traditional 
Michaelis-Menten kinetics to accurately capture the shape of the substrate degradation. 
The fits were further improved through the addition of the distraction hypothesis, where 
active cathepsins could reversibly bind to inactive cathepsins. Furthermore, since 
recombinant cathepsin V had to be activated from procathepsin V form to a catalytically 
active form, there was only about 10% of the expected active cathepsin available for 
hydrolysis at the start of the kinetic studies. Using the kinetic rates of individual and paired 
cathepsin interactions, the substrate of all four cathepsins could be predicted, which 
reduced the error 30-fold for degraded elastin and 16-fold for degraded gelatin compared 
to superposition of individual cathepsin kinetics.  
 The kinetic rates determine the directionality of cathepsin cannibalism interactions. 
For example, cathepsin K had the larger kinetic rate for catalysis of cathepsin L (Table 7-
1, 500 s-1 vs. 336 s-1), while the catalysis reaction between cathepsins S and L were 
equivalent (Table 7-1, both were 500 s-1). Previously it was reported that cathepsin S 




experiments, cathepsin K had a larger rate for catalyzing cathepsin S than cathepsin S 
catalyzing cathepsin K (Table 7-1, 710 s-1 vs. 288 s-1). When the Michaelis-Menten 
constant, KM, was calculated for the two interactions, catalysis by cathepsin S had over a 
2-fold smaller 𝐾 (5.07×10UpM compared to 1.10×10VpM), indicating that cathepsin S 
had a higher affinity for cathepsin K. Between the pairs containing cathepsin V, cathepsin 
V had larger catalytic rates for cathepsins K (Table 7-3, 1.653 s-1) and S (Table 7-3, 0.1448 
s-1) than vice versa.  
 Between cathepsin V pairs, the model predicted substrate degradation was 
improved by incorporating terms for procathepsin V activation by the other cathepsin in 
the pair.  This improvement occurred for the cathepsins L and V pair, but not the cathepsins 
K and V pair. The improvement with paired cathepsin activation was hypothesized to 
happen with cathepsin L, and not cathepsin K, because cathepsins L and V share 80% 
sequence identity [20] compared to the 60% shared between cathepsins K and V . 
Furthermore, cathepsin V is known to activate itself, so since cathepsin L is structurally 
more similar to cathepsin V, it could explain why cathepsin L could also activate 
procathepsin V.  
 The cathepsin V activation experiments revealed that the duration of the 
procathepsin V activation protocol should be shortened, so that more than 10% of the 
enzyme will be catalytically active for the experiment. Furthermore, through the 
development of this model structure, it was clear that the initial amount of active enzyme 




cannibalism interactions. These experiments used 5 picomoles of recombinant enzyme in 
a total volume of 150 µL, which was a concentration of 33 pM. Using an initial 
concentration of 33 pM, the individual cathepsin kinetics were easily determined with 
small error compared to the experimental data, however, when the cathepsin cannibalism 
interaction rates were being fit, only forward binding rates that were three or more orders 
of magnitude above diffusion-limited binding would give a reasonable fit.  Since these high 
forward binding rates seemed unlikely, being greater than the diffusion limit and strongest 
known biological interactions, reducing the initial concentration of active enzyme was the 
only way to achieve good fits (small error) in the paired interactions with less of these rates 
hit the parameter bounds. Furthermore, while this parameter set can accurately describe 
this combination of experiments, it was not robust enough to describe the complexity of 
individual cathepsin interactions. When increasing amounts of cathepsin S were co-
incubated with either DQ-elastin or DQ-gelatin, the addition of more of the same cathepsin 
did not produce much more substrate degradation as shown by the experimental data in 
Figure 7-9. Specifically Figure 7-9A (discrete points) showed total degraded elastin within 
5% of each other at 120 minutes when co-incubated with 1X through 4X amounts of 
recombinant cathepsin S. Predictions for substrate degradation with increasing amounts of 
cathepsin S, using the parameterized cathepsin proteolytic network model described here, 
still over-predicted the experimentally seen substrate degradation (Figure 7-9, prediction 
curves compared to discrete experimental data points). Further experiments varying the 




fit simultaneously to multiple datasets and ensure robust parameters that can predict these 
dynamics.   
 
Figure 7-9. Increasing amounts of cathepsin S does not result in comparable increase 
in substrate degradation. The discrete points were experimental data for substrate 
degradation due to increasing amounts of cathepsin S from a 0.5X concentration (2.5 
pmoles of active enzyme) to a 4X concentration (20 pmoles of active enzyme) and the 
subsequence amount of degraded (A) elastin and (b) gelatin. Using the cathepsin S 
individual kinetics, model simulations with corresponding initial conditions showed a 
wider distribution in total substrate degradation compared to the experimental data.  
This mechanistic model of the cathepsin proteolytic activity (with interactions 
enumerated in Figure 7-10) brings scientists closer to successfully inhibiting cathepsins as 
treatment for tissue destructive diseases or controlling proteolysis in engineered living 
systems. This work demonstrates that complex cathepsin-cathepsin interactions are 
modulating the concentrations of cathepsins catalytically active towards substrates in a 
system. This modulation is critical for accurately targeting cathepsins with well-designed 





















































phase II and III clinical trials have been effective at reducing target substrate degradation, 
but were ultimately discontinued due to off-target side effects.  If the amount of cathepsins 
catalytically active to substrates is actually lower than anticipated, then “excess” inhibitor 
could precipitate these side effects. 
 





























































































































































































CHAPTER 8. GENERATING CANNIBALISM-RESISTANT AND 
ACTIVE SITE DEAD CATHEPSIN MUTANTS  
8.1 Introduction 
Chapter 7 describes computational modeling to parse the hypothesized cathepsins-
cathepsin interactions between cathepsins K, L, S, and V. For pairs of cathepsins, like 
cathepsin K and S, there are two possible cathepsin cannibalism interactions that may be 
happening: (1) cathepsin S bind to cathepsin K and the complex is catalyzed to free 
cathepsin S and degraded cathepsin K or (2) cathepsin K can bind to cathepsins S and the 
complex is catalyzed to free cathepsin K and degraded cathepsin S (Figure 8-1, Reactions 
1 and 2). However, to experimentally validate the cannibalism directionality revealed by 
the cathepsin proteolytic network model, cathepsin mutants were created using site-
directed mutagenesis designed to interrupt these interactions. Two types of cathepsin 
mutants were used to test computational modeling informed hypotheses: (1) active site 
dead mutants, which were not catalytically active toward substrate, but could be degraded 
by other cathepsins (Figure 8-1, Reaction 3) and (2) cleavage-resistant mutants, which were 
immune to cathepsin cannibalism interactions without disrupting proteolytic activity 
(Figure 8-1, Reaction 4). Cleavage-resistant mutants can degrade substrate and other 
cathepsins, but are not hydrolyzed by other cathepsins. Here, we created active site dead 
and cannibalism-resistant mutants of cathepsins K, L, S, and V to validate the cathepsin 
cannibalism interactions hypothesized from the cathepsin proteolytic network model 





Figure 8-1. Cathepsin cannibalism interactions and mutants to disrupt cannibalism 
interactions. Using cathepsins K and S as the model system, reactions (1) and (2) describe 
the possible cannibalism interactions between the two cathepsins. (3) Active site dead 
mutants are not catalytically active and can act as a substrate to a cannibal cathepsin. (4) 
Cannibalism-resistant mutants (or cleavage resistant mutants) can still degrade substrate 
but cannot be hydrolyzed by a cannibal cathepsin. 
8.2 Materials and Methods 
8.2.1 Design of cannibalism-resistant mutants 
 Putative cleavage site locations were determined by comparing each of cathepsin 
K, L, S, and V’s amino acid sequences with active site specificity matrix (available from 
the MEROPS online peptidase database) of each enzyme’s active site to score the 
likelihood that a given amino acid in position P4 through P4’ will be cleaved by the 
cathepsin’s active site [131] using the PACMANS program [129] described in Chapter 3. 
Locations in the propeptide of each enzyme were excluded, since this region was cleaved 
during activation to the mature enzyme and would not be part of the molecule in 





























the sequences locations were reviewed for accessibility by an external protease (as 
described in Figure 3-2).  Once the accessible sequences were identified, each amino acid 
score for the 8 amino acid sequence was reviewed and the greatest scoring residue in the 
sequence was mutated to reduce the overall sequence score combined with the known 
“safe” residue substitutions [137] as shown in the example in Figure 8-2.  
 The active site dead mutants were designed by mutating the three active site 
residues in the catalytic triad that are conserved in all of the cysteine cathepsins: cysteine, 
histidine, and asparagine [3, 21]. The active site cysteine (C) was mutated to alanine (A) 
or serine (S), the active site histidine (H) was mutated to an alanine (A), asparagine (N), or 
glutamine (Q), and the active site asparagine (N) was mutated to alanine (A) or aspartic 
acid (D). 
 
Figure 8-2. Example of how point mutations to interrupt cathepsin cannibalism 
interactions were determined from top scoring PACMAN sequences. 
 
 
P4’ P3’ P2’ P1’/ P1 P2 P3 P4
(251) A S L T		/ S F Q F (258)
63 57 244 76	/ 128 16 37 12




Cumulative Score for (251) ASLTSFQF (258) Sequence: 633




8.2.2 Site-directed mutagenesis using overlap extension PCR  
 The mutant cathepsins were made using site-directed mutagenesis using overlap 
extension polymerase chain reaction (PCR) [133]. Figure 8-3 shows a schematic of the 
method; first forward and reverse mutagenic primers were designed to introduce a mutation 
into the cathepsin gene. The primers were designed such that:  
• Primers had at least 15 bases of conserved sequence (exact match) and at least 15 
nucleotides overlap on their 5’ ends 
• Primers were between 25 and 30 nucleotides long with a high guanine/cytosine 
content (at least 60%) to ensure a high melting temperature (want at least 60°C) 
• Primers had 3 or 4 guanine/cytosine nucleotides in the last six bases as a clamp to 
enhance annealing to the template  
 
Figure 8-3. Schematic of approach for making cathepsin mutants by site-directed 
mutagenesis using overlap extension polymerase chain reaction. Cathepsins mutants 
were made to the wildtype cathepsin gene and then inserted into the pCDNA 4/TO/myc-
His vector. 
Then two rounds of PCR were carried out with the forward and reverse flanking primers 




first two reactions to create the full-length cathepsin gene with the point-mutation. The 
gene was then ligated (T4 DNA Ligase, New England Biolabs) into the pcDNA 4/TO/A 
plasmid (Invitrogen), which had zeocin resistance and a C-terminal polyhistidine tag for 
nickel-column purification. The plasmid was then amplified in bacteria cells and sequenced 
(Genewiz) to verify correct point mutations were introduced.  
8.2.3 Stable expression and purification of mutant cathepsins 
Once the mutant plasmid sequences were sequenced to confirmed the designed 
mutation was introduced, stable cell lines to produce the mutant cathepsins were created to 
purify the mutant enzymes. First the plasmid was linearized with ScaI (New England 
Biolabs) to stably transfect HEK293T cells using Lipofectamine 2000 (Thermo Fisher 
Scientific). After two days, the cells were selected with zeocin (InvivoGen). After the cells 
were selected for four weeks for the plasmid with zeocin resistance and plasmid has been 
incorporated into the cell’s genome through homologous recombination, the cell lysate and 
media were collected for purification by the polyhistidine tag with nickel columns in the 
ProBond Purification System (Invitrogen).   
To induce cathepsin expression, cathepsin mutant cell lines were created in a T-
REx inducible system (ThermoFisher Scientific) [230], where naïve HEK293T cells were 
transfected with 10µg of the Tet repressor plasmid (TetR) and 1µg of mutant cathepsin 
plasmid. Naïve HEK293T cells were simultaneously transfected with linearized TetR and 
mutant cathepsin plasmids and after two days, the cells were selected with both zeocin (230 




media for the TetR plasmid). The TetR repressed the expression of target cathepsin 
sequence transfected and when tetracycline was added to the stable cell lines, the mutant 
cathepsin of interested was then transcribed and translated into protein. 
8.2.4 Western blot and multiplex cathepsin zymography 
Using the stable cell lines or transiently transfected cells, Western blots and 
multiplex cathepsin zymography were performed on cell lysate to first determine if there 
was mature or procathepsin detectable by Western blot and if there was gelatinase activity 
detectable by cathepsin zymography.  Western blot samples were in a reducing loading dye 
with b–mercaptoethanol to break all disulfide bonds.  Samples were resolved on a 12.5% 
SDS-PAGE gel and then transferred to a nitrocellulose membrane (BioRad), blocked for 1 
hour (LI-COR Bioscience), then probed with a primary antibody overnight.  Primary 
antibody solutions for monoclonal mouse anti-human cathepsin K (1:500, Millipore), 
polyclonal goat anti-human cathepsin L (1:1000, R&D Systems), polyclonal goat anti-
human cathepsin S (1:1000, R&D systems) and monoclonal mouse anti-human cathepsin 
V (1:1000, R&D Systems) were made in Odyssey Blocking Buffer (LI-COR Bioscience) 
diluted 1:2 with PBS. The following day, primary antibody solutions were saved and 
membranes were probed with anti-mouse or anti-goat secondary antibodies (1:5000 with 
0.1% Tween, Invitrogen) tagged with an infrared fluorophore and imaged on with a LI-
COR Odyssey scanner.  
The multiplex cathepsin zymography assay was used to quantify cathepsin gelatinase 




polymerized with gelatin and cell lysate samples were loaded with a non-reducing loading 
dye. Then electrophoresis separated the sample proteins by molecularly weight. The gel 
was then put in a renaturing buffer (65 nM Tris buffer at pH 7.4 with 20% glycerol) to 
allow the cathepsins to re-fold into their native confirmation. Gels were then incubated in 
assay buffer, either 0.1 sodium acetate buffer at pH 4.0 or 0.1M sodium phosphate buffer 
at pH 6.0 both with 1mM EDTA and freshly added 2mM dithiothreitol (DTT), overnight 
at 37°C. The gel was stained the following morning with Coomassie blue (4.5% Coomassie 
blue, 10% acetic acid, 25% isopropanol) and destained (10% acetic acid, 10% isopropanol). 
On zymograms, areas with white bands indicate cathepsin activity. Zymograms were 
imaged with ImageQuant LAS 4000 (GE Healthcare). Densitometry quantification using 
ImageJ (NIH) was used to quantify white zymogram intensity bands and Western blot 
bands. These studies gave information about the structural stability of the mutant 
cathepsins. 
8.3 Results 
8.3.1 Verification and validation of cathepsin mutants 
To verify the direction of cannibalism experimentally, cathepsin mutants were 
designed to test both directions: 
(1) Active-site mutant (Figure 8-1, Reaction 3): a cathepsin was mutated to be 
active-site-dead, meaning it does not have catalytic activity, but can still be cleaved by 




histidine, and asparagine, which make up the conserved active site cleft of cysteine 
cathepsins, and  
(2) Cannibalism-resistant (cleavage-site) mutant (Figure 8-1, Reaction 4): 
mutated cathepsin is not cleavable by other cathepsins, but the mutated cathepsin can still 
cannibalize cathepsins. 
Both active-site and cleavage-site mutations could change the folding of cathepsins. 
Some could be produced only the inactive procathepsin form, others may be activated to 
the mature form, and some of the mutations may not produce protein detectable by Western 
blot. The summary of cathepsin mutants generated and whether they produced positive 
Western blot and/or zymography signal was described in Table 8-1.  Cathepsin K mutants 
were generated and tested first to inform other cathepsin mutant design. Seven active-site 
cathepsin K mutants were created and only three of those mutations produced protein 
detectable by Western blot and none of the mutant proteins had detectable gelatin 
zymography signal (Figure 8-4A). All cathepsin K cannibalism-resistant mutants were 
detectable by Western blot and cannibalism-resistant mutants have catalytic activity 
detectable by gelatin zymography (Figure 8-4A). Cathepsin L cannibalism-resistant 
mutants produced procathepsin L and both isoforms of mature cathepsin L were detectable 
by Western blot and most retained their gelatinase activity as detected by gelatin 
zymography (Figure 8-4B). The procathepsin form of cathepsins S and V were detected by 
Western blot, suggesting these mutations fold into a confirmation that could be activated 




mutants had detectable catalytic activity by gelatin zymography, while active site dead 
mutants had reduced catalytic activity (Figure 8-4C, D). 
 
Table 8-1. Summary of protease present of mutant cathepsin protein resulted in 
positive Western blot or gelatin zymography signal. Active-site mutations were made of 
the active site cysteine (C), histidine (H), and asparagine (N). All other mutations made 
were cannibalism-resistant mutations. Not all mutations of the same residue yielded 
detectable protein. For Western blots, positive signal was distinguished between if only the 
procathepsin was detectable or both procathepsin and mature cathepsin detected. 
 
CATHEPSIN K Western Blot Zymography CATHEPSIN L Western Blot Zymography
C139A Pro & mature No L158V Pro & mature Yes
C139S No No E176N Pro & mature Yes
V171A Pro-form Yes V239G Pro & mature No
L253A Pro-form Yes E289N Pro-form No
L253V Pro-form Yes S326A Pro & mature Yes
H276A No No
H276N No No CATHEPSIN V Western Blot Zymography
H276Q Pro-form No C138A Pro & mature No
N296A No No H277Q Pro & mature No
N296D Pro-form No N301D No No
CATHEPSIN S Western Blot Zymography L158V No No
C139A No No V219G Pro & mature Yes
H278Q Pro & mature No
N298D Pro & mature No





Figure 8-4. Designed cathepsin cannibalism-resistant and active site dead mutants for 
cathepsins K, L, S, and V. Cathepsin (cat) mutants were verified for folding and catalytic 
activity with Western blots and gelatin zymography for catK (A), catL (B), catS (C), and 
catV (D).  
8.3.2 Cathepsin K mutants retain elastinolytic activity 
Cathepsin K mutants retained elastinolytic activity (Figure 8-5). To account for the 
elastinolytic activity of other proteases secreted by the cell, each mutant was also inhibited 
with the small molecule inhibitor E-64.  Naïve HEK293T cells have minimal cysteine 
cathepsin activity, so we assumed the elastinolytic activity inhibitable by E-64 was due to 
the overexpression of the mutant cathepsins.  In the case of wildtype cathepsin K, 45% of 
the total elastin cleavage was attributed to cathepsin K. Furthermore, from the cathepsin K 
mutants, the cleavage-site mutants retained some of their elastinolytic activity with at least 
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attributed to wildtype cathepsin K.  Active-site mutants lost much of their elastinolytic 
activity, however the was site-dependent. Mutations of the active site histidine (H) resulted 
in the greatest loss of elastinolytic activity compared to the mutations of the cysteine (C) 
and asparagine (N).  
 
Figure 8-5. Elastinolytic activity of cathepsin K mutant stable cell lines. Cathepsin K 
mutants were overexpressed in HEK293T cells and incubated with DQ-elastin in the 
presence and absence of the small molecule inhibitor E-64 to account for elastinolytic 
degradation by other proteases secreted by the cells. The y-axis shows the percentage of 
elastin degradation attributed to the expression of the cathepsin K mutants.  
8.3.3 Cathepsin K L253A cannibalism-resistant mutant resists hydrolysis by cathepsin S 
and autodigestion by cathepsin K  
Cathepsin K mutants were tested for their cleavage resistance through co-
incubation studies with cannibal cathepsin (recombinant cathepsin S) as well as with 
autodigestion by recombinant cathepsin K. The L253 mutation protected against 




the L253A mutation providing the most protection from degradation by cathepsin S.  The 
V171A mutation also provided some protection from hydrolysis by cathepsin S, when 
compared to wildtype cathepsin K co-incubated with cathepsin S, however there was still 
a significant decrease compared to V171A without cathepsin S present.   
 
Figure 8-6. Cathepsin K L253A mutant was resistant to autodigestion. Cathepsin K 
mutants were co-incubated with and without recombinant cathepsin K for 120 minutes and 
samples were run on a Western blot to detect amount of cathepsin remaining. Mutant 
cathepsins were detected with a His-tag primary antibody to distinguish from the addition 
of recombinant cathepsin K to the system. 
Cathepsin K is known to autodigest, or hydrolyze itself, when incubated without 
substrate [7]. The autodigestion potential of these cannibalism-resistant cathepsin K 
mutants were tested by co-incubated cathepsin K mutants with wildtype recombinant 
cathepsin K (Figure 8-6). In addition to resisting being cannibalized by cathepsin S, the 
L253A cathepsin K mutant was also resistant to autodigestion by wildtype cathepsin K 
over 120 minutes. Cathepsin K V171A and L253V mutants both were autodigested by their 





















































respectively, by 120 minutes; compared to the L253A mutant, where there was only a 
reduction of 19.9% by 120 minutes. At 120 minutes, recombinant wildtype cathepsin K 
autodigested 18.5%, leaving 65.6% of the cathepsin K L253A mutant remaining after co-
incubation with recombinant wildtype cathepsin K. The cathepsin K L253A mutant was 
the most robust cleavage site resistant mutant by being resistant to cleavage by cathepsin 
S and cleavage by wildtype cathepsin K. 
 
8.4 Discussion 
This work shows that multiple cathepsin species in a single system can, in fact, alter 
the expected amounts of cathepsins present. Furthermore, cleavage site mutants provide 
experimental proof that these cathepsins are binding and degrading each other at these 
specific locations, which can be applied as “decoy” cathepsins to protect matrix substrates 
from degradation to prolong the functional lifespan of biological machines. The 
computational model of the cathepsin proteolytic network developed in Chapter 7 can be 
refined by confirming the directionality of cannibalism terms and reducing any 
unnecessary parameters and reactions in the network model. Kinetic studies varying the 
amounts and species of cathepsins present can be performed and used to determine the 







Figure 8-7. Cathepsin K mutant cell lines stop producing cathepsin K over time. 
Comparing freshly thawed cells and cells in culture for two weeks, the stable cell lines 
stopped producing the cathepsin K mutants they were transfected to overexpress. This was 
detected both by gelatin zymography as well as by Western blot. Furthermore, 
overexpression of cathepsin K appears to induce expression of cathepsin L (20kDa) and 
this zymography signal also changes over time as the cathepsin K signal (37kdDa) was 
reduced.  
Purification of these mutant cathepsins was a significant effort in biochemistry, 
overexpressing cathepsin mutants was detrimental to cell health and the cell lines stopped 
overexpressing the cathepsins over time (Figure 8-7). However, to combat issue, we 
created and used tetracycline inducible (Tet-inducible) stable cell lines for each of the 
mutants. Using the Tet-inducible systems, we controlled when cathepsins were being 
produced, so that we can purify directly from the cathepsins secreted into the media for a 
finite amount of time, without having the continual overexpression of cathepsins becoming 
detrimental to cell health and minimizing the changes in cellular regulating. Based on 
observations of the cathepsin cell lines, we hypothesized that cathepsins can cleave cell 





































cells ability to adhere to the cell plates. We have observed that in the overexpression cell 
lines, the cells visually do not have the same cobblestone morphology as the naïve 
HEK293T cells and the cells easily lift of the plate, suggesting they were not adhering as 
well as HEK293T cells without overexpression of cathepsins. This observation was also 
supported by cathepsins purification with the Tet-inducible cell lines, which have not yet 
successfully been able to be revived after collecting secreted cathepsins from these cells. 
During this mutant design and protein purification process, it has become clear that 
much of the enzymes produced from these systems are in the procathepsin form that needs 
to be activated, meaning the propeptide obscuring the active site of the cathepsin must be 
cleaved to detect catalytic activity. We successfully activated our purified samples by 
incubating them in a pH 4.0 sodium acetate buffer as well as through pepsin activation.  As 
we move forward with utilizing these cathepsin mutants to test experimental hypothesis 
and connect back to the cathepsin proteolytic network model, it will be important to make 
sure we have an accurate characterization of the amount of cathepsin used in an experiment.  
As demonstrated with parameter estimation and model structure of the cathepsin 
proteolytic network model described in Chapter 7, even the presence of inactive cathepsin 
can alter the expected substrate degradation. Since most readily purified cathepsins are in 
the procathepsin form, we can characterize the activation profile, like we did with cathepsin 
V (Figure 7-5A) and use that information to calculate the actual amount of active cathepsin 




These cathepsin mutants provide an exciting opportunity to tease apart the complex 
cathepsin-cathepsin interactions within the cathepsin proteolytic network.  Just from 
generating these cathepsin mutants, we found that not all mutations can be introduced into 
the cathepsins structures, and those mutations that can successfully be introduced have 
varying effects on the catalytic activity of these cathepsins. Furthermore, overexpression 
of cathepsins in cellular systems alter the proteolytic network dynamics, as evident by the 
upregulation of cathepsin L in the cathepsin K mutant overexpression (Figure 8-7). This 
further highlights the importance of a comprehensive cathepsin proteolytic network model 
that reliably predicts the cathepsins’ responses to perturbations to effectively target 
cysteine cathepsins in tissue destructive diseases and control biological machine matrix 
proteolysis.  Altering one node in this network results in non-linear and unintuitive changes 
that need to be quantified to effectively inhibit cathepsins without unforeseen consequences 





CHAPTER 9. CONCLUSIONS AND FUTURE DIRECTIONS 
9.1 Major Findings 
Throughout this dissertation, we have improved the current understanding of 
protease-protease interactions and in attempts to exploit these interactions in therapies for 
tissue destructive diseases and development of long-lived, stable, locomoting biological 
machines. This work developed a mechanistic model to quantify the interactions between 
cathepsins K, L, S, and V and extracellular matrix substrates collagen and elastin. 
Extending the previous discovery of cathepsin cannibalism between cathepsins K and S, 
we verified and modeled the cannibalistic interactions between cathepsins K, L, S, and V.  
To confirm the directionality of cathepsin cannibalism interactions, we developed a 
bioinformatics analysis tool, PACMANS, to compare the active site specificity matrix of a 
cannibal cathepsin to the sequences of a substrate cathepsin to validate the cathepsin 
proteolytic network model’s predicted interactions.  This also allowed us to determine the 
specific locations of where one cathepsin species binds to another, through development 
of 23 different cannibalism-resistant and active-site-dead mutants to study these mutant’s 
interactions with wildtype cathepsins. Furthermore, we have shown that by introducing 
point-mutations we can interrupt cathepsin cannibalism interactions from occurring.  
This work explored the role of proteolytic activity in destabilizing locomoting 
biological machines. First, we determined the cathepsin and matrix metalloproteinase 




functional lifespan. We reported that these engineered living systems produce an increasing 
amount of active cathepsin L over this time frame, independent of electrical stimulation.  
MMP-2 and MMP-9 were also expressed by these biological machines, but in contrast to 
cathepsin L, MMP-9 was reduced by day 12 and MMP-2 activity was constant during this 
timeframe. When these bio-bots were culture with ACA, a fibrinolysis inhibitor known to 
stop plasmin degradation of fibrin, although this serine protease inhibitor was not expected 
to affect cathepsin L, the ACA cultured bio-bots showed a reduction in active cathepsin, 
however the cathepsin L was still increasing over time. This temporal increase in cathepsin 
L proteolysis was independent of bio-bot design parameters including cell seeding density, 
hydrogel stiffness, and optogenetic stimulation. Furthermore, when we cultured these bio-
bots with E-64, a broad spectrum cathepsin small molecule inhibitor, we found that we 
could reduce the amount of cathepsin bound to muscle strip matrix protein, without 
affecting cell viability and passive tension in the muscle strips. In fact, the E-64 cultured 
bio-bots had a prolonged the average life expectancy to at least 3.5-fold greater than 1X 
ACA cultured muscle strip. To better understand the life expectancy of these bio-bots, we 
analyzed different survival functions and discovered that a Weibull distribution could 
accurately capture variability and life expectancy of the bio-bots cultured in different 
amounts of ACA. Moreover, we uncovered a possible relationship that between the 
Weibull parameters and the ACA concentration that can be further explored to help predict 




Finally, we explored the possibility of fibrin(ogen) as a novel substrate for cysteine 
cathepsins.  Using independent computational modeling methods, molecular docking and 
active site specificity analysis, we identified locations where cathepsins K, L, and S could 
bind to the three chains of fibrinogen. We also showed experimentally that these potent 
proteases can degrade fibrinogen and although these cathepsins have redundant substrate 
preferences, they all degraded the three chains of fibrinogen different. This novel 
mechanism of fibrinogenolysis has a variety of niches, including in the blood of individuals 
with sickle cell anemia, who have increased cathepsin activity and have been reported to 
have an increased concentration of circulating fibrinopeptide A. This mechanism also plays 
a role in biological machine and other engineering living system construct that uses fibrin 
networks.  Many cell types produce cathepsins and in these synthetic environments where 
fibrinogen is combined with thrombin, other matrix proteins, and cells, cathepsins may 
play a larger role in that network formation than previously understood. 
The cumulative findings of this doctoral thesis provide a novel understanding of the 
cathepsin proteolytic network and exploiting these interactions can be used in therapies for 
tissue destructive disease and for more control of engineered livings systems. However, 
there remains a large body of work yet to be completed with regards to layering on cellular 
complexities to this cathepsin proteolytic network.  The work of this dissertation focused 
primarily on recombinant enzyme work, but studying these systems in cellular systems 
where these cathepsins can be separated by different compartments, they are exposed to a 




regulation can counter-act perturbations to the cathepsin proteolytic network is the next 
major step in controlling this proteolytic activity. 
9.2 Future Research Directions 
9.2.1 Cathepsin Proteolytic Network Dynamics 
Cysteine cathepsin are upregulated in a variety of tissue destructive disease and 
currently researchers have had trouble specifically targeting cathepsin activity [38].  From 
the clinical aspect, all the well-designed cathepsin inhibitors have been effective at 
stopping disease progression, but could not advance to later-stage clinical trials because of 
off-target side-effects [47, 110]. The major findings of this dissertation highlight the 
importance of a complete picture of the proteolytic network to effectively target cathepsins. 
A better picture of the cathepsin proteolytic network offers a way to re-examine those 
pharmaceutical inhibitors to adjust the dosing to find a safe dose for patients that still 
achieve the desired therapeutic effect. Furthermore, with the insights gained in this doctoral 
thesis, researchers can develop more-effective strategies at targeting the cathepsin activity 
with potential combination therapies to treat tissue destructive illnesses. 
9.2.1.1 Cellular effects on the cathepsin proteolytic network 
In this work, we present evidence that cathepsins K, L, S, and V exhibit complex 
cathepsin cannibalism interactions, regulating the amount of enzyme available to degrade 
substrates. We have also demonstrated that even overexpressing a single cathepsin causes 




overexpressed and a compensatory regulator cathepsin is upregulated by the cells for a 
period and eventual the cathepsin of interest is no longer detected, at which point the 
regulatory cathepsin returns to its normal levels. This complicated cellular feedback 
observed within HEK293T cells, a cell line considered easy to transfect, so this underscores 
that complex cathepsin proteolytic dynamics that likely vary between cell types.  
Previous research from our lab and from others has shown that inhibiting cathepsins 
activity in cellular systems does not result in a dose-dependent decrease in cathepsin 
activity [71, 124]. Once it is understood how a given cell type will compensatory for 
varying the concentration of one species of cathepsin over another, layering on cathepsin 
inhibitors may be easier to predict the cellular responses and that information can be used 
to for dosing and determining if inhibitor combination treatments are necessary to 
specifically control the proteolytic activity in a pathological state.  
9.2.1.2 Impact of inter-familial proteases interactions on cathepsin proteolytic dynamics 
Cells do not live in a cysteine cathepsin bubble, and secrete other proteases to 
perform other homeostatic functions. Matrix metalloproteinases (MMPs) are a class of 
protease with similar substrates to cathepsins and are upregulated in tissue destructive 
disease. We have also characterized their proteolytic activity in biological machines.  We 
[129] as well as others [216] have started to explore the inter-familial protease interactions 
between cathepsins and MMPs.  Future work in this area should explore these inter-familial 
interactions and layer on to the cathepsin proteolytic network model developed in Chapter 




prefer acidic environments, while MMPs prefer neutral environments), these two classes 
of enzymes serve similar function and are likely involved in regulating each other. In the 
biological machines cultured with E-64 (discussed in Chapter 6), we observed the 
inhibition of cathepsin L also resulted in an increase in MMP-2 activity. As cellular 
regulation is incorporated in cathepsin proteolytic network model, it is important to 
consider what role other proteases may play a part in this expansion.  
9.2.2 Biological Machine Development 
In order to develop multicellular functional units with the ability to sense, process 
signals, and produce force and motion in response to external stimuli, the interactions 
between cells in the biological machine must first be understood. Specifically, how the 
cells regulate their extracellular matrix through proteolysis and characterizing the 
proteolytic network of these cells is crucial for designing biological machines that can be 
used for prolonged functional times. Moreover, as different cell types are incorporated into 
these engineered living systems, the heterotypic contact can change the protease signature 
in non-intuitive ways, which is an important element to consider in biological machine 
design and development. 
9.2.2.1 Expanding life expectancy model 
Developing a mechanistic model of biological machine life expectancy is important 
for designing interventions to control the life expectancy of future biological machines.  




would need to be expanded to improve its predictive power. First, the protease 
compartment assumes a linear increase in active cathepsin L far beyond the 12 day time 
frame we have characterized. To expand this model, it would be important to characterize 
the protease activity of these “older” bio-bots to make sure that compartment is not just 
linearly increasing indefinitely, especially since there is some evidence in other 
mammalian muscle development that cathepsin activity is turned down after a certain time 
point [222].  Likewise, it would be good to confirm that other proteases are not turned up 
at later time points to a shift in the proteolytic network if cathepsin L is turned down. A 
more well-defined protease compartment could allow design of different interventions to 
control the life expectancy.   
Addition of mechanical information could also be beneficial to the predictive power 
of the life expectancy model.  Currently this information is excluded, but especially if these 
bio-bots are living for months, what is the effect of the continual passive tension on the 
mechanical integrity of the bio-bot muscle strip? There could be a certain “age” at which 
extracellular matrix stiffening can prolong the functional lifespan, which would need to be 
further investigated. Stress information overlaid on this graph model could also help predict 
if muscle strips break in certain locations that would need to be appropriate reinforced for 
a designed life expectancy. No pattern has been seen in the simulations analyzed of the 
current model, edges are just cleaved until a certain proportion of all the edges are gone, 
but in dynamic system that is constantly held in tension, certain cleaved edges may have 




histological stained Masson’s Trichrome samples could be used to help information the 
thresholds values used.   
9.2.2.2 Inducible control of cysteine cathepsin expression in bio-bots 
Work discussed in this dissertation has underscored the importance and hydrolytic 
potential of cysteine cathepsins on fibrin(ogen). Biological machines express increasing 
amounts of cathepsin L over time and cathepsin L can degrade the major matrix 
components of the muscle strips. Through the work discussed in Chapter 8, we created 
tetracycline inducible wildtype and mutant cathepsins and the lab has tetracycline inducible 
cystatin, which is an endogenous inhibitor of cathepsin activity. Future generations of 
biological machines can be genetically engineered to controllably express “decoy” 
cathepsins or cystatins to control the proteolytic activity of these biological machines over 
time. For example, if a future, self-sustaining biological machine muscle strip expressed 
inducible cystatin C, the bio-bot can be cultured in (or pre-treated with time-release with) 
tetracycline to have the muscle strip express cystatin C while it performed its designed 
function, then when the tetracycline ran out, the cathepsin activity of the biological 
machine could increase and degrade the matrix. This same example would also apply to a 
muscle strip expressing inducible active site dead cathepsins that can act as a decoy 
substrate. The scenario to choose would be dictated by that would be the downstream effect 
of adding in an inhibitor to the system over another cathepsin (interactions that could be 
teased apart as described in 9.2.1.1). Moreover, if the goal is to shorten the life expectancy 




cannibalism-resistant mutant could be employed to speed up the muscle strip 






APPENDIX A. PACMANS GUI CODE 
 The PACMANS GUI developed in Chapter 3 [129] is available online for 
download at http://platt.gatech.edu/PACMANS. This GUI was developed in MATLAB as 
an application that can be download and run through MATLAB.  The base code for the 
GUI is included in this Appendix. 
A.1  PACMANS User Interface 
 
Figure A-1. User interface for PACMANS. User inputs include: (1) the MEROPS link 
to the specificity matrix of the protease-ase and (2) the amino acid sequence for the 




A.2  PACMANS Main GUI Code 
function varargout = PutSiteCleavageGUI(varargin) 
% PUTSITECLEAVAGEGUI MATLAB code for PutSiteCleavageGUI.fig 
%      PUTSITECLEAVAGEGUI, by itself, creates a new PUTSITECLEAVAGEGUI or 
raises the existing 
%      singleton*. 
% 
%      H = PUTSITECLEAVAGEGUI returns the handle to a new 
PUTSITECLEAVAGEGUI or the handle to 
%      the existing singleton*. 
% 
%      PUTSITECLEAVAGEGUI('CALLBACK',hObject,eventData,handles,...) calls the 
local 
%      function named CALLBACK in PUTSITECLEAVAGEGUI.M with the given 
input arguments. 
% 
%      PUTSITECLEAVAGEGUI('Property','Value',...) creates a new 
PUTSITECLEAVAGEGUI or raises the 
%      existing singleton*.  Starting from the left, property value pairs are 
%      applied to the GUI before PutSiteCleavageGUI_OpeningFcn gets called.  An 
%      unrecognized property name or invalid value makes property application 
%      stop.  All inputs are passed to PutSiteCleavageGUI_OpeningFcn via varargin. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
  
% Edit the above text to modify the response to help PutSiteCleavageGUI 
  
% Last Modified by GUIDE v2.5 22-Dec-2016 15:15:01 
  
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @PutSiteCleavageGUI_OpeningFcn, ... 
                   'gui_OutputFcn',  @PutSiteCleavageGUI_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 







    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
  
  
% --- Executes just before PutSiteCleavageGUI is made visible. 
function PutSiteCleavageGUI_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to PutSiteCleavageGUI (see VARARGIN) 
  
% Choose default command line output for PutSiteCleavageGUI 
handles.output = hObject; 
  
% Update handles structure 
guidata(hObject, handles); 
  
% Adds in graphics 
imshow('PlattLogo2.jpg', 'Parent', handles.axes6); 
imshow('ProteaseAseSchematic.jpg', 'Parent', handles.axes7); 
  
% --- Outputs from this function are returned to the command line. 
function varargout = PutSiteCleavageGUI_OutputFcn(hObject, eventdata, handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Get default command line output from handles structure 
varargout{1} = handles.output; 
  
% --- Executes on button press in calcScoresButton. 
function calcScoresButton_Callback(hObject, eventdata, handles) 
% hObject    handle to calcScoresButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 





% Getting loaded components 
 matrixLink = get(handles.SpecMat, 'string'); 
 if(strncmpi(matrixLink, 'https://', 5)) 
     matrixLink = strrep(matrixLink, 'https://merops.sanger.ac.uk/cgi-bin/pepsum?id=', ... 
         'http://meghan.ferrall-fairbanks.com/merops_data/'); 
 elseif (strncmpi(matrixLink, 'http://', 4)) 
     matrixLink = strrep(matrixLink, 'http://merops.sanger.ac.uk/cgi-bin/pepsum?id=', ... 
         'http://meghan.ferrall-fairbanks.com/merops_data/');     
 else 
      matrixLink = strrep(matrixLink, 'merops.sanger.ac.uk/cgi-bin/pepsum?id=', ... 
     'http://meghan.ferrall-fairbanks.com/merops_data/');  
 end 
  
 matrixLink = strcat(matrixLink, '.csv'); 
 specmat = getSpecifMat(matrixLink); 
  
sequence = get(handles.AAseq, 'string'); 
  
% Removes any spaces from sequence 
% temp2 = sequence; 
% temp1 = ''; 
%  
% while ~strcmp(temp1, temp2) 
%     temp1 = temp2; 
%     temp2 = regexprep(temp1, ' ', ''); 
% end 
%sequence = temp2; 
  
% saving three components into matfile needed for csa_calscore  
% followed along with example:  
% http://www.mathworks.com/help/matlab/import_export/load-parts-of-variables-from-
mat-files.html 
save MatForScoring.mat sequence specmat -v7.3; 
  
% create output file name 
% csa_analyze will store the scoring of cleavage sites in this file 
%loadedData = load('MatForScoring.mat'); 
outputFileName = strcat(get(handles.protease, 'string'), 'on', get(handles.substrate, 
'string')); 
  
% convert bounds from strings to numbers 




highB = str2num(get(handles.highBound, 'string')); 
  
% account for if something weird is entered or if nothing is entered 
if  isempty(lowB) 
    lowB = 1; 
elseif (lowB < 1) || (lowB > 8) 
    lowB = 1; 
end  
  
if  isempty(highB) 
    highB = 8; 
elseif (highB < 1) || (highB > 8) 
    highB = 8; 
end 
  
% run csa_analyze code 
% looking at all 8 amino acid combinations 
csa_analyze('MatForScoring.mat', outputFileName, lowB, highB) 
  
  
function SpecMat_Callback(hObject, eventdata, handles) 
% hObject    handle to SpecMat (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of SpecMat as text 
%        str2double(get(hObject,'String')) returns contents of SpecMat as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function SpecMat_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to SpecMat (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 








function AAseq_Callback(hObject, eventdata, handles) 
% hObject    handle to AAseq (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of AAseq as text 
%        str2double(get(hObject,'String')) returns contents of AAseq as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function AAseq_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to AAseq (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 




function NTseq_Callback(hObject, eventdata, handles) 
% hObject    handle to NTseq (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of NTseq as text 
%        str2double(get(hObject,'String')) returns contents of NTseq as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function NTseq_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to NTseq (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 









% --- Executes on button press in loadDataButton. 
function loadDataButton_Callback(hObject, eventdata, handles) 
% hObject    handle to loadDataButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Getting loaded components 
 matrixLink = get(handles.SpecMat, 'string'); 
 if(strncmpi(matrixLink, 'https://', 5)) 
     matrixLink = strrep(matrixLink, 'https://merops.sanger.ac.uk/cgi-bin/pepsum?id=', ... 
         'http://meghan.ferrall-fairbanks.com/merops_data/'); 
 elseif (strncmpi(matrixLink, 'http://', 4)) 
     matrixLink = strrep(matrixLink, 'http://merops.sanger.ac.uk/cgi-bin/pepsum?id=', ... 
         'http://meghan.ferrall-fairbanks.com/merops_data/');     
 else 
      matrixLink = strrep(matrixLink, 'merops.sanger.ac.uk/cgi-bin/pepsum?id=', ... 
     'http://meghan.ferrall-fairbanks.com/merops_data/');  
 end 
matrixLink = strcat(matrixLink, '.csv'); 
SpecMatr = getSpecifMat(matrixLink); 
AminoAcidSeq = get(handles.AAseq, 'string'); 
  
% saving three components into matfile needed for csa_calscore  
% followed along with example:  
% http://www.mathworks.com/help/matlab/import_export/load-parts-of-variables-from-
mat-files.html 




function protease_Callback(hObject, eventdata, handles) 
% hObject    handle to protease (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
%  
  






% Hints: get(hObject,'String') returns contents of protease as text 
%        str2double(get(hObject,'String')) returns contents of protease as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function protease_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to protease (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function substrate_Callback(hObject, eventdata, handles) 
% hObject    handle to substrate (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% name of the substrate proteases 
get(handles.substrate, 'string'); 
  
% Hints: get(hObject,'String') returns contents of substrate as text 
%        str2double(get(hObject,'String')) returns contents of substrate as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function substrate_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to substrate (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  




% hObject    handle to lowBound (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of lowBound as text 
%        str2double(get(hObject,'String')) returns contents of lowBound as a double 
get(handles.lowBound, 'string'); 
  
% --- Executes during object creation, after setting all properties. 
function lowBound_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to lowBound (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 




function highBound_Callback(hObject, eventdata, handles) 
% hObject    handle to highBound (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of highBound as text 
%        str2double(get(hObject,'String')) returns contents of highBound as a double 
get(handles.highBound, 'string'); 
  
% --- Executes during object creation, after setting all properties. 
function highBound_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to highBound (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 







% --- Executes during object creation, after setting all properties. 
function axes6_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to axes6 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  




% --- Executes during object creation, after setting all properties. 
function axes7_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to axes7 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
  
% Hint: place code in OpeningFcn to populate axes7 
axes(hObject) 
imshow('ProteaseAseSchematic.jpg') 
A.3  PACMANS Supporting Functions Code 
function [ scores ] = csa_analyze( csafile, outfile, startp, endp ) 
%CSA_ANALYZE csafile outfile startp endp - perform cleavage site analysis on csafile 
%   csafile is a matlab .mat file with two variables - sequence and specmat 
%   sequence - text string of protein under analysis 
%   specmat - cell matrix of specificity values for the enzyme 
%   preference for substrate 
%   matrix format:  column 1: amino acid letter code 
%                   columns 2-x: specificity numbers for substrate sites 
  
if ~exist(csafile,'file') 





if ~exist('sequence','var') || ~exist('specmat','var') 






filehdl = fopen(strcat(outfile, '.txt') ,'w'); 
  
sequence = upper(sequence); 
  




residuesperline = 60; 
residuespergroup = 10; % Must be factor of residuesperline 
  
seqlen = length(sequence); 
numlines = ceil(seqlen / residuesperline); 
  
for i = 1:numlines 
    startpos = (i-1)*residuesperline + 1; 
     
    endpos = 0; 
     
    if i == numlines 
        remainder = mod(seqlen,residuesperline); 
        if remainder == 0 
            remainder = residuesperline; 
        end 
        endpos = startpos + remainder - 1; 
    else 
        endpos = i*residuesperline; 
    end 
     
    curline = sequence(startpos:endpos); 
     
    outline = ''; 
    curlinelen = length(curline); 
    numgroups = ceil(curlinelen / residuespergroup); 
    for j = 1:numgroups; 
        linestartpos = (j-1)*residuespergroup + 1; 
        lineendpos = 0; 
         
        if j == numgroups 
            remainder = mod(curlinelen,residuespergroup); 
            if remainder == 0 
                remainder = residuespergroup; 




            lineendpos = linestartpos + remainder - 1; 
        else 
            lineendpos = j*residuespergroup; 
        end 
         
        outline = [outline, curline(linestartpos:lineendpos), ' ']; 
    end 
     
    fprintf(filehdl,'%i\t%s\t%i\r\n', startpos,outline,endpos); 
end 
  





fprintf(filehdl,'Using site pockets %i through %i for analysis...\r\n\r\n', startp,endp); 
  
scores = struct('sequence',{},'score',{}, ... 
    'scoreNorm', {}, 'startpos',{},'endpos',{}, ... 
    'eachScore', {}, 'rangeScores', {}, 'medianScore', {}, ... 
    'leftcleavagelen',{},'rightcleavagelen',{});  
  
% pre-define matrix for individual scores 
  
  
testlen = endp - startp + 1; 
  
numsequences = seqlen - testlen + 1; 
% AA = zeros(1,testlen); 
% scores.eachScore = AA; 
  
  
singleLetterAA = {'G';'P';'A';'V';'L';'I';'M';'F';'Y';'W';'S';'T';'C';'N';'Q';'D';'E';'K';'R';'H'};  
  
% Specificity matrix where the columns correspond to each subsite from P4' 
% to P4 and the rows correspond to each of the 20 amino acids. Scores are 
% from MEROPS, which are generated based on pure counts (i.e. out of all 
% the substrate cleavages known, X number are known to the Gly in the P4' 
% position, etc.)  
specmat = specmat.data; 
  





totalNumSubstrates = sum(specmat,1); 
  
for i = 1:numsequences 
    curseq = sequence(i:i + testlen-1); 
    % Calculate scores 
   
    curscore = 0; 
    curseqscore = zeros(1, testlen); 
    curseqPscore = zeros(1, testlen); 
     
    for j = 1:length(curseq) 
        correctedJ = startp - 1 + j; 
        specmatrow = find(strcmp(singleLetterAA,curseq(j))); 
        curseqscore(1,j) = specmat(specmatrow,correctedJ);  
        curseqPscore(1,j) = 
specmat(specmatrow,correctedJ)/totalNumSubstrates(correctedJ);  
        curscore = curscore + specmat(specmatrow,correctedJ); 
    end 
     
    % Calculating range and median scores 
    maxScore = max(curseqscore); 
    minScore = min(curseqscore); 
    range = [minScore; maxScore]; 
     
    medianSco = median(curseqscore); 
  
%% Normalized Cumulative Score 
     
    % Normalize matrix scores to the total num substrates used to fill the 
    % MEROPS Specificity Matrix  
    % Snormi = counti / total 
     
    Snormi = 0;  
    for ii = 1:length(curseq) 
        Snormi = Snormi + curseqPscore (1, ii);  
    end 
     
%%   
    % convert each score matrix to a string 
    EachScoreStr = mat2str(curseqscore); 
     




    scores(i).sequence = curseq; 
    scores(i).score = curscore; 
    scores(i).scoreNorm = Snormi; 
    scores(i).startpos = i; 
    scores(i).endpos = i + testlen - 1; 
    scores(i).eachScore = EachScoreStr; 
    scores(i).medianScore = medianSco; 
    scores(i).rangeScores = range; 
    scores(i).leftcleavagelen = i + (testlen / 2) - 1; 
    scores(i).rightcleavagelen = seqlen - (i + (testlen / 2) - 1); 
    scores(i).leftcleavageweight = molweight(sequence(1:i + (testlen / 2) - 1)) / 1e3; 
    scores(i).rightcleavageweight = molweight(sequence(i + (testlen / 2):end)) / 1e3; 
     
end 
  
fprintf(filehdl, 'Scores sorted by cumulative score \n'); 
  
[unused, order] = sort([scores(:).score],2,'descend'); 
scores = scores(order);  
  
cumScores = zeros(length(scores), 2); 
  
for i = 1:length(scores) 
     
    fprintf(filehdl, '%i, \t', i); 
    fprintf(filehdl,'Score: %i,\t Norm: %5.2f,\t Start Pos: %i\t %s\t End Pos: %i\t 
Individual Scores: %s\t Range: [%5.2f,\t  %5.2f]\t Median: %5.2f\t (size,molweight): L: 
(%i,%6.2f)\tR: (%i,%6.2f)\r\n',... 
        scores(i).score, scores(i).scoreNorm, ... 
        scores(i).startpos,scores(i).sequence,scores(i).endpos,... 
        scores(i).eachScore, ... 
        scores(i).rangeScores(1), scores(i).rangeScores(2), scores(i).medianScore,... 
        scores(i).leftcleavagelen,scores(i).leftcleavageweight,... 
        scores(i).rightcleavagelen,scores(i).rightcleavageweight); 
    cumScores(i, 1) = scores(i).score; 
    cumScores(i, 2) = scores(i).scoreNorm; 
     
end 
  
if length(scores) > 8 
y1 = quantile(cumScores(:,1),0.95); 








h1 = histogram(cumScores(:,1)) 




h2 = histogram(cumScores(:,2)) 














function [tot,scores] = csa_calcscore(csafile, seq) 
  
    seq = upper(seq); 
  
    if ~exist(csafile,'file') 
        error('Input csafile does not exist.') 
    end 
  
    load(csafile); 
  
    scores = []; 
     
    for j = 1:length(seq) 
        specmatrow = find(strcmp(specmat(:,1),seq(j))); 
         
        scores = [scores, specmat{specmatrow,1+j}]; 
    end 
     






function out = getSpecifMat(url) 
  
%webopt = weboptions('ContentType', 'table');  
%out = webread(url, webopt); 
  
  
% matrixLink = get(handles.SpecMat, 'string'); 
% matrixLink = strrep(matrixLink, 'https://merops.sanger.ac.uk/cgi-bin/pepsum?id=', ... 
%     'http://meghan.ferrall-fairbanks.com/merops_data/'); 





%data = webread(matrixLink); 
%SpecMat = readtable(data, 'Delimiter',','); 
%SpecMat = cell2table(data); 
  








APPENDIX B. FULL PACMANS TOP SCORING TABLES FOR 
CATHEPSINS ON FIBRINOGEN CHAINS 
These are the supplemental tables of the full top 5% of PACMANS scores for 
fibrinogen a, b, and g chains cleaved by cathepsins K (Tables B-1 through B-3), L (Tables 
B-4 through B-6), and S (Tables B-7 through B-9) submitted with Ferrall-Fairbanks, 
M.C.*, West, D. M.*, et al. Computational predictions of cysteine cathepsin-mediated 
fibrinogen degradation. Blue sequences are those with molecular docking model with the 
active site facing the fibrinogen chain included in the paper and Chapter 4.   
 
B.1  Cathepsin K on Fibrinogen a, b, and g Chains 
Table B-1. Top 5% of PACMANS predicted fibrinogen a chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
182   1.06 26 DFLAEGGG 33 not in crystal structure 
170   1.00 821 YYPGGSYD 828 not in crystal structure 
168   0.96 167 KRLEVDID 174 allosteric/hairpin 
165   0.96 667 TSLGGWLL 674 not in crystal structure 
156   0.90 186 RALAREVD 193 allosteric/hairpin 
155   0.91 111 EILRGDFS 118 active site facing 
153   0.90 239 SQLQKVPP 246 not in crystal structure 
152   0.87 202 KQLEQVIA 209 active site facing 
150   0.88 490 DCPEAMDL 497 not in crystal structure 
150   0.88 769 GSVEEGAE 776 not in crystal structure 
145   0.83 259 MELERPGG 266 not in crystal structure 
145   0.84 726 VELEDWAG 733 not in crystal structure 
144   0.84 262 ERPGGNEI 269 not in crystal structure 
144   0.86 759 EGTAGDAL 766 not in crystal structure 
143   0.82 535 PMLGEFVS 542 not in crystal structure 
142   0.83 498 GTLSGIGT 505 not in crystal structure 
141   0.84 396 DSPGSGNA 403 not in crystal structure 




Table B-1 continued. 




Score Fibrinogen Sequence  
Inclusion/Exclusion 
Rationale 
139   0.81 132 EDLRSRIE 139 active site facing 
138   0.82 244 VPPEWKAL 251 not in crystal structure 
138   0.82 563 HHPGIAEF 570 not in crystal structure 
136   0.79 27 FLAEGGGV 34 not in crystal structure 
136   0.80 694 RGFGSLND 701 not in crystal structure 
135   0.83 73 LIDEVNQD 80 active site facing 
135   0.80 192 VDLKDYED 199 allosteric/hairpin 
135   0.78 650 IKLPGSSK 657 not in crystal structure 
135   0.79 765 ALIEGSVE 772 not in crystal structure 
134   0.80 715 HLLTQRGS 722 not in crystal structure 
133   0.79 21 DSGEGDFL 28 not in crystal structure 
133   0.79 211 DLLPSRDR 218 no docking models near  
133   0.81 699 LNDEGEGE 706 not in crystal structure 
132   0.80 844 VSFRGADY 851 not in crystal structure 
131   0.79 9 LVLSVVGT 16 not in crystal structure 
131   0.77 565 PGIAEFPS 572 not in crystal structure 
130   0.78 103 HSLTTNIM 110 no docking models near  
130   0.75 495 MDLGTLSG 502 not in crystal structure 
129   0.77 32 GGVRGPRV 39 not in crystal structure 
128   0.75 90 NSLFEYQK 97 active site facing 
128   0.76 377 SSVSGSTG 384 not in crystal structure 
128   0.75 627 RPVRDCDD 634 not in crystal structure 
127   0.75 300 SGPGSTGN 307 not in crystal structure 
127   0.75 326 SGPGSTGS 333 not in crystal structure 
127   0.77 724 LRVELEDW 731 not in crystal structure 









Table B-2. Top 5% of PACMANS predicted fibrinogen b chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
169   0.98 110 CQLQEALL 117 no docking models near  
158   0.92 210 QKLESDVS 217 no docking models near  
156   0.92 94 GCLHADPD 101 no docking models near  
155   0.91 339 ELLIEMED 346 globular 
148   0.85 174 SELEKHQL 181 no docking models near  
146   0.86 388 SQLMGENR 395 globular 
144   0.84 57 PSLRPAPP 64 not in crystal structure 
144   0.83 200 SILENLRS 207 active site facing 
141   0.85 179 HQLYIDET 186 active site facing 
139   0.82 376 RGTAGNAL 383 globular 
137   0.82 28 VKSQGVND 35 not in crystal structure 
137   0.84 105 LCPTGCQL 112 active site facing 
136   0.82 59 LRPAPPPI 66 not in crystal structure 
133   0.78 203 ENLRSKIQ 210 active site facing 
132   0.78 304 GNVATNTD 311 globular 
132   0.78 335 MGPTELLI 342 globular 
129   0.75 316 CGLPGEYW 323 globular 
127   0.76 89 APDAGGCL 96 no docking models near  
127   0.75 317 GLPGEYWL 324 globular 
127   0.73 322 YWLGNDKI 329 globular 
126   0.73 115 ALLQQERP 122 no docking models near  
125   0.73 254 MYLIQPDS 261 globular 
125   0.73 414 GWLTSDPR 421 globular 
124   0.76 20 LLLLCVFL 27 not in crystal structure 
124   0.77 116 LLQQERPI 123 no docking models near  






Table B-3. Top 5% of PACMANS predicted fibrinogen g chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
166   0.98 426 HHLGGAKQ 433 not in crystal structure 
160   0.92 222 KRLDGSVD 229 globular 
156   0.89 64 KDLQSLED 71 allosteric 
156   0.91 274 VELEDWNG 281 globular 
154   0.90 90 IQLTYNPD 97 active site facing 
153   0.91 445 DSLYPEDD 452 not in crystal structure 
150   0.89 305 AYFAGGDA 312 globular 
148   0.84 114 KMLEEIMK 121 active site facing 
147   0.86 67 QSLEDILH 74 allosteric 
147   0.85 155 AQLEAQCQ 162 active site facing 
143   0.83 416 NRLTIGEG 423 globular 
141   0.82 134 RYLQEIYN 141 active site facing 
139   0.80 35 CILDERFG 42 not in crystal structure 
137   0.83 438 HPAETEYD 445 not in crystal structure 
136   0.83 244 LSPTGTTE 251 globular 
135   0.80 148 VNLKEKVA 155 no docking models near  
135   0.80 293 VGPEADKY 300 globular 
134   0.82 317 DGFDFGDD 324 globular 
132   0.78 26 AYVATRDN 33 not in crystal structure 
130   0.78 18 LFLSSTCV 25 not in crystal structure 
128   0.75 3 WSLHPRNL 10 not in crystal structure 
127   0.77 272 LRVELEDW 279 globular 








B.2  Cathepsin L on Fibrinogen a, b, and g Chains 
Table B-4. Top 5% of PACMANS predicted fibrinogen a chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
1006   0.95 498 GTLSGIGT 505 not in crystal structure 
962   0.90 667 TSLGGWLL 674 not in crystal structure 
944   0.89 377 SSVSGSTG 384 not in crystal structure 
941   0.88 432 KLVTSKGD 439 not in crystal structure 
921   0.88 765 ALIEGSVE 772 not in crystal structure 
914   0.86 742 FRVGSEAE 749 not in crystal structure 
909   0.86 239 SQLQKVPP 246 not in crystal structure 
897   0.84 694 RGFGSLND 701 not in crystal structure 
888   0.83 26 DFLAEGGG 33 not in crystal structure 
887   0.83 495 MDLGTLSG 502 not in crystal structure 
878   0.83 481 EVVTSEDG 488 not in crystal structure 
878   0.82 634 DVLQTHPS 641 not in crystal structure 
877   0.83 447 EKVTSGST 454 not in crystal structure 
863   0.82 111 EILRGDFS 118 active site facing 
852   0.80 8 CLVLSVVG 15 not in crystal structure 
852   0.81 32 GGVRGPRV 39 not in crystal structure 
846   0.80 326 SGPGSTGS 333 not in crystal structure 
844   0.80 313 SGTGGTAT 320 not in crystal structure 
837   0.80 769 GSVEEGAE 776 not in crystal structure 
834   0.78 715 HLLTQRGS 722 not in crystal structure 
832   0.79 756 SSYEGTAG 763 not in crystal structure 
830   0.78 467 KTVIGPDG 474 not in crystal structure 
829   0.78 259 MELERPGG 266 not in crystal structure 
829   0.79 297 SGSSGPGS 304 not in crystal structure 
828   0.79 414 EEVSGNVS 421 not in crystal structure 
828   0.78 535 PMLGEFVS 542 not in crystal structure 
823   0.78 697 GSLNDEGE 704 not in crystal structure 
820   0.77 347 QNPGSPRP 354 not in crystal structure 
816   0.77 501 SGIGTLDG 508 not in crystal structure 
816   0.78 545 ESRGSESG 552 not in crystal structure 
815   0.76 295 WNSGSSGP 302 not in crystal structure 









Score Fibrinogen Sequence  
Inclusion/Exclusion 
Rationale 
805   0.76 12 SVVGTAWT 19 not in crystal structure 
805   0.75 186 RALAREVD 193 no docking models near  
805   0.76 300 SGPGSTGN 307 not in crystal structure 
804   0.76 9 LVLSVVGT 16 not in crystal structure 
803   0.76 650 IKLPGSSK 657 not in crystal structure 
803   0.76 815 ANLNGIYY 822 not in crystal structure 
800   0.76 753 LQVSSYEG 760 not in crystal structure 
794   0.75 504 GTLDGFRH 511 not in crystal structure 
791   0.75 339 SGTGSTGN 346 not in crystal structure 
789   0.75 132 EDLRSRIE 139 active site facing 
















Table B-5. Top 5% of PACMANS predicted fibrinogen b chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
936   0.89 115 ALLQQERP 122 no docking models near  
894   0.85 94 GCLHADPD 101 no docking models near  
894   0.85 414 GWLTSDPR 421 globular 
885   0.83 57 PSLRPAPP 64 not in crystal structure 
862   0.81 26 FLVKSQGV 33 not in crystal structure 
842   0.79 210 QKLESDVS 217 no docking models near  
840   0.79 100 PDLGVLCP 107 no docking models near  
839   0.80 185 ETVNSNIP 192 active site facing 
823   0.78 330 SQLTRMGP 337 globular 
822   0.78 339 ELLIEMED 346 globular 
815   0.78 38 EGFFSARG 45 not in crystal structure 
813   0.76 196 RVLRSILE 203 active site facing 
802   0.77 58 SLRPAPPP 65 not in crystal structure 
795   0.76 203 ENLRSKIQ 210 no docking models near  
789   0.74 64 PPISGGGY 71 not in crystal structure 
782   0.74 233 IPVVSGKE 240 globular 
782   0.74 301 QGFGNVAT 308 globular 
782   0.74 388 SQLMGENR 395 globular 
776   0.74 135 EAVSQTSS 142 active site facing 
776   0.73 381 NALMDGAS 388 globular 
764   0.71 110 CQLQEALL 117 no docking models near  
750   0.71 200 SILENLRS 207 active site facing 
745   0.71 214 SDVSAQME 221 no docking models near  
744   0.70 316 CGLPGEYW 323 globular 
742   0.70 234 PVVSGKEC 241 globular 






Table B-6. Top 5% of PACMANS predicted fibrinogen g chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
989   0.92 426 HHLGGAKQ 433 not in crystal structure 
915   0.87 239 EGFGHLSP 246 globular 
894   0.83 64 KDLQSLED 71 no docking models near  
877   0.83 16 ALLFLSST 23 not in crystal structure 
861   0.81 18 LFLSSTCV 25 not in crystal structure 
861   0.80 222 KRLDGSVD 229 globular 
840   0.80 125 SILTHDSS 132 active site facing 
828   0.78 259 IHLISTQS 266 globular 
827   0.78 39 ERFGSYCP 46 not in crystal structure 
804   0.76 305 AYFAGGDA 312 globular 
803   0.76 155 AQLEAQCQ 162 allosteric facing 
801   0.75 90 IQLTYNPD 97 active site facing 
792   0.75 209 EIDGSGNG 216 globular 
786   0.75 190 SGLYFIKP 197 globular 
785   0.75 242 GHLSPTGT 249 globular 
785   0.75 368 GHLNGVYY 375 globular 
770   0.72 306 YFAGGDAG 313 globular 
769   0.73 17 LLFLSSTC 24 not in crystal structure 
766   0.72 262 ISTQSAIP 269 globular 
759   0.71 416 NRLTIGEG 423 globular 
758   0.71 291 FKVGPEAD 298 globular 
748   0.70 53 DFLSTYQT 60 allosteric facing 








B.3  Cathepsin S on Fibrinogen a, b, and g Chains 
Table B-7. Top 5% of PACMANS predicted fibrinogen a chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
735   0.99 26 DFLAEGGG 33 not in crystal structure 
696   0.94 498 GTLSGIGT 505 not in crystal structure 
685   0.93 377 SSVSGSTG 384 not in crystal structure 
682   0.93 481 EVVTSEDG 488 not in crystal structure 
674   0.91 769 GSVEEGAE 776 not in crystal structure 
665   0.89 742 FRVGSEAE 749 not in crystal structure 
642   0.87 239 SQLQKVPP 246 not in crystal structure 
638   0.86 259 MELERPGG 266 not in crystal structure 
637   0.85 432 KLVTSKGD 439 not in crystal structure 
636   0.86 634 DVLQTHPS 641 not in crystal structure 
636   0.86 726 VELEDWAG 733 not in crystal structure 
627   0.85 447 EKVTSGST 454 not in crystal structure 
624   0.84 495 MDLGTLSG 502 not in crystal structure 
621   0.84 697 GSLNDEGE 704 not in crystal structure 
621   0.83 715 HLLTQRGS 722 not in crystal structure 
618   0.83 667 TSLGGWLL 674 not in crystal structure 
607   0.82 9 LVLSVVGT 16 not in crystal structure 
597   0.81 753 LQVSSYEG 760 not in crystal structure 
596   0.80 535 PMLGEFVS 542 not in crystal structure 
595   0.81 414 EEVSGNVS 421 not in crystal structure 
595   0.80 764 DALIEGSV 771 not in crystal structure 
592   0.81 111 EILRGDFS 118 active site facing 
591   0.79 249 KALTDMPQ 256 not in crystal structure 
590   0.80 12 SVVGTAWT 19 not in crystal structure 
588   0.79 296 NSGSSGPG 303 not in crystal structure 
588   0.80 765 ALIEGSVE 772 not in crystal structure 
583   0.78 8 CLVLSVVG 15 not in crystal structure 
581   0.79 800 AEVYGGGW 807 not in crystal structure 
579   0.79 365 SERGSAGH 372 not in crystal structure 
578   0.79 539 EFVSETES 546 not in crystal structure 
576   0.78 132 EDLRSRIE 139 active site facing 









Score Fibrinogen Sequence  
Inclusion/Exclusion 
Rationale 
572   0.76 467 KTVIGPDG 474 not in crystal structure 
567   0.76 751 YALQVSSY 758 not in crystal structure 
567   0.77 756 SSYEGTAG 763 not in crystal structure 
565   0.77 326 SGPGSTGS 333 not in crystal structure 
565   0.76 605 DEAGSEAD 612 not in crystal structure 
564   0.77 313 SGTGGTAT 320 not in crystal structure 
560   0.76 815 ANLNGIYY 822 not in crystal structure 
559   0.75 322 KPGSSGPG 329 not in crystal structure 
556   0.76 339 SGTGSTGN 346 not in crystal structure 
555   0.74 186 RALAREVD 193 no docking models near  
















Table B-8. Top 5% of PACMANS predicted fibrinogen b chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
652   0.89 115 ALLQQERP 122 no docking models near  
646   0.87 94 GCLHADPD 101 no docking models near  
644   0.87 414 GWLTSDPR 421 globular 
639   0.86 57 PSLRPAPP 64 not in crystal structure 
614   0.84 135 EAVSQTSS 142 active site facing 
611   0.82 381 NALMDGAS 388 globular 
605   0.82 210 QKLESDVS 217 no docking models near  
585   0.80 114 EALLQQER 121 no docking models near  
579   0.77 110 CQLQEALL 117 no docking models near  
578   0.79 339 ELLIEMED 346 globular 
577   0.78 330 SQLTRMGP 337 globular 
575   0.77 196 RVLRSILE 203 active site facing 
573   0.77 100 PDLGVLCP 107 no docking models near  
572   0.78 203 ENLRSKIQ 210 active site facing 
571   0.78 185 ETVNSNIP 192 active site facing 
570   0.77 26 FLVKSQGV 33 not in crystal structure 
567   0.77 214 SDVSAQME 221 no docking models near  
563   0.76 132 NNVEAVSQ 139 active site facing 
563   0.76 233 IPVVSGKE 240 globular 
552   0.75 200 SILENLRS 207 active site facing 
548   0.74 64 PPISGGGY 71 not in crystal structure 
546   0.74 25 VFLVKSQG 32 not in crystal structure 
546   0.74 234 PVVSGKEC 241 globular 
546   0.74 388 SQLMGENR 395 globular 
540   0.73 128 DELNNNVE 135 active site facing 






Table B-9. Top 5% of PACMANS predicted fibrinogen g chain cleavage sites by 




Score Fibriongen Sequence  
Inclusion/Exclusion 
Rationale 
687   0.92 426 HHLGGAKQ 433 not in crystal structure 
634   0.86 18 LFLSSTCV 25 not in crystal structure 
632   0.86 155 AQLEAQCQ 162 active site facing 
630   0.84 64 KDLQSLED 71 no binding 
604   0.81 90 IQLTYNPD 97 no docking models near  
595   0.80 416 NRLTIGEG 423 globular 
593   0.80 274 VELEDWNG 281 globular 
589   0.80 209 EIDGSGNG 216 globular 
584   0.79 125 SILTHDSS 132 active site facing 
581   0.79 16 ALLFLSST 23 not in crystal structure 
580   0.77 222 KRLDGSVD 229 globular 
579   0.78 242 GHLSPTGT 249 globular 
570   0.77 259 IHLISTQS 266 globular 
561   0.76 305 AYFAGGDA 312 globular 
550   0.74 67 QSLEDILH 74 no docking models near  
537   0.73 53 DFLSTYQT 60 active site facing 
536   0.72 71 DILHQVEN 78 no docking models near  
536   0.72 291 FKVGPEAD 298 globular 
535   0.73 368 GHLNGVYY 375 globular 
532   0.71 35 CILDERFG 42 not in crystal structure 
531   0.71 196 KPLKANQQ 203 globular 
529   0.72 445 DSLYPEDD 452 not in crystal structure 





APPENDIX C. BIOBOT LIFE EXPECTANCY MODEL CODE 
 This appendix has the MATLAB code for estimating the Weibull distribution 
parameters for the 0X, 1X, and 3X ACA treated biological machine life expectancy data. 
The code for the protease-informed life expectancy model and corresponding grid search 
are also included in this Appendix.  
C.1  Weibull Distribution MATLAB CODE 
function pd = fittingWeibull(ACA) 
% Biobot time until breaking can be estimated as a Weibull distribution 
% 
% Weibull: y = a*b*x^(b-1)*exp(-1*a*x^b) 
% parameters to fit: a & b 
  
% Determining Weibull parameters for each dataset: 
%      data is the age at which the biobots break 
%      outliers removed: 0X - 1 lived to 38days 
%                        1X - 1 lived to 164 & 1 to 233 days 
  
data0X = [6, 7, 7, 7, 7, 7, 8, 8, 9, 9, 9, 11, 11]'; 
data1X = [11, 11, 13, 16, 17, 34]'; 
data3X = [9, 11, 23, 28, 32, 54, 107, 198, 228, 250]'; 
  
if ACA == 0 
    pd= fitdist(data0X, 'Weibull') 
elseif ACA == 1 
    pd= fitdist(data1X, 'Weibull') 
elseif ACA == 3 
    pd= fitdist(data3X, 'Weibull') 
end 
  
% Results for Fitted Weibull Distribution 
% 
% 0X Weibull Distribution 
% A = 8.80037   [7.93074, 9.76535] 





% 1X Weibull Distribution 
% A = 19.2933   [13.2657, 28.0598] 
% B = 2.27744   [1.28885, 4.02432] 
% 
% 3X Weibull Distribution 
% A =  92.4197   [46.7841, 182.571] 
% B = 0.963603   [0.589746, 1.57446] 






% 0X ACA 
obstime0X = [6, 7, 7, 7, 7, 7, 8, 8, 9, 9, 9, 11, 11]'; 
figure() 
T = 11; 
subplot(1,2,1); 





xlabel('Time'); ylabel('Proportion failed'); title('Empirical CDF') 
subplot(1,2,2); 
paramEsts = wblfit(obstime0X); 
[nlogl,paramCov] = wbllike(paramEsts,obstime0X); 
xx = linspace(1,2*T,500); 
[wblF,wblFlo,wblFup] = wblcdf(xx,paramEsts(1),paramEsts(2),paramCov); 
stairs(x,empF); 
hold on 
handles = plot(xx,wblF,'r-',xx,wblFlo,'r:',xx,wblFup,'r:'); 
hold off 
xlabel('Time'); ylabel('Fitted failure probability'); title('Weibull Model vs. Empirical') 
  
% 1X ACA 
obstime1X = [11, 11, 13, 16, 17, 34]'; 
figure() 
T = 34; 
subplot(1,2,1); 








xlabel('Time'); ylabel('Proportion failed'); title('Empirical CDF') 
subplot(1,2,2); 
paramEsts1X = wblfit(obstime1X); 
[nlogl,paramCov1X] = wbllike(paramEsts1X,obstime1X); 
xx = linspace(1,2*T,500); 
[wblF,wblFlo,wblFup] = wblcdf(xx,paramEsts1X(1),paramEsts1X(2),paramCov1X); 
stairs(x,empF); 
hold on 
handles = plot(xx,wblF,'r-',xx,wblFlo,'r:',xx,wblFup,'r:'); 
hold off 
xlabel('Time'); ylabel('Fitted failure probability'); title('Weibull Model vs. Empirical') 
  
% 3X ACA 
obstime3X = [9, 11, 23, 28, 32, 54, 107, 198, 228, 250]'; 
figure() 
T = 250; 
subplot(1,2,1); 





xlabel('Time'); ylabel('Proportion failed'); title('Empirical CDF') 
subplot(1,2,2); 
paramEsts3X = wblfit(obstime3X); 
[nlogl,paramCov3X] = wbllike(paramEsts3X,obstime3X); 
xx = linspace(1,2*T,500); 
[wblF,wblFlo,wblFup] = wblcdf(xx,paramEsts3X(1),paramEsts3X(2),paramCov3X); 
stairs(x,empF); 
hold on 
handles = plot(xx,wblF,'r-',xx,wblFlo,'r:',xx,wblFup,'r:'); 
hold off 
xlabel('Time'); ylabel('Fitted failure probability'); title('Weibull Model vs. Empirical') 
end 
C.2  Bio-Bot Life Expectancy Model MATLAB Code 
function lifeSpan = biobotModel20170626(ProbCleav,ProbDead, ACA, writegraph, 
plotgraph) 




% 0X outlier - removed 1 bot that lived for 38 days 
t0X = [6, 7, 8, 9, 11]; 
d0X = [1, 5, 2, 3, 2]; 
r0X = [13, 12, 7, 5, 2]; 
lifeTable0X = biobotSurvival(t0X,d0X,r0X);  
average0X = mean(t0X); 
stdDev0X = std(t0X); 
SEM0X = stdDev0X/sqrt(size(t0X,2)-1); 
  
% 1X outlier - removed 2 bot that lived for 233 & 164 days 
t1X = [11, 13, 16, 17, 34]; 
d1X = [2, 1, 1, 1, 1]; 
r1X = [6, 4, 3, 2, 1]; 
lifeTable1X = biobotSurvival(t1X,d1X,r1X);  
average1X = mean(t1X); 
stdDev1X = std(t1X); 
SEM1X = stdDev1X/sqrt(size(t1X,2)-1); 
  
% 3X outlier - additional timepoints and no outliers 
t3X = [9, 11, 23, 28, 32, 54, 107, 198, 228, 250]; 
d3X = [1, 1, 1, 1, 1, 1, 1, 1, 1, 1]; 
r3X = [10, 9, 8, 7, 6, 5, 4, 3, 2, 1]; 
lifeTable3X = biobotSurvival(t3X,d3X,r3X); 
average3X = mean(t3X); 
stdDev3X = std(t3X); 
SEM3X = stdDev3X/sqrt(size(t3X,2)-1); 
  
lifeSpanData = [average0X, stdDev0X, SEM0X;... 
    average1X, stdDev1X, SEM1X;... 
    average3X, stdDev3X, SEM3X]; 
  
if ACA == 0 
    lifeSpanData(1,:); 
elseif ACA == 1 
    lifeSpanData(2,:); 
elseif ACA == 3 
    lifeSpanData(3,:); 
end 
  
% Data for formatted for Weibull distribution 
if ACA == 0  
    obstime = [6, 7, 7, 7, 7, 7, 8, 8, 9, 9, 9, 11, 11]'; 




    obstime = [11, 11, 13, 16, 17, 34]'; 
elseif ACA == 3 
    obstime = [9, 11, 23, 28, 32, 54, 107, 198, 228, 250]'; 
end 
  
% Define muscle strip dimensions (scale 1/10 mm, 2D) 
RanNum = 1;  
MSwidth = 40;  
MSlength = 80; 
MSdepth = 1; 
  
iterNum = 200; 
lifeSpanVec = zeros(iterNum,1); 
if ACA == 0 
    fileName = 'Biobot-Failure-Sim_0X_2017-06-26.txt'; 
elseif ACA == 1 
    fileName = 'Biobot-Failure-Sim_1X_2017-06-26.txt'; 
elseif ACA == 3 
    fileName = 'Biobot-Failure-Sim_3X_2017-06-26.txt'; 
end 
  
% M = 'Biobot Lifespan Failure Model Simulation'; 
% dlmwrite(fileName,M); 
  
fnameBase = 'Graph_Edges_2017-06-26_'; 
g=graph(laplacian3(MSlength,MSwidth,MSdepth), 'OmitSelfLoops'); 
g=remove_posts(g, MSlength, MSwidth, MSdepth); 
fname = strcat(fnameBase,num2str(0),'.txt'); 
write_graph(g,fname); 
            if plotgraph 
                gplot(adjacency(g), graphCoords); 
                graphvizfname = strcat(fnameBase, 'viz.', ... 
                                       num2str(0), '.fig'); 
                savefig(graphvizfname); 
            end 
variabilityCleave = 0.75 + (1.25-0.75)*rand; 
for a = 1:iterNum 
    % Set loop conditions 
    cond = 0; 
    condStop = 1; 
    p = ProbCleav * variabilityCleave; 
    % create 3D grid 




    g = remove_posts(g, MSlength, MSwidth, MSdepth); 
    if writegraph 
        [X,Y] = ind2sub([MSlength, MSwidth], 1:size(g.Nodes,1)); 
        graphCoords = [transpose(X), transpose(Y)]; 
        fnameCoords = strcat(fnameBase,'Coordinates.csv'); 
        dlmwrite(fnameCoords, graphCoords); 
    end 
    iteration_number = 0; 
    while (cond < condStop) 
        iteration_number = iteration_number + 1; 
        if ACA == 1 && iteration_number > 164 
            disp(['strip reached maximum iteration_number: ', num2str(iteration_number)]) 
            break 
        end 
        if ACA == 3 && iteration_number > 250 
            disp(['strip reached maximum iteration_number: ', num2str(iteration_number)]) 
            break 
        end 
        for v = 1:numnodes(g) 
                % need to search through length & width to get to all graph 
                % vertices 
                % identify the neighbors 
                neighb = neighbors(g,v); 
                incIfLessEdges = size(neighb,1); 
                % Generate random number based on protease 
                    RanNum = proteaseComp20170521(iteration_number, ACA); 
                    % increase prob of cleavage proportional to number of 
                    % edges cleaved 
                    if incIfLessEdges ~= 0 
                        RanNum = RanNum*(1-(1/incIfLessEdges)+(1/4)); 
                    end 
                    % Determine if cleavage occurs 
                    if RanNum <= p 
                        % if cleaved remove one edge from (i,j)'s 
                        % neighborhood 
                        % if there are no more neighbors skip it. 
                        if size(neighb,1) == 0 
                            continue 
                        end 
                        % if there is/are neighbors, choose one at random 
                        nN = randi([1,size(neighb,1)],1); 
                        %nN = 1; 




                        neighRm = neighb(nN); 
                        % remove that neighbor 
                        g = rmedge(g, v, neighRm); 
                    end   
        end 
        %% check if graph is still connected 
        % first computer connected components 
        cc = conncomp(g); 
        % record the edges for the graph 
        if writegraph; 
            fname = strcat(fnameBase,num2str(iteration_number),'.txt'); 
            write_graph(g,fname); 
            if plotgraph 
                gplot(adjacency(g), graphCoords); 
                graphvizfname = strcat(fnameBase, 'viz.', ... 
                                       num2str(iteration_number), '.fig'); 
                savefig(graphvizfname); 
            end 
        end 
        % the biobot is broken if the largest component contains no more 
        % than 1/4 of the fibrin molecules 
        variabilityBreak = 0.75 + (1.25-0.75)*rand; 
        if max(histc(cc, unique(cc))) < numnodes(g)*ProbDead*variabilityBreak 
           disp('Graph is disconnected making plot'); 
           %figure() 
           %gplot(adjacency(g), gcoords); % turn on here to see the final graph 
           %figure() 
           %plot(g) 
           cond = condStop; 
           X = ['strip broke on iteration: ', num2str(iteration_number)]; 
           disp(X) 
        end 
    end 
     
     lifeSpanVec(a,1) = iteration_number; 
          
end 
  
dlmwrite(fileName, lifeSpanVec, '-append'); 
  
% figure() 
% T = 11; 






% obstime0X = [6, 7, 7, 7, 7, 7, 8, 8, 9, 9, 9, 11, 11]'; 
% [empF0X,x0X,empFlo0X,empFup0X] = ecdf(obstime0X); 
% params0X = wblfit(obstime0X); 
% [nlogl,paramCov0X] = wbllike(params0X,obstime0X); 
% [wblF0X,wblFlo0X,wblFup0X] = 
wblcdf(xx,params0X(1),params0X(2),paramCov0X); 
% stairs(x0X,empF0X); 
% hold on 
% handles = plot(xx,wblF0X,'r-',xx,wblFlo0X,'r:',xx,wblFup0X,'r:'); 
% hold off 
% xlabel('Time'); ylabel('Fitted failure probability'); title('Weibull Model vs. Empirical') 
% title('0X Biobot Data') 
%  
% subplot(1,2,2) 
% [empF,x,empFlo,empFup] = ecdf(lifeSpanVec); 
WeibullParams = wblfit(lifeSpanVec); 
% [nlogl,paramCov] = wbllike(WeibullParams,lifeSpanVec); 
% [wblF,wblFlo,wblFup] = wblcdf(xx,WeibullParams(1),WeibullParams(2),paramCov); 
% stairs(x,empF); 
% hold on 
% handles = plot(xx,wblF,'r-',xx,wblFlo,'r:',xx,wblFup,'r:'); 
% hold off 
% xlabel('Time'); ylabel('Fitted failure probability'); title('Weibull Model vs. Empirical') 
% title('Simulated 0X Biobot Data') 
  





function amt = proteaseComp20170521 (day, ACA) 
  
% 0X ACA 
mCatL0Xdays = [3 6 6 8 8 12 12]; 
mCatL0Xng = [5.25922 12.0436 20.6688 12.7273 ... 
    21.3525 14.8836 26.0332]; 
  
MMP20Xdays = [3 6 6 8 8 12 12]; 
MMP20Xng = [0.0057 0.002988 0.004812 0.0044 ... 





mCatL0Xhi = @(t) 2.14*t + 2.8135; 
mCatL0Xlo = @(t) 1.002*t + 3.9638; 
  
MMP20Xhi = @(t) 0.0008*t + 0.0023; 
MMP20Xlo = @(t) 0.0002*t + 0.0037; 
  
% 1X ACA 
mCatL1Xdays = [3 6 6 8 8 12 12]; 
mCatL1Xng = [5.25922 3.103 3.8392 2.2615 ... 
    12.5695 3.4711 5.8903]; 
  
MMP21Xdays = [3 6 6 8 8 12 12]; 
MMP21Xng = [0.0057 0.005045 0.006755 0.003916 ... 
    0.005284 0.0046 0.0082]; 
  
mCatL1Xhi = @(t) 0.2399*t + 5.1503; 
mCatL1Xlo = @(t) -0.1882*t + 4.8883; 
  
MMP21Xhi = @(t) 0.0002*t + 0.0047; 
MMP21Xlo = @(t) -0.0001*t + 0.0058; 
  
% 3X ACA 
mCatL3Xdays = [3 6 6 8 8 12 12]; 
mCatL3Xng = [5.25922 2.0511 4.4703 3.4185 ... 
    9.6243 2.1563 5.6273]; 
  
MMP23Xdays = [3 6 6 8 8 12 12]; 
MMP23Xng = [0.0057 0.0064 0.0098 0.003773 ... 
    0.005027 0.0041 0.0101]; 
  
mCatL3Xhi = @(t) 0.1405*t + 5.2263; 
mCatL3Xlo = @(t) -0.2833*t + 5.2749; 
  
MMP23Xhi = @(t) 0.0004*t + 0.0051; 
MMP23Xlo = @(t) -0.0002*t + 0.0067; 
  
% Determine probability of cleavage 
amt = 0; 
if day<3 
    amt = rand; 
else 
    if ACA == 0 




        minCatL = mCatL0Xlo(day); 
        rangeCatL = maxCatL - minCatL; 
        maxMMP2 = MMP20Xhi(day); 
        minMMP2 = MMP20Xlo(day); 
        rangeMMP2 = maxMMP2 - minMMP2; 
        catL = mCatL0Xlo(day) + rangeCatL*rand(1,1); 
        MMP2 = MMP20Xlo(day) + rangeMMP2*rand(1,1); 
         
    elseif ACA == 1 
        maxCatL = mCatL1Xhi(day); 
        minCatL = mCatL1Xlo(day); 
        rangeCatL = maxCatL - minCatL; 
        maxMMP2 = MMP21Xhi(day); 
        minMMP2 = MMP21Xlo(day); 
        rangeMMP2 = maxMMP2 - minMMP2; 
        catL = mCatL1Xlo(day) + rangeCatL*rand(1,1); 
        MMP2 = MMP21Xlo(day) + rangeMMP2*rand(1,1); 
         
    elseif ACA == 3 
        maxCatL = mCatL3Xhi(day); 
        minCatL = mCatL3Xlo(day); 
        rangeCatL = maxCatL - minCatL; 
        maxMMP2 = MMP23Xhi(day); 
        minMMP2 = MMP23Xlo(day); 
        rangeMMP2 = maxMMP2 - minMMP2; 
        catL = mCatL3Xlo(day) + rangeCatL*rand(1,1); 
        MMP2 = MMP20Xlo(day) + rangeMMP2*rand(1,1); 
         
    end 
    
       protease = catL+MMP2; 
       minProtease = minCatL + minMMP2; 
       maxProtease = maxCatL + maxMMP2; 
       rangeProtease = maxProtease - minProtease; 
       proportion = (protease - minProtease)/rangeProtease; 




function lifeTable = biobotSurvival(t, d, r) 
  
% Populating the Life Table 




% (r), hazard rate (h(t)), cumulative hazard rate, survival probability   
% (S(t)), cumulative distribution function (CDF) 
lifeTable = zeros(length(t),7); 
  
lifeTable(:,1) = t;     % failure time 
lifeTable(:,2) = d;     % number of failed 
lifeTable(:,3) = r;     % number at risk 
  
% Hazard Rate (h(t)) 
for i=1:length(t) 
    lifeTable(i,4) = d(i)/r(i); 
end 
  
% Cumulative Hazard Rate 
for i=1:length(t) 
    if i == 1 
        lifeTable(i,5) = 0; 
    else 
        lifeTable(i,5) = lifeTable(i-1,5) + lifeTable(i,4); 
    end 
end 
  
% Survival Probability (S(t)) 
for i=1:length(t) 
    if i == 1 
        lifeTable(i,6) = 1 - lifeTable(i,4); 
    else 
        lifeTable(i,6) = lifeTable(i-1,6)*(1 - lifeTable(i,4)); 
    end 
end 
  
% Cumulative Distribution Function (CDF) 
for i=1:length(t) 





function A = laplacian3(nx,ny,nz) 
ex=ones(nx,1); 
Lx=spdiags([ex -3*ex ex],[-1 0 1],nx,nx); 
ey=ones(ny,1); 


















function [ g ] = remove_posts( g, length, width, depth) 
%UNTITLED Summary of this function goes here 
%   Detailed explanation goes here 
nv = size(g.Nodes); 
[X,Y,Z] = ind2sub([length, width, depth], 1:size(g.Nodes,1)); 
for i = 1:nv 
    % post 1 
    if (1/4 * width < Y(i) && Y(i) < 3/4 * width) && (1/8*length <  X(i) && X(i) < 1/4* 
length) 
        for j = neighbors(g, i) 
            g = rmedge(g, i,j); 
        end 
    end 
    % post 2 
    if 1/4 * width < Y(i) && Y(i) < 3/4 * width && 3/4*length <  X(i) && X(i) < 7/8* 
length 
        for j = neighbors(g, i) 
            g = rmedge(g, i,j); 
        end 
    end 
end 




function [  ] = write_graph( graph, fname ) 
%write_graph writes a graph to a file in edgelist form 














probCleavMin = 0.10; 
probCleavMax = 0.40; 
probCleavStep = 0.05; 
  
probCleav = probCleavMin:probCleavStep:probCleavMax; 
  
probDeadMin = 0.10; 
probDeadMax = 0.40; 
probDeadStep = 0.05; 
  




parfor a = 1:length(probCleav) 
    for b = 1:length(probDead) 
            
           % Simulated biobots & determine failure times 
           % Weibull's distribution parameters are the output 
           res0X = biobotModel20170625(probCleav(a), probDead(b), 0, 0, 0); 
           res1X = biobotModel20170625(probCleav(a), probDead(b), 1, 0, 0); 
           res3X = biobotModel20170625(probCleav(a), probDead(b), 3, 0, 0); 
           % Store combo of biobot parameter values and Weibull parameters 
           resAll = [probCleav(a), probDead(b), res0X(1), res0X(2), res1X(1), res1X(2), 
res3X(1), res3X(2)]; 
            
           % to avoid issues with the parfor loop & writing to files 
           % concurrently 
           t = getCurrentTask(); 
           tID = t.ID; 
            




            










APPENDIX D. CATHEPSIN MUTANT SEQUENCES 
 This appendix contains specific sequences information for plasmids, cathepsin 
genes, as well as primers used to design and generate cathepsin mutants (Chapter 8).  
D.1  Plasmid Sequence 
D.1.1 pCMV6 Plasmid   
The original cathepsin wildtype plasmids were purchased from OriGene and were on 
the pCMV6 plasmid (Figure D-1).  
 
Figure D-1. pCMV6 plasmid map (from OriGene) with the wildtype cathepsin 
sequences. Cathepsins K, L, and S were on the pCMV6-AC backbone and cathepsin 
V was on the pCMV-XL5 backbone. 
D.1.2 pcDNA 4/TO/Myc-His A Plasmid   
 The wildtype cathepsin genes were PCR’ed off the pCMV6 plasmids and were 
mutated or inserted as wildtype cathepsin into Invitrogen’s pcDNA 4/TO/Myc-His A 





Figure D-2.  Invitrogen's pcDNA 4/TO/myc-His plasmid map that the backbone for 
the mutant cathepsin plasmids. 
The multiple cloning sites of version A is give in Figure D-3. Cathepsins K and S were 
cloned between EcoRI and AgeI and cathepsins L and V were cloned between BamHI and 
AgeI, which removed the c-myc epitope (which if included would prevent the cathepsins 
from folding). 
 





CMV priming site  c-myc isotope   His tagging  Stop codon 












































































































D.1.3 pCDNA6-TETR  
 This is the sequence of the Tet Repressor plasmid used in combination with the 
































































D.2  Wildtype Cathepsin Sequences 
D.2.1 Cathepsin K  
EcoRI   Start/Stop  Primer binding  Cathepsin K Sequence  









































D.2.2 Cathepsin L  
Start/Stop  Primer binding  Cathepsin L Sequence  
The PCR subcloning primer will insert the BamHI site before the cathepsin L gene. Starting 






































D.2.3 Cathepsin S 
EcoRI   Start/Stop  Primer binding  Cathepsin S Sequence  










































D.2.4 Cathepsin V  
GC/CCGGCG NOTI  Start/Stop Primer binding  Cathepsin V Sequence  












































D.3  Mutant Cathepsin Primers 
D.3.1 Wildtype cathepsin subcloning primers  
• Forward binding primer for cathepsins K, S: 
o 5’-AGAGCTCGTTTAGTGAACCGTCAG-3’ 
o This primer binds upstream of an EcoRI restriction site that will be used to 
clone the gene into pcDNA4-TO-A 
• Forward binding primer for cathepsin L1: 
o 5’-GATAGGATCCAGAGCTCGTTTAGTGAACCGTCAG-3’ 
o Primer generates a BamHI site upstream of the gene 
• Forward binding primer for cathepsin V (L2): 
o 5’-ATATGGATCCAGCAGAGCTCGTTTAGTGAACCGT-3' 
o Primer generates a BamHI site upstream of the gene 
• Cathepsin K AgeI reverse primer: 
o 5’-GCTGACCGGTCATCTTGGGGAAGCTGGC-3’ 
• Cathepsin S AgeI reverse primer: 
o 5’-TCTAACCGGTGATTTCTGGGTAAGAGGG-3’ 
• Cathepsin L AgeI reverse primer: 
o 5’-GTGGACCGGTCACAGTGGGGTAGCTGGCTGCT-3’ 
• Cathepsin V (L2) AgeI reverse primer: 
o 5’-GTAGACCGGTCACATTGGGGTAGCTGGC-3’ 
D.3.2 Cathepsin mutagenic primers  
D.3.2.1 Cathepsin S Active Site Mutations 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
C139A Fwd: 5’-tct tgt ggg gcg gcc tgg gct ttc 
agt gc-3’ 
NarI site added 65.5%; 70.9°C 
 Rev: 5’-agc cca ggc cgc ccc aca aga acc 
ttg a-3’ 
 66.7%; 70.2°C 





 Rev: 5’-c acc ctg gtt cac att ctg agt aca 
gga gt-3’ 
 50.0%; 61.1°C 





 Rev: 5’-gct atc ctt caca ag cca gta ttc ttt 
ccc-3’ 





D.3.2.2 Cathepsin S Cleavage Site Mutations 




L159V Fwd: 5’-aaa acc ggg aag gtg gtg tct ctc 
agt gcc-3’ 
NciI site added 56.7%; 66.5°C 
 Rev: 5’-ga cac cac ctt ccc ggt ttt cag ctt 
cag c-3’ 
 56.7%; 65.8°C 





 Rev: 5’-ttt ccc gtt aac gtc acc ata gcc aac 
cac-3’ 
 50.0%; 63.6°C 





 Rev: 5’-ggg aaa ggc agc aatccc aca atg 
aat tcc-3’ 
 46.7%; 61.5°C 
• Here I assumed that catL & catV have the same specificity matrix 
• Didn’t make any cathepsin K on cathepsin S mutants 
 
D.3.2.3 Cathepsin L Active Site Mutations 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
C138A Fwd: 5’-tgt ggt agc gct tgg gct ttt agt gct 
ac-3’ 
AfeI site added 51.7%; 63.8°C 
 Rev: 5’-agc cca agc gct acc aca ctg acc 
aca ctg-3’ 
 60.0%; 68.1°C 
H276Q Fwd: 5’-atg gac cag ggt gtc ctg gtg gtt 
ggc tac -3’ 
DrdI site added 60.0%; 67.7°C 
 Rev: 5’-c cag gac acc ctg gtc cat gtc ttc 
act cg-3’ 
 60.0%; 66.6°C 





 Rev: 5’-c acc cca gct atc ctt cac cag cca 
ata-3’ 




D.3.2.4 Cathepsin L Cleavage Site Mutations 
Cathepsins K on Cathepsin L 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
E176N Fwd: 5’-ggc aat aac ggt tgg aat ggt ggc cta 
atg g-3’ 
AclI site added 51.6%; 64.2°C 
 Rev: 5’-att cca acc gtt att gcc ttg agg gcc 
aga-3’ 
 50.0%; 64.8°C 
E289N Fwd: 5’-gaa agt act aac tcc gat aac aat aaa 
tat tgg-3’ 
ScaI site added 30.3%; 54.4°C 
 Rev: 5’-atc gga gtt agt act ttc aaa tcc gta 
gcc-3’ 
 43.3%; 59.5°C 
 
E289N – doesn’t really have good primers, very low GC content, partially because of 
location in the gene; also the forward primer is too many nucleotides (30nt – without gaa 
– sequence, 30%, 53.2deg) 
 
Cathepsins S on Cathepsin L 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
S326A Fwd: 5’-att gcc gca gcg gcc agc tac ccc 
act gtg-3’ 
BglI site added 66.7%; 71.8°C 
 Rev: 5’-gct ggc cgc tgc ggc aat tcc aca 
atg g-3’ 
 64.3%; 69.3°C 
L158V Fwd: 5’-ggc agg gtg atc agc ctg agt gag 
cag aat-3’ 
BclI site added 56.7%; 66.3°C 
 Rev: 5’-ct cag gct gat cac cct gcc agt ttt 
ccg g-3’ 
 60.0%; 66.9°C 
V239A Fwd: 5’-atg aag gcg gcc gca act gtg ggg 
ccc-3’ 
NotI site added 70.4%; 72.3°C 
 Rev: 5’-agt tgc ggc cgc ctt cat cag ggc 
ttc ctc-3’ 
 63.3%; 69.9°C 
V239G Fwd: 5’-atg aag gcc ggg gca act gtg ggg 
ccc-3’ 
NciI site added 70.4%; 72.1°C 
 Rev: 5’-c agt tgc ccc ggc ctt cat cag ggc 
c-3’ 





Cathepsin V on Cathepsin L: Sites have not yet been identified since catV does not have a 
defined specificity matrix.  
D.3.2.5 Cathepsin V Active Site Mutants 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
C138A Fwd: 5’-gt ggt agc gct tgg gct ttt agt gcg 
act gg-3’ 
AfeI site added 58.1%; 66.9°C 
 Rev: 5’-agc cca agc gct acc aca ctg ttt 
ctg-3’ 
 55.6%; 64.6°C 
H277Q Fwd: 5’-aac ctt gat caa ggt gtt ctg gtt ggc 
tac-3’ 
BclI site added  46.7%; 61.9°C 
 Rev: 5’-aac acc ttg atc aag gtt ttt gct gct 
gc-3’ 
 44.8%; 61.5°C 





 Rev: 5’-c cca gct atc ctt gac gag cca ata 
ctt gc-3’ 
 53.3%; 63.2°C 
 
D.3.2.6 Cathepsin V Cleavage Site Mutations 
Cathepsins K on Cathepsin V 
Mutation Primers 
Restriction 
Enzyme  Characteristics 





 Rev: 5’-att tgc gcc gtt gaa gcc gtc gcc aac 
cac-3’ 
 60.0%; 69.4°C 





 Rev: 5’-tt ggg gac gtc aag aaa cag agg ctc 
acg g-3’ 
 56.7%; 66.3°C 





 Rev: 5’-cc cca att ggg acc cca gct gtt ttt gac 
g-3’ 




Cathepsins S on Cathepsin V 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
L158V Also location for catL on catV, see table below for primers 
    
L280V Fwd: 5’-gat cac ggc gtg gtg gtg gtt ggc 
tac ggc-3’ 
BsiEI site added 66.7%; 70.3°C 
 Rev: 5’-c cac cac gcc gtg atc cag gtt ttt 
gct gc-3’ 
 60.0%; 68.0°C 
G288A Also location for catL on catV, see table below for primers 
    
V219A Fwd: 5’-cct gag aat agc gct gct aat gac 
act ggc-3’ 
AfeI site added 53.3%; 63.7°C 
 Rev: 5’-agc agc gct att ctc agg tct gta c-
3’ 
 52.0%; 60.1°C 





 Rev: 5’-agc ccc gct att cac agg tct gta c-
3’ 
 56.0%; 62.2°C 
L236V Fwd: 5’-g gag aag gcc gtc atg aaa gca 
gtc gca ac-3’ 
BspHI site added 56.7%; 65.8°C 
 Rev: 5’-cat gac ggc ctt ctc ctt tcc agg cgt 
gac-3’ 
 60.0%; 66.9°C 
 
 
Cathepsins L on Cathepsin V 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
L158V Fwd: 5’-aaa acc ggg aag gtg gtc tca ctg 
agc gag-3’ 
NciI site added 56.7%; 66.1°C 
 Rev: 5’-gac cac ctt ccc ggt ttt ccg gaa cat 
ctg-3’ 
 56.7%; 65.4°C 





 Rev: 5’-cga att ggc cgc ctc aaa gcc gta 
gcc aac-3’ 






D.3.2.7 Cathepsin K Cleavage Site Mutants  
(Designed by and created in Ellen Moomaw’s Lab Class) 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
C139A Fwd: 5’ – tgt ggt agc gct tgg gct ttt agc 
tct gtg – 3’  
AfeI site  53.3%; 65.2°C 
 Rev: 5’ – agc cca agc gct acc aca ctg acc 
ctg – 3’  
 63.0%; 67.7°C 
C139S Fwd: 5’ – ggt tcc agc tgg gct ttt agc tct 
gtg – 3’  
PvuII site added 55.6%; 63.2°C 
 Rev: 5’ – agc cca gct gga acc aca ctg acc 
ctg – 3’  
 63.0%; 67.7°C 
H276A Fwd: 5’ – ctg aac gct gca gtt ttg gca gtg 
gga – 3’  
PstI site 55.6%; 65.1°C 
 Rev: 5’ – c tgc caa aac tgc agc gtt cag att 
atc gct – 3’   
 48.4%; 63.9°C 
H276N Fwd: 5’ – ctg aac cag gca gta ctg gca gtg 
gga – 3’  
ScaI site added  59.3%; 65.5°C 
 Rev: 5’ – gc cag tac tgc gtt gtt cag att atc 
gc – 3’  
 50.0%; 61.3°C 
H276Q Fwd: 5’ – ctg aac cag gca gta ctg gca gtg 
gga – 3’  
ScaI site added 59.3%; 65.5°C 
 Rev: 5’ – gc cag tac tgc ctg gtt cag att 
atc gc – 3’   
 53.6%; 62.5°C 
N296A Fwd: 5’ – atc aag gcg agc tgg gga gaa 




 Rev: 5’ – cca gct cgc ctt gat tat cca gtg 
ctt g – 3’  
 53.6%; 62.9°C 
N296D Fwd: 5’ – aag gat agc tgg gga gaa aac 




 Rev: 5’ – cca gct atc ctt gat tat cca gtg 
ctt g – 3’  







D.3.2.8 Cathepsin K Cleavage Site Mutants 
Cathepsins S on Cathepsin K (Designed by and created in Ellen Moomaw’s Lab Class) 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
L62A Fwd: 5’ – cat aac gct gag gct agc ctt ggt 
gtc cat ac – 3’ 
NheI site 53.1%; 64.3°C 
 Rev: 5’ – acc aag gct agc ctc agc gtt atg 
gat gg – 3’  
 55.2%; 64.9°C 
L62V Fwd: 5’ – cat aac gtg gag gct agc cct ggt 
gtc cat ac – 3’  
NheI site 56.2%; 65.5°C 
 Rev: 5’ – acc aag gct agc ctc gtg gtt atg 
gat gg – 3’ 
 55.2%; 64.8°C 
L97A Fwd: 5’ – gta ccc gcg tct cat tcc cgc agt 
– 3’  
BsmBI site 62.5%; 65.0°C 
 Rev: 5’ – gga at gaga cgc ggg tac ttt gag 
tcc – 3’  
 55.6%; 62.4°C 
L97V Fwd: 5’ – ctc aag gta ccg gtg tct cat tcc 
cgc agt – 3’   
AgeI site added 56.7%; 65.8°C 
 Rev: 5’ – gga at gaga cac cgg tac ctt gag 
tcc agt c – 3’  
 54.8%; 64.0°C 
V171A Fwd: 5’ – cta gtg gat tgc gca tct gag aat 
gat – 3’  
FspI site 44.4%; 58.7°C 
 Rev: 5’ – ctc aga tgc gca atc cac tag gtt 
ctg ggg – 3’   
 56.7%; 64.9°C 
L253A Fwd: 5’ – gcc att gat gca agc gct acc tcc 
ttc cag – 3’  
AfeI site  56.7%; 65.7°C 
 Rev: 5’ – gga ggt agc gct tgc atc aat ggc 
cac aga – 3’  
 56.7%; 66.8°C 
L253V Fwd: 5’ – gat gct agc gtg acct cc ttc cag 
ttt tac agc – 3’ 
NheI site 51.5%; 64.3°C 
 Rev: 5’ – gga ggt cac gct agc atc aat ggc 
cac – 3’  








Cathepsins L/V on Cathepsin K (Designed by Esmarline, EBICS REU 2014) 
Mutation Primers 
Restriction 
Enzyme  Characteristics 
L159V To be designed   
    
L274V Fwd: 5’-gc gat aac gtt aac cat gcg gtt ttg 
gca g-3’ 
AclI site added 50.0%; 63.4°C 
 Rev: 5’-c cgc atg gtt aac gtt atc gct aat 
gca gc-3’ 
 50.0%; 62.9°C 
G284A Fwd: 5’-ggc taa gca atc cag aag gga aac 
aag cac-3’ 
BlpI site added  50.0%; 62.9°C 
 Rev: 5’-ctg gat tgc tta gcc cac tgc caa 
aac cgc-3’ 
 56.7%; 66.4°C 
 
Here we assumed that catL & catV have the same specificity matrix 
 
All characterization (GC content percentage and Melting temperature) were determined 
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